WO2008130551A2 - Antibiotic resistance free listeria strains and methods for constructing and using same - Google Patents
Antibiotic resistance free listeria strains and methods for constructing and using same Download PDFInfo
- Publication number
- WO2008130551A2 WO2008130551A2 PCT/US2008/004861 US2008004861W WO2008130551A2 WO 2008130551 A2 WO2008130551 A2 WO 2008130551A2 US 2008004861 W US2008004861 W US 2008004861W WO 2008130551 A2 WO2008130551 A2 WO 2008130551A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- another embodiment
- vector
- nucleic acid
- gene
- protein
- Prior art date
Links
- 241000186781 Listeria Species 0.000 title claims abstract description 188
- 238000000034 method Methods 0.000 title claims abstract description 134
- 230000003115 biocidal effect Effects 0.000 title claims description 36
- 102000004190 Enzymes Human genes 0.000 claims abstract description 170
- 108090000790 Enzymes Proteins 0.000 claims abstract description 170
- 230000002503 metabolic effect Effects 0.000 claims abstract description 169
- 108091007433 antigens Proteins 0.000 claims abstract description 137
- 102000036639 antigens Human genes 0.000 claims abstract description 137
- 108010061833 Integrases Proteins 0.000 claims abstract description 97
- 230000028993 immune response Effects 0.000 claims abstract description 20
- 230000001939 inductive effect Effects 0.000 claims abstract description 17
- 239000013598 vector Substances 0.000 claims description 295
- 108090000623 proteins and genes Proteins 0.000 claims description 205
- 150000007523 nucleic acids Chemical class 0.000 claims description 183
- 102000039446 nucleic acids Human genes 0.000 claims description 149
- 108020004707 nucleic acids Proteins 0.000 claims description 149
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 119
- 239000012634 fragment Substances 0.000 claims description 107
- 230000010354 integration Effects 0.000 claims description 77
- 229920001184 polypeptide Polymers 0.000 claims description 75
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 75
- 230000001580 bacterial effect Effects 0.000 claims description 70
- 230000015572 biosynthetic process Effects 0.000 claims description 59
- 150000001413 amino acids Chemical group 0.000 claims description 55
- 101710164436 Listeriolysin O Proteins 0.000 claims description 49
- 108700026244 Open Reading Frames Proteins 0.000 claims description 44
- 230000010076 replication Effects 0.000 claims description 39
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 239000003242 anti bacterial agent Substances 0.000 claims description 26
- 108091023040 Transcription factor Proteins 0.000 claims description 18
- 102000040945 Transcription factor Human genes 0.000 claims description 18
- 108020001507 fusion proteins Proteins 0.000 claims description 18
- 102000037865 fusion proteins Human genes 0.000 claims description 18
- 230000002949 hemolytic effect Effects 0.000 claims description 13
- 230000037354 amino acid metabolism Effects 0.000 claims description 12
- 230000005847 immunogenicity Effects 0.000 claims description 12
- 108010041525 Alanine racemase Proteins 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 9
- 230000004260 plant-type cell wall biogenesis Effects 0.000 claims description 8
- 102000004357 Transferases Human genes 0.000 claims description 7
- 108090000992 Transferases Proteins 0.000 claims description 7
- 150000008574 D-amino acids Chemical class 0.000 claims description 5
- 230000000415 inactivating effect Effects 0.000 claims description 5
- 239000000427 antigen Substances 0.000 abstract description 98
- 102100034343 Integrase Human genes 0.000 abstract description 52
- 239000013612 plasmid Substances 0.000 description 161
- 229940088598 enzyme Drugs 0.000 description 157
- 206010028980 Neoplasm Diseases 0.000 description 87
- 241000894006 Bacteria Species 0.000 description 66
- 101150070828 alr gene Proteins 0.000 description 65
- 201000011510 cancer Diseases 0.000 description 63
- 102000004169 proteins and genes Human genes 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 61
- 241000186779 Listeria monocytogenes Species 0.000 description 51
- 241000588724 Escherichia coli Species 0.000 description 49
- 101150082952 ACTA1 gene Chemical group 0.000 description 43
- 229960005486 vaccine Drugs 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 38
- 125000003729 nucleotide group Chemical group 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 35
- 210000000349 chromosome Anatomy 0.000 description 35
- 238000003752 polymerase chain reaction Methods 0.000 description 35
- 239000000203 mixture Substances 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 description 29
- 229960005091 chloramphenicol Drugs 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 26
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 26
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 25
- 238000010367 cloning Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 230000001105 regulatory effect Effects 0.000 description 21
- 102100022399 Ribosome biogenesis protein NOP53 Human genes 0.000 description 19
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 229920001817 Agar Polymers 0.000 description 16
- 239000008272 agar Substances 0.000 description 16
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 16
- 230000004927 fusion Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 13
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 229960003767 alanine Drugs 0.000 description 12
- 229960001212 bacterial vaccine Drugs 0.000 description 12
- 235000004279 alanine Nutrition 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 208000035473 Communicable disease Diseases 0.000 description 10
- 229930182847 D-glutamic acid Natural products 0.000 description 10
- 241000607479 Yersinia pestis Species 0.000 description 10
- 101150024289 hly gene Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 230000002238 attenuated effect Effects 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 101150012893 dat gene Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000001018 virulence Effects 0.000 description 9
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000007918 pathogenicity Effects 0.000 description 8
- 229960005322 streptomycin Drugs 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002759 chromosomal effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 6
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- 239000006137 Luria-Bertani broth Substances 0.000 description 5
- 108090001066 Racemases and epimerases Proteins 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 210000004898 n-terminal fragment Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 101150093386 prfA gene Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 101000746457 Neisseria gonorrhoeae UPF0213 protein in glnA 3'region Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 102000004879 Racemases and epimerases Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 101150055766 cat gene Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000012737 microarray-based gene expression Methods 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 4
- 229940055726 pantothenic acid Drugs 0.000 description 4
- 235000019161 pantothenic acid Nutrition 0.000 description 4
- 239000011713 pantothenic acid Substances 0.000 description 4
- 230000027086 plasmid maintenance Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 3
- 101100221537 Bacillus subtilis (strain 168) comK gene Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101150013359 E7 gene Proteins 0.000 description 3
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 102100023472 P-selectin Human genes 0.000 description 3
- 108010013639 Peptidoglycan Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 102100040396 Transcobalamin-1 Human genes 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 101150037081 aroA gene Proteins 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000002169 hydrotherapy Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001320 lysogenic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 101150114864 plcA gene Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 108010075210 streptolysin O Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- MPUUQNGXJSEWTF-BYPYZUCNSA-N (S)-4-amino-5-oxopentanoic acid Chemical compound O=C[C@@H]([NH3+])CCC([O-])=O MPUUQNGXJSEWTF-BYPYZUCNSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 2
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 2
- 241001167018 Aroa Species 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 108010000916 Fimbriae Proteins Proteins 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102100034867 Kallikrein-7 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000186806 Listeria grayi Species 0.000 description 2
- 241000186807 Listeria seeligeri Species 0.000 description 2
- 206010024641 Listeriosis Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 229930191564 Monensin Natural products 0.000 description 2
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 101100055397 Wigglesworthia glossinidia brevipalpis alr gene Proteins 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 101150023527 actA gene Proteins 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- -1 arginine (R) Chemical class 0.000 description 2
- 101150040872 aroE gene Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 101150049467 dadX gene Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229920002672 di-trans,poly-cis-Undecaprenol Polymers 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007852 inverse PCR Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960005358 monensin Drugs 0.000 description 2
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000010469 pro-virus integration Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 101150059846 trpS gene Proteins 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KWIBRHGQCHIETC-CWSFPBCASA-N (7s)-3-[(3s)-3-[[(2r)-2-acetamido-4-[(2r,3s,4r,5r,6s)-5-amino-2-[[[[(2r,3s,4r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,6-dihydroxyoxan-4-yl]oxy-2-methyl-3-oxopentanoyl]amino]-4-[[(2 Chemical group O[C@H]1[C@H](OC(C)C(=O)[C@@](C)(NC(C)=O)C(=O)N[C@@H](CCC(C(N)C(O)=O)C(=O)CC[C@H](N)C(O)=O)C(=O)N[C@H](C)C(=O)N[C@H](C)C(O)=O)[C@@H](N)[C@@H](O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)C(N2C(NC(=O)C=C2)=O)O1 KWIBRHGQCHIETC-CWSFPBCASA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- WVMWZWGZRAXUBK-SYTVJDICSA-N 3-dehydroquinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)CC(=O)[C@H]1O WVMWZWGZRAXUBK-SYTVJDICSA-N 0.000 description 1
- WVMWZWGZRAXUBK-UHFFFAOYSA-N 3-dehydroquinic acid Natural products OC1CC(O)(C(O)=O)CC(=O)C1O WVMWZWGZRAXUBK-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101100163490 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) aroA1 gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101000640990 Arabidopsis thaliana Tryptophan-tRNA ligase, chloroplastic/mitochondrial Proteins 0.000 description 1
- 108020004652 Aspartate-Semialdehyde Dehydrogenase Proteins 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 101000755953 Bacillus subtilis (strain 168) Ribosome maturation factor RimP Proteins 0.000 description 1
- 101100216993 Bacillus subtilis (strain 168) aroD gene Proteins 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 201000007155 CD40 ligand deficiency Diseases 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 101710178953 Cell wall teichoic acid glycosylation protein GtcA Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
- 241000193401 Clostridium acetobutylicum Species 0.000 description 1
- 101100163308 Clostridium perfringens (strain 13 / Type A) argR1 gene Proteins 0.000 description 1
- 108010065693 Clostridium perfringens theta-toxin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 108050004635 D-amino acid aminotransferases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100337176 Escherichia coli (strain K12) gltB gene Proteins 0.000 description 1
- 101100505027 Escherichia coli (strain K12) gltD gene Proteins 0.000 description 1
- 101100540759 Escherichia coli (strain K12) wecE gene Proteins 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101150082479 GAL gene Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010057891 Glutamate-1-semialdehyde 2,1-aminomutase Proteins 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101000777488 Heteractis magnifica DELTA-stichotoxin-Hmg2b Proteins 0.000 description 1
- 108050003783 Histidinol-phosphate aminotransferase Proteins 0.000 description 1
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 description 1
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 1
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 101710176222 Kallikrein-7 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 101000743006 Lactococcus lactis subsp. cremoris UPF0177 protein in abiGi 5'region Proteins 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000186780 Listeria ivanovii Species 0.000 description 1
- 241000866438 Listeria monocytogenes 10403S Species 0.000 description 1
- 108700027766 Listeria monocytogenes hlyA Proteins 0.000 description 1
- 101100354184 Listeria monocytogenes serotype 4b (strain F2365) ptcA gene Proteins 0.000 description 1
- 101100426447 Listeria monocytogenes serotype 4b (strain F2365) trpC gene Proteins 0.000 description 1
- 241000186814 Listeria welshimeri Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101100327514 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) cfbE gene Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000707232 Mus musculus SH2 domain-containing protein 2A Proteins 0.000 description 1
- 102100030397 N-acetylmuramoyl-L-alanine amidase Human genes 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101100276922 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) dapF2 gene Proteins 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035718 Pneumonia legionella Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 240000003801 Sigesbeckia orientalis Species 0.000 description 1
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241001219481 Spongospora subterranea Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 101100125907 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) ilvC1 gene Proteins 0.000 description 1
- 101100116197 Streptomyces lavendulae dcsC gene Proteins 0.000 description 1
- 101100116199 Streptomyces lavendulae dcsE gene Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101100057034 Talaromyces wortmannii astB gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 241001664469 Tibicina haematodes Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 102000002501 Tryptophan-tRNA Ligase Human genes 0.000 description 1
- 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical group O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150089004 argR gene Proteins 0.000 description 1
- 101150090235 aroB gene Proteins 0.000 description 1
- 101150042732 aroC gene Proteins 0.000 description 1
- 101150102858 aroD gene Proteins 0.000 description 1
- 101150108612 aroQ gene Proteins 0.000 description 1
- 101150070145 aspB gene Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 101150062988 dapF gene Proteins 0.000 description 1
- 101150100742 dapL gene Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 101150107671 hisB gene Proteins 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- 101150032598 hisG gene Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 description 1
- 101150090497 ilvC gene Proteins 0.000 description 1
- 101150043028 ilvD gene Proteins 0.000 description 1
- 101150105723 ilvD1 gene Proteins 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 101150062334 int gene Proteins 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 101150087199 leuA gene Proteins 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 101150030499 lnt gene Proteins 0.000 description 1
- 101150082124 lso gene Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 101150095438 metK gene Proteins 0.000 description 1
- 101150115974 metX gene Proteins 0.000 description 1
- 101150043924 metXA gene Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 101150023205 murA1 gene Proteins 0.000 description 1
- 101150089003 murA2 gene Proteins 0.000 description 1
- 101150093075 murD gene Proteins 0.000 description 1
- 101150037968 murG gene Proteins 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 102000030592 phosphoserine aminotransferase Human genes 0.000 description 1
- 108010088694 phosphoserine aminotransferase Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220277134 rs776745497 Human genes 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 101150003830 serC gene Proteins 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 101150072448 thrB gene Proteins 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 208000016367 transient hypogammaglobulinemia of infancy Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 101150004782 trpS2 gene Proteins 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- Figure 8 depicts bacterial growth as measured by optical density (600 nanometers [nm]) plotted vs. time.
- +AIa media contains D-alanine
- +ChI media contains chloramphenicol .
- FIG 10 Top of left panel- Plasmid map of pPLl . Chloramphenicol resistance genes and E. coli origin of replication, RP4 origin of transfer, and the U 153 integrase gene and L. monocytogenes p60 promoter are depicted.
- the multiple cloning site (MCS) is shown at the bottom of the plasmid, with unique restriction sites noted below in a box.
- pPL24 and pPL25 inserts are shown schematically below the multiple cloning site. Final sizes of the plasmid constructs and the restriction sites used in cloning are noted for each of the inserts. Bottom of left panel- pPL24 and pPL25. Right panel- Plasmid map of pPL2.
- the present invention provides a method of inducing an immune response against a protein antigen of interest in a subject, comprising the step of administering to the subject a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises said protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a third open reading frame encoding a Al 18 or Ul 53 integrase gene, thereby inducing an immune response against said protein antigen of interest in said subject.
- nucleic acids or “nucleotide” refers to a string of at least two base-sugar-phosphate combinations.
- the term includes, in one embodiment, DNA and RNA.
- Nucleotides refers, in one embodiment, to the monomelic units of nucleic acid polymers.
- RNA may be, in one embodiment, in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), mRNA (messenger RNA), anti-sense RNA, small inhibitory RNA (siRNA), micro RNA (miRNA) and ribozymes.
- the transcription factor is mutated in the chromosome. In another embodiment, the transcription factor is deleted from the chromosome.
- the metabolic enzyme is encoded by serC, a phosphoserine aminotransferase.
- the metabolic enzyme is encoded by asd (aspartate beta-semialdehyde dehydrogenase), involved in synthesis of the cell wall constituent diaminopimelic acid.
- the metabolic enzyme is encoded by gsaB- glutamate-1-semialdehyde aminotransferase, which catalyzes the formation of 5- aminolevulinate from (S)-4-amino-5-oxopentanoate.
- the metabolic enzyme is encoded by HemL, which catalyzes the formation of 5-aminolevulinate from (S)- 4-amino-5-oxopentanoate.
- the metabolic enzyme is encoded by aspB, an aspartate aminotransferase that catalyzes the formation of oxalozcetate and L- glutamate from L-aspartate and 2-oxoglutarate.
- the metabolic enzyme is encoded by argF-1, involved in arginine biosynthesis.
- the metabolic enzyme is encoded by aroE, involved in amino acid biosynthesis.
- the metabolic enzyme is encoded by aroB, involved in 3-dehydroquinate biosynthesis.
- the integrase is homologous to SEQ ID No: 27.
- the integrase is a variant of SEQ ID No: 27.
- the integrase is an isoform of SEQ ID No: 27.
- the integrase is a fragment of SEQ ID No: 27.
- the integrase is any other Ul 53 integrase known in the art. Each possibility represents a separate embodiment of the present invention.
- the integrase gene is any other integrase gene known in the art. Each possibility represents a separate embodiment of the present invention.
- the present invention provides a bacterial vaccine strain constructed by the method of the present invention.
- the antigen-encoding gene is expressed under the control of the Listeria p60 promoter.
- the inlA (encodes internalin) promoter is used.
- the hly promoter is used.
- the ActA promoter is used.
- the integrase gene is expressed under the control of any other gram positive promoter.
- the antigen-encoding gene is expressed under the control of any other promoter that functions in Listeria.
- promoters or polycistronic expression cassettes may be used to drive the expression of the gene. Each possibility represents a separate embodiment of the present invention.
- the LLO protein utilized to construct vaccines of the present invention has, in another embodiment, the sequence:
- a PEST-like AA sequence is fused to the antigen peptide.
- the PEST- like AA sequence has a sequence selected from SEQ ID No: 62-70.
- the PEST-like sequence is any other PEST-like sequence known in the art. Each possibility represents a separate embodiment of the present invention.
- the quality of a PEST motif is refined by means of a scoring parameter based on the local enrichment of critical AA as well as the motifs hydrophobicity.
- Enrichment of D, E, P, S and T is expressed in mass percent (w/w) and corrected for 1 equivalent of D or E, 1 of P and 1 of S or T.
- calculation of hydrophobicity follows in principle the method of J. Kyte and R.F. Doolittle (Kyte, J and Dootlittle, RF. J. MoI. Biol. 157, 105 (1982).
- the antigen is associated with one of the following diseases; cholera, diphtheria, Haemophilus, hepatitis A, hepatitis B, influenza, measles, meningitis, mumps, herpes simplex 1, herpes simplex 2, herpes zoster, Epstein-Barr virus, cytomegalovirus, pertussis, small pox, pneumococcal pneumonia, polio, rabies, rubella, tetanus, tuberculosis, typhoid, Varicella-zoster, whooping cough3 yellow fever, the immunogens and antigens from Addison's disease, allergies, anaphylaxis, Bruton's syndrome, cancer, including solid and blood borne tumors, eczema, Alzheimer's disease, Hashimoto's thyroiditis, polymyositis, dermatomyositis, type 1 diabetes mellitus, acquired
- diseases cholera, dip
- Describing two polynucleotides as "operably linked” means, in another embodiment, that a single-stranded or double-stranded nucleic acid moiety comprises the two polynucleotides arranged within the nucleic acid moiety in such a manner that at least one of the two polynucleotides is able to exert a physiological effect by which it is characterized upon the other.
- a promoter operably linked to the coding region of a gene is able to promote transcription of the coding region.
- metabolic enzyme-containing plasmids are efficacious as a therapeutic cancer vaccine. Because immune responses required for a therapeutic cancer vaccine are stronger than those required for a prophylactic cancer vaccine, these results demonstrate utility as well for a prophylactic cancer vaccine.
- H-2D b tetramers loaded with the E7 peptide (RAHYNIVTF, SEQ ID NO: 18) or a control (HIV-Gag) peptide at a 1 :200 dilution.
- Tetramers were provided by the National Institute of Allergy and Infectious Diseases Tetramer Core Facility and the National Institutes of Health AIDS Research and Reference Reagent Program.
- the hly gene was subcloned from plasmid pDP-906 (Jones, S et al. 1994.
Abstract
The present invention provides Listeria strains that express a heterologous antigen, a metabolic enzyme, and a phage integrase and use of such Listeria strains in methods of inducing an immune response to an antigen of interest.
Description
ANTIBIOTIC RESISTANCE FREE LISTERIA STRAINS AND METHODS FOR CONSTRUCTING AND USING SAME
FIELD OF INVENTION
[001] The present invention provides Listeria strains that express a heterologous antigen, a metabolic enzyme, and a phage integrase and use of such Listeria strains in methods of inducing an immune response to an antigen of interest.
BACKGROUND OF THE INVENTION
[002] Vaccines represent the most beneficial and cost effective public health measure currently known. However, as the understanding of neoplasias and infectious diseases grows, it has become apparent that traditional vaccine strategies may not be completely effective. Traditional vaccines have employed killed or attenuated organisms or antigen subunits in order to elicit immunity in an animal. A limit with these approaches, especially with killed or subunit vaccines, is that the immune response is primarily humoral in nature, and therefore not effective in combating intracellular organism or tumors that require cell mediated immunity for their destruction. Similarly, attenuated or inactivated bacteria often only induce immunization for a short period of time and immunity is limited to a humoral response. Further, traditional attenuated or inactivated bacterial vaccines do not elicit the cytotoxic T-lymphocyte (CTL) immune response necessary for the lysis of tumor cells and cells infected with intracellular pathogens. 3] Viral vaccines are often used to induce a CTL response in a vaccinee. Viral vaccines are usually pathogenic viruses attenuated by serial passage in cell culture or by deletion of one or more known virulence genes or viruses killed through heat or chemical inactivation. Killed viruses are incapable of infecting cells, and thus, like subunit vaccines, primarily elicit a humoral immune response. "Attenuated viruses are capable of infecting cells, and can induce a CTL response in an individual. However, attenuated virus vaccines are not without drawbacks. First, attenuating a virus is often a process of trial and error. Second, there is a serious safety issue in using attenuated viruses, especially in children, the elderly, and the immuno-compromised. A solution to the problems of traditional bacterial and viral vaccines
exists with bacterial vaccine vectors such as Listeria monocytogenes (LM). LM is a beta hemolytic gram positive facultative intracellular microbe.
[004] Three methods are currently used to express a heterologous antigen in Listeria monocytogenes, and include plasmid-based expression systems and chromosome expression systems.
[005] One method of expressing foreign antigen in Listeria is to express the antigen episomally from a plasmid. This method is described in Ikonomidis et al. (1994 J. Exp. Med. 180: 2209 - 2218) and Gunn et al. (2001, J Immunol 167: 6471-6479). This method has the advantage that the gene does not have to be integrated into the chromosome and can be expressed in multiple copies, which may enhance immunogenicity. However, in order to select for plasmid transformants and ensure the retention of the plasmid during propagation in vitro, it is necessary to include two drug resistance genes on the plasmid, one for the construction of the plasmid in E. coli and one for the propagation of the transformed Listeria monocytogenes.
[006] A second method is chromosomal based and is described in Frankel et al. (1995, J. Immunol. 155:4775-4782) and Mata et al. (2001, Vaccine 19: 1435-1445). Briefly, a gene encoding the antigen of interest is placed, along with a suitable promoter and signal sequence, between two regions of DNA homologous to a region of the Listeria chromosome. This homologous recombination allows specific integration of the antigen in the Listeria chromosome. The cassette comprising the antigen and the homologous DNA is ligated into a plasmid with a temperature sensitive origin of replication which renders it incapable of replication at temperatures above 40° C. The plasmid further comprises drug resistance markers for selection and plasmid maintenance purposes. The manipulation and replication of this plasmid usually takes place in E. coli, because of its rapid replication and ease of transformation compared to Listeria. Because Listeria is a gram positive organism and E. coli is a gram negative organism, the drug resistance genes can be specific to each category of organism, or there may be two copies of the same drug resistance gene effective in both types of organism, but under the control of separate gram positive and gram negative promoters. After assembly, the plasmid is transformed into LM by direct conjugation with the E. coli comprising the plasmid, or by lysis and isolation of the plasmid from the E. coli, followed by electroporation of competent LM.
[007] In order to integrate the plasmid into the desired region of the Listeria chromosome, the two-step allelic exchange method of Camilli et al. (1992, MoI. Microbiol. 8:143-157) is followed. Briefly, the Listeria is passaged at greater than 40° C to prevent plasmid replication. Integration of the plasmid into the Listeria chromosome is selected by growth at 40° C in the presence of a selecting drug, e.g. chloramphenicol. After selection of transformants, bacteria are passaged at 30° C and selected for drug sensitivity to screen for Listeria in which excision of extraneous vector sequences has occurred. The disadvantage of this method is that the double allelic exchange method is time consuming and requires the selection of many clones in order to arrive at a suitable vaccine strain.
[008] A third method of producing Listeria strains comprising a heterologous antigen is described by Lauer et al. (2002, J. Bacteriol. 184:4177-4186). This method does not require allelic exchange, but instead requires phage-based integration vectors. This chromosomal integration method utilizes one or two drug resistance genes for selection of integrants, resulting in a Listeria organism comprising resistance to one or more drugs. The disadvantage of the methods of Lauer et al is the presence of drug resistance genes, which are not considered safe because of concern over the spread of antibiotic resistance from the vaccine strain to microorganisms previously susceptible to antibiotic therapy. Therefore, the presence of antibiotic resistance genes in a vaccine vector is considered undesirable from a safety perspective.
[009] Thus, given the demonstrated uses of Listeria as a vaccine vector, methods for constructing Listeria vaccine vectors without antibiotic resistance, yet capable of eliciting a strong immune response, are needed in the field.
SUMMARY OF THE INVENTION
[010] The present invention provides Listeria strains that express a heterologous antigen, a metabolic enzyme, and a phage integrase and use of such Listeria strains in methods of inducing an immune response to an antigen of interest.
[011] In one embodiment, the present invention provides a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein the integrated nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises a protein antigen of interest; (b) a second open reading frame
encoding a metabolic enzyme; and (c) a third open reading frame encoding a Al 18 or U153 integrase gene.
[012] In one embodiment, the nucleic acid molecule does not comprise an antibiotic resistance gene. In another embodiment, the nucleic acid molecule does not contain a replication region that functions in said auxotrophic bacterial strain. In another embodiment, the nucleic acid molecule further comprises a gene encoding a transcription factor. In another embodiment, the recombinant Listeria strain comprises an inactivating mutation in the endogenous gene encoding said transcription factor. In another embodiment, the polypeptide is a fusion protein comprising said protein antigen and an additional polypeptide, wherein said additional peptide enhances the immunogenicity of said protein antigen. In another embodiment, the additional polypeptide is a non-hemolytic LLO protein or fragment thereof, a PEST-like amino acid sequence, or an ActA fragment. In another embodiment, the integrated nucleic acid molecule is a phage integration vector. In another embodiment, the metabolic enzyme is an amino acid metabolism enzyme. In another embodiment, the metabolic enzyme catalyzes a formation of an amino acid used for a cell wall synthesis in said recombinant Listeria strain. In another embodiment, the metabolic enzyme is an alanine racemase enzyme. In another embodiment, the metabolic enzyme is a D-amino acid transferase enzyme. In another embodiment, the recombinant Listeria strain has been passaged through an animal host. In another embodiment, the polypeptide is expressed under the control of a hly promoter, an ActA promoter, or a p60 promoter. Each possibility represents a separate embodiment of the present invention.
[013] In another embodiment, the present invention provides a method of inducing an immune response against a protein antigen of interest in a subject, comprising the step of administering to the subject a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises said protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a third open reading frame encoding a Al 18 or U 153 integrase gene, thereby inducing an immune response against said protein antigen of interest in said subject.
BRIEF DESCRIPTION OF THE DRAWINGS
[014] Figure 1 is a schematic map of E. coli-Listeria shuttle plasmids pGG55 (upper panel) and pTV3 (lower panel). CAT(-): E. coli chloramphenicol transferase; CAT(+): Listeria chloramphenicol transferase; Ori Lm: replication origin for Listeria; Ori Ec: pi 5 origin of replication for E. coli; prfA: Listeria pathogenicity regulating factor A; LLO: C- terminally truncated listeriolysin O, including its promoter; E7: HPV E7; p60-dal; expression cassette of p60 promoter and Listeria dal gene. Selected restriction sites are also depicted.
[015] Figure 2 Plasmid preparation of pTV3 from E. coli strain MB2159. Qiagen® midi- preparation of nucleic acids was following the manufacturer's protocol. Lanes from left to right: Lanes 1 and 7: Molecular Weight Marker, lOOBp ladder (Invitrogen). Lane 2: pTV3, clone #15. Lane 3: pTV3, clone #16. Lane 4: pTV3C, clone #22. Lane 5: pTV3C, clone #24. Lane 6: pGG55 control.
[016] Figure 3 Plasmid maintenance in vitro (A) and in vivo (B). To determine in vitro stability, strains were cultured with (GG55-Chl) and without (GG55-no ChI) chloramphenicol (LM-LLO-E7) or with and without D-alanine [Lmdd(pTV3)] . The cultures were diluted 1 : 1000 daily into fresh LB. The CFU of the cultures were determined daily on
BHI (BHI) and on BHI with chloramphenicol (BHI-ChI) for LM-LLO-E7 or on BHI with
D-alanine (BHI-AIa) for Lmdd(pTV3). All liquid medium and plates contained an additional 50 μg of streptomycin per ml, to which Listeria monocytogenes (LM) strain
10403S is naturally resistant. To determine in vivo plasmid maintenance, LM was injected intraperitoneally at a dose of 1/10 the LD50 in5O C57BL/6 mice. Spleens were harvested at different time points post-injection and homogenized in phosphate-buffered saline (PBS).
CFU counts were prepared on BHI plates with (closed triangles) and without (open triangles) D-alanine for Lmdd(pTV3), on BHI plates with (closed squares) and without
(open squares) chloramphenicol for LM-LLO-E7, and on BHI plates only for wild-type
10403S (stars).
[017] Figure 4 depicts growth on Luria-Bertoni (LB) agar plates of E. coli strain MB2159
(alanine racemace negative) transformed with the pTV3 vector. Bacteria were plated on different media. Upper left: agar alone. MB2159-TV3 is able to grow. Upper right: agar with alanine. MB2159-TV3 is able to grow. Lower left: agar with chloramphenicol.
MB2159-TV3 does not grow because the CAT gene is missing. Lower right: agar with chloramphenicol and alanine. MB2159-TV3 does not grow because the CAT gene is missing.
[018] Figure 5 depicts growth on LB-agar plates of E. coli strain MB2159 without the pTV3 vector. Agar plates are arranged as in Figure 4. Upper left: MB2159 does not grow. Upper right: agar with alanine. MB2159 is able to grow. Lower left: agar with chloramphenicol. MB2159 does not grow. Lower right. MB2159 does not grow.
[019] Figure 6 depicts growth on LB-agar plates of LM strain Lmdd(-) transformed with the pTV3 vector. Bacteria were plated on different media: Top: agar with streptomycin, no added alanine. Lmdd-pTV3 is able to grow (the host strain 10403s is streptomycin resistant). Lower left (agar with chloramphenicol) and lower right (agar with chloramphenicol and alanine): Lmdd-pTV3 does not grow because the CAT gene is not present in pTV3.
[020] Figure 7 depicts growth on LB-agar plates of LM strain Lmdd(-) without the pTV3 vector. Upper left: agar with streptomycin. Lmdd (-) cannot grow in the absence of d- alanine. Upper right: agar with alanine. Lmdd (-) grows. Lower left (agar with chloramphenicol and alanine) and lower right (agar with chloramphenicol): Lmdd(-) is sensitive to chloramphenicol and does not grow.
[021] Figure 8 depicts bacterial growth as measured by optical density (600 nanometers [nm]) plotted vs. time. +AIa: media contains D-alanine; +ChI: media contains chloramphenicol .
[022] Figure 9 depicts 2 separate experiments (top panel and bottom panel) showing tumor regression in response to administration of LM vaccine strains. Circles represent naive mice, inverted triangles represent mice administered Lmdd-TV3, and crosses represent mice administered Lm-LLOE7.
[023] Figure 10 Top of left panel- Plasmid map of pPLl . Chloramphenicol resistance genes and E. coli origin of replication, RP4 origin of transfer, and the U 153 integrase gene and L. monocytogenes p60 promoter are depicted. The multiple cloning site (MCS) is shown at the bottom of the plasmid, with unique restriction sites noted below in a box. pPL24 and pPL25 inserts are shown schematically below the multiple cloning site. Final sizes of the
plasmid constructs and the restriction sites used in cloning are noted for each of the inserts. Bottom of left panel- pPL24 and pPL25. Right panel- Plasmid map of pPL2. The genes are the same as for pPLl, except for the PSA integrase and PSA attPP' sites, as noted. The multiple cloning site with 13 unique restriction sites is shown below the plasmid. Note: the HindIII site, at base pair position 69, indicated as unique in the multiple cloning site (MCS) is not unique. There are two additional HindIII sites in the PSA integrase gene at base pair positions 3244 and 3454 of the pPL2 sequence (GenBank accession no. AJ417449). Hence, there are 12 unique restriction sites in the pPL2 MCS.
[024] Figure 11 A. Map of pTV6. B. Map of pTV7. The U 153 integrase gene and the U 153 attPP' integration site from pPLl are modified by PCR to contain restriction sites at the 5'-end and the 3'-end that are compatible with cloning these nucleic acids into shuttle plasmid pTV3. The Listeria replication region from pTV3 is removed, resulting in plasmid pTV6, containing replication functions for its amplification in E. coli, a dal gene for complementation of dal auxotroph E. coli and Listeria, and integration functions (U 153 integrase, attPP' site) for integration of the plasmid into the Listeria genome. pTV6 also contains a prf A (pathogenicity regulating factor A) gene (A) or is lacking the prfA gene (B).
[025] Figure 12 Map of pTV8. The PSA integrase gene and attPP' integration site from pPL2 are modified by PCR to contain restriction sites at the 5'-end and the 3'-end that are compatible with cloning these nucleic acids into shuttle plasmid pTV3 and the Listeria replication region from pTV3 is removed, resulting in plasmid pTV8, containing replication functions for its amplification in E. coli, a dal gene for complementation of dal auxotroph E. coli and Listeria, and integration functions (PSA integrase, attPP' site) for integration of the plasmid into the Listeria genome. pTV8 also contains a prfA (pathogenicity regulating factor) gene.
[026] Figure 13 Map of pTV9. The PSA integrase gene and attPP' integration site from pPL2 are modified by PCR to contain restriction sites at the 5'-end and the 3'-end that are compatible with cloning these nucleic acids into shuttle plasmid pTV3 and the Listeria replication region from pTV3 is removed, resulting in plasmid pTV9, containing replication functions for its amplification in E. coli, a dal gene for complementation of dal auxotroph E. coli and Listeria, and integration functions (PSA integrase, attPP' site) for integration of the plasmid into the Listeria genome. pTV9 does not comprise a prfA (pathogenicity regulating factor) gene.
[027] Figure 14 Map of pTVIO. The Al 18 integrase gene and attPP' integration site from Al 18 DNA (GenBank Accession No. NC_003216) are modified by PCR to contain restriction sites at the 5'-end and the 3'-end that are compatible with cloning these nucleic acids into shuttle plasmid pTV3 and the Listeria replication region from pTV3 is removed, resulting in plasmid pTVIO, containing replication functions for its amplification in E. coli, a dal gene for complementation of dal auxotroph E. coli and Listeria, and integration functions (Al 18 integrase, attPP' site) for integration of the plasmid into the Listeria genome. pTVIO also comprises a prfA (pathogenicity regulating factor) gene.
[028] Figure 15 Map of pTVl 1. The Al 18 integrase gene and attPP' integration site from Al 18 DNA (GenBank Accession No. NC_003216) are modified by PCR to contain restriction sites at the 5'-end and the 3'-end that are compatible with cloning these nucleic acids into shuttle plasmid pTV3 and the Listeria replication region from pTV3 is removed, resulting in plasmid pTVIO, containing replication functions for its amplification in E. coli, a dal gene for complementation of dal auxotroph E. coli and Listeria, and integration functions (Al 18 integrase, attPP' site) for integration of the plasmid into the Listeria genome. pTVl 1 does not comprise a prfA (pathogenicity regulating factor) gene.
DETAILED DESCRIPTION OF THE INVENTION
[029] The present invention provides Listeria strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.
[030] In one embodiment, the present invention provides a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein the integrated nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises a protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a third open reading frame encoding a A118 or U153 integrase gene.
[031] In one embodiment, the nucleic acid molecule does not comprise an antibiotic resistance gene. In another embodiment, the nucleic acid molecule does not contain a replication region that functions in said auxotrophic bacterial strain. In another embodiment, the nucleic acid molecule further comprises a gene encoding a transcription factor. In another embodiment, the recombinant Listeria strain comprises an inactivating mutation in
the endogenous gene encoding said transcription factor. In another embodiment, the polypeptide is a fusion protein comprising said protein antigen and an additional polypeptide, wherein said additional peptide enhances the immunogenicity of said protein antigen. In another embodiment, the additional polypeptide is a non-hemolytic LLO protein or fragment thereof, a PEST-like amino acid sequence, or an ActA fragment. In another embodiment, the integrated nucleic acid molecule is a phage integration vector. In another embodiment, the metabolic enzyme is an amino acid metabolism enzyme. In another embodiment, the metabolic enzyme catalyzes a formation of an amino acid used for a cell wall synthesis in said recombinant Listeria strain. In another embodiment, the metabolic enzyme is an alanine racemase enzyme. In another embodiment, the metabolic enzyme is a D-amino acid transferase enzyme. In another embodiment, the recombinant Listeria strain has been passaged through an animal host. In another embodiment, the polypeptide is expressed under the control of an hly promoter, an ActA promoter, or a p60 promoter. Each possibility represents a separate embodiment of the present invention.
[032] In another embodiment, the present invention provides a method of inducing an immune response against a protein antigen of interest in a subject, comprising the step of administering to the subject a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises said protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a third open reading frame encoding a Al 18 or Ul 53 integrase gene, thereby inducing an immune response against said protein antigen of interest in said subject.
[033] In one embodiment, the present invention provides a recombinant bacterial strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises a first open reading frame encoding a polypeptide, wherein the polypeptide comprises a protein antigen, and the nucleic acid molecule further comprises a second open reading frame encoding a metabolic enzyme. In another embodiment, the integrated nucleic acid molecule is integrated into the chromosome. In another embodiment, the recombinant bacterial strain is a recombinant Listeria strain. In another embodiment, the strain is a Listeria vaccine strain. In another embodiment, the metabolic enzyme complements an endogenous metabolic gene that is lacking in the remainder of the chromosome of the recombinant bacterial strain. In another embodiment, the nucleic acid molecule is stably
maintained in the recombinant bacterial strain in the absence of an antibiotic selection. Each possibility represents a separate embodiment of the present invention.
[034] In one embodiment, the present invention provides a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein the integrated nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises a protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a Al 18 or U153 attPP' gene.
[035] In one embodiment, the present invention provides a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein the integrated nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises a protein antigen of interest and (b) a second open reading frame encoding a metabolic enzyme, wherein said integrated nucleic acid molecule is a phage integration vector.
[036] In one embodiment, an inactivating mutation is a deletion, substitution, or insertion, as is known in the art.
[037] "Metabolic enzyme" refers, in another embodiment, to an enzyme involved in synthesis of a nutrient required by the host bacteria. In another embodiment, the term refers to an enzyme required for synthesis of a nutrient required by the host bacteria. In another embodiment, the term refers to an enzyme involved in synthesis of a nutrient utilized by the host bacteria. In another embodiment, the term refers to an enzyme involved in synthesis of a nutrient required for sustained growth of the host bacteria. In another embodiment, the enzyme is required for synthesis of the nutrient. Each possibility represents a separate embodiment of the present invention.
[038] In another embodiment, the present invention provides a method of inducing an immune response against a protein antigen of interest in a subject, comprising the step of administering to the subject a recombinant bacterial strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises a first open reading frame encoding a polypeptide, wherein the polypeptide comprises the protein antigen of interest, and the nucleic acid molecule further comprises a second open reading frame encoding a metabolic enzyme, thereby inducing an immune response against a protein
antigen of interest in a subject. In another embodiment, the integrated nucleic acid molecule is integrated into the chromosome. In another embodiment, the recombinant bacterial strain is a recombinant bacterial strain. In another embodiment, the strain is a bacterial vaccine strain. In another embodiment, the metabolic enzyme complements an endogenous metabolic gene that is lacking in the remainder of the chromosome of the recombinant bacterial strain. In another embodiment, the nucleic acid molecule is stably maintained in the recombinant bacterial strain in the absence of an antibiotic selection. Each possibility represents a separate embodiment of the present invention.
[039] In another embodiment, the present invention provides a method of inducing an immune response against a tumor of interest in a subject, comprising the step of administering to the subject a recombinant bacterial strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises a first open reading frame encoding a polypeptide, wherein the polypeptide comprises the protein antigen of interest, whereby said tumor expresses said antigen, and the nucleic acid molecule further comprises a second open reading frame encoding a metabolic enzyme, thereby inducing an immune response against a protein antigen of interest in a subject. In another embodiment, the integrated nucleic acid molecule is integrated into the chromosome. In another embodiment, the recombinant bacterial strain is a recombinant bacterial strain. In another embodiment, the strain is a bacterial vaccine strain. In another embodiment, the metabolic enzyme complements an endogenous metabolic gene that is lacking in the remainder of the chromosome of the recombinant bacterial strain. In another embodiment, the nucleic acid molecule is stably maintained in the recombinant bacterial strain in the absence of an antibiotic selection. Each possibility represents a separate embodiment of the present invention.
[040] In another embodiment, the present invention provides a method of treating a cancer in a subject, comprising the step of administering to the subject a recombinant bacterial strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises a first open reading frame encoding a polypeptide, wherein the polypeptide comprises the protein antigen of interest, the cancer expresses the protein antigen of interest, and the nucleic acid molecule further comprises a second open reading frame encoding a metabolic enzyme, thereby treating a cancer in a subject. In another embodiment, the integrated nucleic acid molecule is integrated into the chromosome. In l l
another embodiment, the recombinant bacterial strain is a recombinant bacterial strain. In another embodiment, the strain is a bacterial vaccine strain. In another embodiment, the metabolic enzyme complements an endogenous metabolic gene that is lacking in the remainder of the chromosome of the recombinant bacterial strain. In another embodiment, the nucleic acid molecule is stably maintained in the recombinant bacterial strain in the absence of an antibiotic selection. Each possibility represents a separate embodiment of the present invention.
[041] In another embodiment, the present invention provides a method of reducing an incidence of a cancer in a subject, comprising the step of administering to the subject a recombinant bacterial strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises a first open reading frame encoding a polypeptide, wherein the polypeptide comprises the protein antigen of interest, the cancer expresses the protein antigen of interest, and the nucleic acid molecule further comprises a second open reading frame encoding a metabolic enzyme, thereby reducing an incidence of a cancer in a subject. In another embodiment, the integrated nucleic acid molecule is integrated into the chromosome. In another embodiment, the recombinant bacterial strain is a recombinant bacterial strain. In another embodiment, the strain is a bacterial vaccine strain. In another embodiment, the metabolic enzyme complements an endogenous metabolic gene that is lacking in the remainder of the chromosome of the recombinant bacterial strain. In another embodiment, the nucleic acid molecule is stably maintained in the recombinant bacterial strain in the absence of an antibiotic selection. Each possibility represents a separate embodiment of the present invention.
[042] In another embodiment, the present invention provides a method of treating an infectious disease in a subject, comprising the step of administering to the subject a recombinant bacterial strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises a first open reading frame encoding a polypeptide, wherein the polypeptide comprises the protein antigen of interest, the infectious disease organism expresses the protein antigen of interest, and the nucleic acid molecule further comprises a second open reading frame encoding a metabolic enzyme, thereby treating an infectious disease in a subject. In another embodiment, the integrated nucleic acid molecule is integrated into the chromosome. In another embodiment, the recombinant bacterial strain is a recombinant bacterial strain. In another embodiment, the strain is a bacterial vaccine
strain. In another embodiment, the metabolic enzyme complements an endogenous metabolic gene that is lacking in the remainder of the chromosome of the recombinant bacterial strain. In another embodiment, the nucleic acid molecule is stably maintained in the recombinant bacterial strain in the absence of an antibiotic selection. Each possibility represents a separate embodiment of the present invention.
[043] In another embodiment, the present invention provides a method of reducing an incidence of an infectious disease in a subject, comprising the step of administering to the subject a recombinant bacterial strain, comprising an integrated nucleic acid molecule, wherein the nucleic acid molecule comprises a first open reading frame encoding a polypeptide, wherein the polypeptide comprises the protein antigen of interest, the infectious disease organism expresses the protein antigen of interest, and the nucleic acid molecule further comprises a second open reading frame encoding a metabolic enzyme, thereby reducing an incidence of an infectious disease in a subject. In another embodiment, the integrated nucleic acid molecule is integrated into the chromosome. In another embodiment, the recombinant bacterial strain is a recombinant bacterial strain. In another embodiment, the strain is a bacterial vaccine strain. In another embodiment, the metabolic enzyme complements an endogenous metabolic gene that is lacking in the remainder of the chromosome of the recombinant bacterial strain. In another embodiment, the nucleic acid molecule is stably maintained in the recombinant bacterial strain in the absence of an antibiotic selection. Each possibility represents a separate embodiment of the present invention.
[044] "Nucleic acid molecule" refers, in another embodiment, to a plasmid. In another embodiment, the term refers to an integration vector. In another embodiment, the term refers to a plasmid comprising an integration vector. In another embodiment, the integration vector is a site-specific integration vector. In another embodiment, a nucleic acid molecule of methods and compositions of the present invention can be composed of any type of nucleotide known in the art. Each possibility represents a separate embodiment of the present invention. Each possibility represents a separate embodiment of the present invention.
[045] In another embodiment of the present invention, "nucleic acids" or "nucleotide" refers to a string of at least two base-sugar-phosphate combinations. The term includes, in one embodiment, DNA and RNA. "Nucleotides" refers, in one embodiment, to the
monomelic units of nucleic acid polymers. RNA may be, in one embodiment, in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), mRNA (messenger RNA), anti-sense RNA, small inhibitory RNA (siRNA), micro RNA (miRNA) and ribozymes. The use of siRNA and miRNA has been described (Caudy AA et al, Genes & Devel 16: 2491-96 and references cited therein). DNA may be in form of plasmid DNA, viral DNA, linear DNA, or chromosomal DNA or derivatives of these groups. In addition, these forms of DNA and RNA may be single, double, triple, or quadruple stranded. The term also includes, in another embodiment, artificial nucleic acids that may contain other types of backbones but the same bases. In one embodiment, the artificial nucleic acid is a PNA (peptide nucleic acid). PNA contain peptide backbones and nucleotide bases and are able to bind, in one embodiment, to both DNA and RNA molecules. In another embodiment, the nucleotide is oxetane modified. In another embodiment, the nucleotide is modified by replacement of one or more phosphodiester bonds with a phosphorothioate bond. In another embodiment, the artificial nucleic acid contains any other variant of the phosphate backbone of native nucleic acids known in the art. The use of phosphothiorate nucleic acids and PNA are known to those skilled in the art, and are described in, for example, Neilsen PE, Curr Opin Struct Biol 9:353-57; and Raz NK et al Biochem Biophys Res Commun. 297:1075-84. The production and use of nucleic acids is known to those skilled in art and is described, for example, in Molecular Cloning, (2001), Sambrook and Russell, eds. and Methods in Enzymology: Methods for molecular cloning in eukaryotic cells (2003) Purchio and G. C. Fareed. Each nucleic acid derivative represents a separate embodiment of the present invention.
[046] "Stably maintained" refers, in another embodiment, to maintenance of a nucleic acid molecule or plasmid in the absence of selection (e.g. antibiotic selection) for 10 generations, without detectable loss. In another embodiment, the period is 15 generations. In another embodiment, the period is 20 generations. In another embodiment, the period is 25 generations. In another embodiment, the period is 30 generations. In another embodiment, the period is 40 generations. In another embodiment, the period is 50 generations. In another embodiment, the period is 60 generations. In another embodiment, the period is 80 generations. In another embodiment, the period is 100 generations. In another embodiment, the period is 150 generations. In another embodiment, the period is 200 generations. In another embodiment, the period is 300 generations. In another embodiment, the period is 500 generations. In another embodiment, the period is more than
generations. In another embodiment, the nucleic acid molecule or plasmid is maintained stably in vitro (e.g. in culture). In another embodiment, the nucleic acid molecule or plasmid is maintained stably in vivo. In another embodiment, the nucleic acid molecule or plasmid is maintained stably both in vitro and in vitro. Each possibility represents a separate embodiment of the present invention.
[047] In another embodiment, the present invention provides a method of engineering an auxotrophic bacterial strain to express a heterologous antigen, the method comprising the step of contacting the auxotrophic bacterial strain with a nucleic acid molecule, the nucleic acid construct comprising a first nucleic acid sequence encoding a polypeptide that comprises the heterologous antigen, and the nucleic acid construct further comprising a second nucleic acid sequence encoding a metabolic enzyme, thereby engineering an auxotrophic bacterial strain to express a heterologous antigen. In another embodiment, the integrated nucleic acid molecule is integrated into the chromosome. In another embodiment, the recombinant bacterial strain is a recombinant Listeria strain. In another embodiment, the strain is a Listeria vaccine strain. In another embodiment, the metabolic enzyme complements an endogenous metabolic gene that is lacking in the remainder of the chromosome of the recombinant bacterial strain. In another embodiment, the nucleic acid molecule is stably maintained in the recombinant bacterial strain in the absence of an antibiotic selection. Each possibility represents a separate embodiment of the present invention.
[048] In another embodiment, the present invention provides a method of engineering a Listeria vaccine strain to express a heterologous antigen, the method comprising contacting an auxotrophic Listeria strain with a plasmid, the plasmid comprising a first nucleic acid sequence encoding a polypeptide that comprises the heterologous antigen, and the plasmid further comprising a second nucleic acid sequence encoding a metabolic enzyme, whereby the auxotrophic Listeria strain takes up the plasmid, and whereby the metabolic enzyme complements a metabolic deficiency of the auxotrophic Listeria strain, thereby engineering a Listeria vaccine strain to express a heterologous antigen.
[049] In another embodiment, the present invention provides a method of engineering a Listeria vaccine strain to express a heterologous antigen, the method comprising transforming an auxotrophic Listeria strain with a plasmid comprising a first nucleic acid encoding the heterologous antigen and a second nucleic acid encoding a metabolic enzyme,
whereby the metabolic enzyme complements a metabolic deficiency of the auxotrophic Listeria strain, thereby engineering a Listeria vaccine strain to express a heterologous antigen.
[050] "Transforming," in one embodiment, is used identically with the term "transfecting," and refers to engineering a bacterial cell to take up a plasmid or other heterologous DNA molecule. In another embodiment, "transforming" refers to engineering a bacterial cell to express a gene of a plasmid or other heterologous DNA molecule. Each possibility represents a separate embodiment of the present invention.
[051] In another embodiment, conjugation is used to introduce genetic material and/or plasmids into bacteria. Methods for conjugation are well known in the art, and are described, for example, in Nikodinovic J et al (A second generation snp-derived Escherichia coli-Streptomyces shuttle expression vector that is generally transferable by conjugation.
Plasmid. 2006 Nov;56(3):223-7) and Auchtung JM et al (Regulation of a Bacillus subtilis mobile genetic element by intercellular signaling and the global DNA damage response. Proc Natl Acad Sci U S A. 2005 Aug 30; 102(35): 12554-9). Each method represents a separate embodiment of the present invention.
[052] In another embodiment, the plasmid or nucleic acid molecule of methods and compositions of the present invention further comprises a gene encoding a transcription factor. In another embodiment, the transcription factor is lacking in the auxotrophic Listeria strain or in the bacteria chromosome of a Listeria strain of the present invention. In one embodiment, the transcription factor is prfA (Examples herein). In another embodiment, the transcription factor is any other transcription factor known in the art. Each possibility represents a separate embodiment of the present invention.
[053] In one embodiment, the metabolic gene, transcription factor-encoding gene, etc. is lacking in a chromosome of the bacterial strain. In another embodiment, the metabolic gene, transcription factor, etc. is lacking in the chromosome and in any episomal genetic elements of the bacterial strain. In another embodiment, the metabolic gene, transcription factor, etc. is lacking in the genome of the bacterial strain.
[054] In one embodiment, the gene encoding a transcription factor is mutated in the chromosome. In another embodiment, the gene is deleted from the chromosome. Each possibility represents a separate embodiment of the present invention.
[055] In one embodiment, the transcription factor is mutated in the chromosome. In another embodiment, the transcription factor is deleted from the chromosome. Each possibility represents a separate embodiment of the present invention.
[056] In another embodiment, the integration vector or plasmid of methods and compositions of the present invention does not confer antibiotic resistance to the Listeria vaccine strain. In another embodiment, the integration vector or plasmid does not contain an antibiotic resistance gene. Each possibility represents a separate embodiment of the present invention.
[057] In another embodiment, the first nucleic acid sequence of methods and compositions of the present invention is operably linked to a promoter/regulatory sequence. In another embodiment, the second nucleic acid sequence is operably linked to a promoter/regulatory sequence. In another embodiment, each of the nucleic acid sequences is operably linked to a promoter/regulatory sequence. Each possibility represents a separate embodiment of the present invention.
[058] In another embodiment, the promoter/regulatory sequence of the second nucleic acid sequence functions in E. coli, thereby enabling stable maintenance of the plasmid or nucleic acid molecule in the E. coli strain. In another embodiment, the second nucleic acid sequence is expressed in an E. coli strain upon transfecting the E. coli strain with a plasmid or nucleic acid molecule of the present invention, thereby enabling stable maintenance thereof in the E. coli strain.
[059] Methods for introducing a prophage into LM are well known in the art. In another embodiment, conjugation is utilized. In another embodiment, electroporation is utilized. In another embodiment, any other method known in the art is utilized. Each possibility represents a separate embodiment of the present invention.
[060] In another embodiment, the present invention provides a Listeria vaccine strain, comprising a plasmid, wherein the plasmid comprises a first nucleic acid sequence encoding a polypeptide, wherein the polypeptide comprises a protein antigen, and the plasmid further
comprises a second nucleic acid sequence encoding a metabolic enzyme, whereby the metabolic enzyme complements an endogenous metabolic gene that is lacking in a chromosome of the Listeria vaccine strain, and whereby the plasmid is stably maintained in the Listeria vaccine strain in the absence of an antibiotic selection.
[061] In one embodiment, the endogenous metabolic gene is mutated in the chromosome. In another embodiment, the endogenous metabolic gene is deleted from the chromosome. Each possibility represents a separate embodiment of the present invention.
[062] In another embodiment, the present invention provides a method of engineering a Listeria vaccine strain to express a heterologous antigen, the method comprising contacting an auxotrophic Listeria strain with a nucleic acid construct, the nucleic acid construct comprising a first nucleic acid sequence encoding a polypeptide that comprises the heterologous antigen, and the nucleic acid construct further comprising a second nucleic acid sequence encoding a metabolic enzyme, whereby the nucleic acid construct is incorporated into a genome of the auxotrophic Listeria strain, and whereby the metabolic enzyme complements a metabolic deficiency of the auxotrophic Listeria strain, thereby engineering a Listeria vaccine strain to express a heterologous antigen.
[063] In one embodiment, the nucleic acid construct lacks a Listeria replication region. In another embodiment, only Listeria that contain a copy of the nucleic acid construct that is integrated into the genome are selected upon growth in LB media. In another embodiment, the nucleic acid construct contains a Listeria replication region. Each possibility represents a separate embodiment of the present invention.
[064] In one embodiment, the nucleic acid construct contains an integration site. In one embodiment, the site is a PSA (phage from Scott A) attPP1 integration site. PSA is, in another embodiment, the prophage of L. monocytogenes strain ScottA (Loessner, M. J., I. B. Krause, T. Henle, and S. Scherer. 1994. Structural proteins and DNA characteristics of 14 Listeria typing bacteriophages. J. Gen. Virol. 75:701-710), a serotype 4b strain that was isolated during an epidemic of human listeriosis. In another embodiment, the site is any another integration site known in the art. Each possibility represents a separate embodiment of the present invention.
[065] In another embodiment, the nucleic acid construct contains an integrase gene. In another embodiment, the integrase gene is a PSA integrase gene. In another embodiment, the integrase gene is any other integrase gene known in the art. Each possibility represents a separate embodiment of the present invention.
[066] In one embodiment, the nucleic acid construct is a plasmid. In another embodiment, the nucleic acid construct is a shuttle plasmid. In another embodiment, the nucleic acid construct is an integration vector. In another embodiment, the nucleic acid construct is a site-specific integration vector. In another embodiment, the nucleic acid construct is any other type of nucleic acid construct known in the art. Each possibility represents a separate embodiment of the present invention.
[067] The integration vector of methods and compositions of the present invention is, in another embodiment, a phage vector. In another embodiment, the integration vector is a site- specific integration vector. In another embodiment, the vector further comprises an integrase gene. In another embodiment, the vector further comprises an attPP' site. Each possibility represents a separate embodiment of the present invention.
[068] In another embodiment, the integration vector is a U 153 vector. In another embodiment, the integration vector is an Al 18 vector. In another embodiment, the integration vector is a PSA vector.
[069] In another embodiment, the vector is an A51 1 vector (e.g. GenBank Accession No: X91069). In another embodiment, the vector is an A006 vector. In another embodiment, the vector is a B545 vector. In another embodiment, the vector is a B053 vector. In another embodiment, the vector is an A020 vector. In another embodiment, the vector is an A500 vector (e.g. GenBank Accession No: X85009). In another embodiment, the vector is a B051 vector. In another embodiment, the vector is a B052 vector. In another embodiment, the vector is a B054 vector. In another embodiment, the vector is a B055 vector. In another embodiment, the vector is a B056 vector. In another embodiment, the vector is a BlOl vector. In another embodiment, the vector is a BI lO vector. In another embodiment, the vector is a B i ll vector. In another embodiment, the vector is an Al 53 vector. In another embodiment, the vector is a D441 vector. In another embodiment, the vector is an A538 vector. In another embodiment, the vector is a B653 vector. In another embodiment, the vector is an A513 vector. In another embodiment, the vector is an A507 vector. In another
embodiment, the vector is an A502 vector. In another embodiment, the vector is an A505 vector. In another embodiment, the vector is an A519 vector. In another embodiment, the vector is a B604 vector. In another embodiment, the vector is a C703 vector. In another embodiment, the vector is a B025 vector. In another embodiment, the vector is an A528 vector. In another embodiment, the vector is a B024 vector. In another embodiment, the vector is a BOl 2 vector. In another embodiment, the vector is a B035 vector. In another embodiment, the vector is a C707 vector.
[070] In another embodiment, the vector is an A005 vector. In another embodiment, the vector is an A620 vector. In another embodiment, the vector is an A640 vector. In another embodiment, the vector is a B021 vector. In another embodiment, the vector is an HSO47 vector. In another embodiment, the vector is an HlOG vector. In another embodiment, the vector is an H8/73 vector. In another embodiment, the vector is an Hl 9 vector. In another embodiment, the vector is an H21 vector. In another embodiment, the vector is an H43 vector. In another embodiment, the vector is an H46 vector. In another embodiment, the vector is an H107 vector. In another embodiment, the vector is an H108 vector. In another embodiment, the vector is an HI lO vector. In another embodiment, the vector is an H163/84 vector. In another embodiment, the vector is an H312 vector. In another embodiment, the vector is an H340 vector. In another embodiment, the vector is an H387 vector. In another embodiment, the vector is an H391/73 vector. In another embodiment, the vector is an H684/74 vector. In another embodiment, the vector is an H924A vector. In another embodiment, the vector is an fMLUP5 vector. In another embodiment, the vector is a syn (=P35) vector. In another embodiment, the vector is a 00241 vector. In another embodiment, the vector is a 0061 1 vector. In another embodiment, the vector is a 0297 IA vector. In another embodiment, the vector is a 02971C vector. In another embodiment, the vector is a 51 Al 6 vector. In another embodiment, the vector is a 5/91 1 vector. In another embodiment, the vector is a 5/939 vector. In another embodiment, the vector is a 5/1 1302 vector. In another embodiment, the vector is a 5/1 1605 vector. In another embodiment, the vector is a 5/1 1704 vector. In another embodiment, the vector is a 184 vector. In another embodiment, the vector is a 575 vector. In another embodiment, the vector is a 633 vector. In another embodiment, the vector is a 699/694 vector. In another embodiment, the vector is a 744 vector. In another embodiment, the vector is a 900 vector. In another embodiment, the
vector is a 1090 vector. In another embodiment, the vector is a 1317 vector. In another embodiment, the vector is a 1444 vector. In another embodiment, the vector is a 1652 vector. In another embodiment, the vector is a 1806 vector. In another embodiment, the vector is a 1807 vector. In another embodiment, the vector is a 1921/959 vector. In another embodiment, the vector is a 1921/11367 vector. In another embodiment, the vector is a 1921/11500 vector. In another embodiment, the vector is a 1921/11566 vector. In another embodiment, the vector is a 1921/12460 vector. In another embodiment, the vector is a 1921/12582 vector. In another embodiment, the vector is a 1967 vector. In another embodiment, the vector is a 2389 vector. In another embodiment, the vector is a 2425 vector. In another embodiment, the vector is a 2671 vector. In another embodiment, the vector is a 2685 vector. In another embodiment, the vector is a 3274 vector. In another embodiment, the vector is a 3550 vector. In another embodiment, the vector is a 3551 vector. In another embodiment, the vector is a 3552 vector. In another embodiment, the vector is a 4276 vector. In another embodiment, the vector is a 4277 vector. In another embodiment, the vector is a 4292 vector. In another embodiment, the vector is a 4477 vector. In another embodiment, the vector is a 5337 vector. In another embodiment, the vector is a 5348/11363 vector. In another embodiment, the vector is a 5348/11646 vector. In another embodiment, the vector is a 5348/12430 vector. In another embodiment, the vector is a 5348/12434 vector. In another embodiment, the vector is a 10072 vector. In another embodiment, the vector is a 11355C vector. In another embodiment, the vector is a 1 171 IA vector. In another embodiment, the vector is a 12029 vector. In another embodiment, the vector is a 12981 vector. In another embodiment, the vector is a 13441 vector. In another embodiment, the vector is a 90666 vector. In another embodiment, the vector is a 90816 vector. In another embodiment, the vector is a 93253 vector. In another embodiment, the vector is a 907515 vector. In another embodiment, the vector is a 910716 vector. In another embodiment, the vector is a NN-Listeria vector. In another embodiment, the vector is a 01761 vector. In another embodiment, the vector is a 421 1 vector. In another embodiment, the vector is a 4286 vector.
[071] In another embodiment, the integration vector is any other site-specific integration vector known in the art that is capable of infecting Listeria. Each possibility represents a separate embodiment of the present invention.
[072] The metabolic enzyme of methods and compositions of the present invention is, in another embodiment, an amino acid metabolism enzyme. In another embodiment, the metabolic enzyme is an alanine racemase (dal) enzyme. In another embodiment, the metabolic enzyme is a D-amino acid transferase enzyme (dat). The LM dal and dat genes were cloned and isolated from LM as described in Thompson et al (Infec Immun 66: 3552- 3561, 1998).
[073] In another embodiment, the metabolic enzyme metabolizes an amino acid (AA) that is used for a bacterial growth process. In another embodiment, the product AA is used for a replication process. In another embodiment, the product AA is used for cell wall synthesis. In another embodiment, the product AA is used for protein synthesis. In another embodiment, the product AA is used for metabolism of a fatty acid. In another embodiment, the product AA is used for any other growth or replication process known in the art. Each possibility represents a separate embodiment of the present invention.
[074] In another embodiment, the metabolic enzyme catalyzes the formation of an AA used in cell wall synthesis. In another embodiment, the metabolic enzyme catalyzes synthesis of an AA used in cell wall synthesis. In another embodiment, the metabolic enzyme is involved in synthesis of an AA used in cell wall synthesis. In another embodiment, the AA is used in cell wall biogenesis. Each possibility represents a separate embodiment of the present invention.
[075] In another embodiment, the metabolic enzyme is a synthetic enzyme for D-glutamic acid, a cell wall component.
[076] In another embodiment, the metabolic enzyme is encoded by an alanine racemase gene (dal) gene. D-glutamic acid synthesis is controlled in part by the dal gene, which is involved in the conversion of D-glu + pyr to alpha-ketoglutarate + D-ala, and the reverse reaction.
[077] The dal gene of methods and compositions of the present invention is encoded, in another embodiment, by the sequence:
[078] atggtgacaggctggcatcgtccaacatggattgaaatagaccgcgcagcaattcgcgaaaatataaaaaatgaacaaa ataaactcccggaaagtgtcgacttatgggcagtagtcaaagctaatgcatatggtcacggaattatcgaagttgctaggacggcgaa agaagctggagcaaaaggtttctgcgtagccattttagatgaggcactggctcttagagaagctggatttcaagatgactttattcttgt
gcttggtgcaaccagaaaagaagatgctaatctggcagccaaaaaccacatttcacttactgtttttagagaagattggctagagaatc taacgctagaagcaacacttcgaattcatttaaaagtagatagcggtatggggcgtctcggtattcgtacgactgaagaagcacggcg aattgaagcaaccagtactaatgatcaccaattacaactggaaggtatttacacgcattttgcaacagccgaccagctagaaactagtt attttgaacaacaattagctaagttccaaacgattttaacgagtttaaaaaaacgaccaacttatgttcatacagccaattcagctgcttca ttgttacagccacaaatcgggtttgatgcgattcgctttggtatttcgatgtatggattaactccctccacagaaatcaaaactagcttgcc gtttgagcttaaacctgcacttgcactctataccgagatggttcatgtgaaagaacttgcaccaggcgatagcgttagctacggagcaa cttatacagcaacagagcgagaatgggttgcgacattaccaattggctatgcggatggattgattcgtcattacagtggtttccatgtttt agtagacggtgaaccagctccaatcattggtcgagtttgtatggatcaaaccatcataaaactaccacgtgaatttcaaactggttcaaa agtaacgataattggcaaagatcatggtaacacggtaacagcagatgatgccgctcaatatttagatacaattaattatgaggtaacttg tttgttaaatgagcgcatacctagaaaatacatccattag (SEQ ID No: 50; GenBank Accession No: AF038438). In another embodiment, the nucleotide encoding dal is homologous to SEQ ID No: 50. In another embodiment, the nucleotide encoding dal is a variant of SEQ ID No: 50. In another embodiment, the nucleotide encoding dal is a fragment of SEQ ID No: 50. In another embodiment, the dal protein is encoded by any other dal gene known in the art. Each possibility represents a separate embodiment of the present invention.
[079] In another embodiment, the dal protein has the sequence:
[080] MVTGWHRPTWIEIDRAAIRENIKNEQNKLPESVDLWAVVKANAYGHGIIEV ARTAKEAGAKGFCVAILDEALALREAGFQDDFILVLGATRKEDANLAAKNHISLTV FREDWLENLTLEATLRIHLKVDSGMGRLGIRTTEEARRIEATSTNDHQLQLEGIYTH FATADQLETSYFEQQLAKFQTILTSLKKRPTYVHTANSAASLLQPQIGFDAIRFGISM YGLTPSTEIKTSLPFΈLKPALALYTEMVHVKELAPGDSVSYGATYTATEREWVATLP IGYADGLIRHYSGFHVLVDGEPAPIIGRVCMDQTIIKLPREFQTGSKVTIIGKDHGNT
VTADDAAQYLDTINYEVTCLLNERIPRKYIH (SEQ ID NO: 51 ; GenBank Accession No: AF038438). In another embodiment, the dal protein is homologous to SEQ ID No: 51. In another embodiment, the dal protein is a variant of SEQ ID No: 51. In another embodiment, the dal protein is an isomer of SEQ ID No: 51. In another embodiment, the dal protein is a fragment of SEQ ID No: 51. In another embodiment, the dal protein is a fragment of a homologue of SEQ ED No: 51. In another embodiment, the dal protein is a fragment of a variant of SEQ ID No: 51. In another embodiment, the dal protein is a fragment of an isomer of SEQ ID No: 51.
[081] In another embodiment, the dal protein any other Listeria dal protein known in the art. In another embodiment, the dal protein any other gram-positive dal protein known in the
art. In another embodiment, the dal protein any other dal protein known in the art. Each possibility represents a separate embodiment of the present invention.
[082] "Gram positive" and "gram positive bacteria" refer, in another embodiment, to any gram positive bacteria known in the art. In another embodiment, the gram positive bacterium is a Bacillus subtilis bacterium. In another embodiment, the gram positive bacterium is an Escherichia coli bacterium. In another embodiment, the gram positive bacterium is a Streptomyces bacterium. In another embodiment, the gram positive bacterium is a Staphylococcus (e.g. Staphylococcus aureus and Staphylococcus epidermidis) bacterium. In another embodiment, the gram positive bacterium is an Enterococcus (e.g. Enterococcus faecalis) bacterium. In another embodiment, the gram positive bacterium is a S. agalactiae bacterium. In another embodiment, the gram positive bacterium is a S. pneumoniae bacterium. In another embodiment, the gram positive bacterium is an L. lactis bacterium. In another embodiment, the gram positive bacterium is a B. thuringiensis bacterium. In another embodiment, the gram positive bacterium is any other gram positive bacterium known in the art. Each possibility represents a separate embodiment of the present invention.
[083] In another embodiment, the dal protein of methods and compositions of the present invention retains its enzymatic activity. In another embodiment, the dal protein retains 90% of wild-type activity. In another embodiment, the dal protein retains 80% of wild-type activity. In another embodiment, the dal protein retains 70% of wild-type activity. In another embodiment, the dal protein retains 60% of wild-type activity. In another embodiment, the dal protein retains 50% of wild-type activity. In another embodiment, the dal protein retains 40% of wild-type activity. In another embodiment, the dal protein retains 30% of wild-type activity. In another embodiment, the dal protein retains 20% of wild-type activity. In another embodiment, the dal protein retains 10% of wild-type activity. In another embodiment, the dal protein retains 5% of wild-type activity. Each possibility represents a separate embodiment of the present invention.
[084] In another embodiment, the metabolic enzyme is encoded by a D-amino acid aminotransferase gene (dat). D-glutamic acid synthesis is controlled in part by the dat gene, which is involved in the conversion of D-glu + pyr to alpha-ketoglutarate + D-ala, and the reverse reaction.
[085] In another embodiment, a dat gene utilized in the present invention has the sequence set forth in GenBank Accession Number AF038439. In another embodiment, the dat gene is any another dat gene known in the art. Each possibility represents a separate embodiment of the present invention.
[086] The dat gene of methods and compositions of the present invention is encoded, in another embodiment, by the sequence:
[087] atgaaagtattagtaaataaccatttagttgaaagagaagatgccacagttgacattgaagaccgcggatatcagtttggtg atggtgtatatgaagtagttcgtctatataatggaaaattctttacttataatgaacacattgatcgcttatatgctagtgcagcaaaaattg acttagttattccttattccaaagaagagctacgtgaattacttgaaaaattagttgccgaaaataatatcaatacagggaatgtctatttac aagtgactcgtggtgttcaaaacccacgtaatcatgtaatccctgatgatttccctctagaaggcgttttaacagcagcagctcgtgaag tacctagaaacgagcgtcaattcgttgaaggtggaacggcgattacagaagaagatgtgcgctggttacgctgtgatattaagagctt aaaccttttaggaaatattctagcaaaaaataaagcacatcaacaaaatgctttggaagctattttacatcgcggggaacaagtaacag aatgttctgcttcaaacgtttctattattaaagatggtgtattatggacgcatgcggcagataacttaatcttaaatggtatcactcgtcaag ttatcattgatgttgcgaaaaagaatggcattcctgttaaagaagcggatttcactttaacagaccttcgtgaagcggatgaagtgttcat ttcaagtacaactattgaaattacacctattacgcatattgacggagttcaagtagctgacggaaaacgtggaccaattacagcgcaac ttcatcaatattttgtagaagaaatcactcgtgcatgtggcgaattagagtttgcaaaataa (SEQ ID No: 52; GenBank Accession No: AF038439). In another embodiment, the nucleotide encoding dat is homologous to SEQ ID No: 52. In another embodiment, the nucleotide encoding dat is a variant of SEQ ID No: 52. In another embodiment, the nucleotide encoding dat is a fragment of SEQ ID No: 52. In another embodiment, the dat protein is encoded by any other dat gene known in the art. Each possibility represents a separate embodiment of the present invention.
[088] In another embodiment, the dat protein has the sequence:
[089] MKVLVNNHLVEREDATVDIEDRGYQFGDGVYEVVRLYNGKFFTYNEHIDR LYASAAKIDLVIPYSKEELRELLEKLVAENNINTGNVYLQVTRGVQNPRNHVIPDDF
PLEGVLTAAAREVPRNERQFVEGGTAITEEDVRWLRCDIKSLNLLGNILAKNKAHQ
QNALEAILHRGEQVTECSASNVSΠKDGVLWTHAADNLILNGΓΓRQVIIDVAKKNGIP
VKEADFTLTDLREADEVFISSTTEITPITHIDGVQVADGKRGPITAQLHQYFVEEITR ACGELEFAK (SEQ ID No: 53; GenBank Accession No: AF038439). In another embodiment, the dat protein is homologous to SEQ ID No: 53. In another embodiment, the dat protein is a variant of SEQ ID No: 53. In another embodiment, the dat protein is an
isomer of SEQ ID No: 53. In another embodiment, the dat protein is a fragment of SEQ ID No: 53. In another embodiment, the dat protein is a fragment of a homologue of SEQ ID No: 53. In another embodiment, the dat protein is a fragment of a variant of SEQ ID No: 53. In another embodiment, the dat protein is a fragment of an isomer of SEQ ID No: 53.
[090] In another embodiment, the dat protein any other Listeria dat protein known in the art. In another embodiment, the dat protein any other gram-positive dat protein known in the art. In another embodiment, the dat protein any other dat protein known in the art. Each possibility represents a separate embodiment of the present invention.
[091] In another embodiment, the dat protein of methods and compositions of the present invention retains its enzymatic activity. In another embodiment, the dat protein retains 90% of wild-type activity. In another embodiment, the dat protein retains 80% of wild-type activity. In another embodiment, the dat protein retains 70% of wild-type activity. In another embodiment, the dat protein retains 60% of wild-type activity. In another embodiment, the dat protein retains 50% of wild-type activity. In another embodiment, the dat protein retains 40% of wild-type activity. In another embodiment, the dat protein retains 30% of wild-type activity. In another embodiment, the dat protein retains 20% of wild-type activity. In another embodiment, the dat protein retains 10% of wild-type activity. In another embodiment, the dat protein retains 5% of wild-type activity. Each possibility represents a separate embodiment of the present invention.
[092] In another embodiment, the metabolic enzyme is encoded by dga. D-glutamic acid synthesis is also controlled in part by the dga gene, and an auxotrophic mutant for D- glutamic acid synthesis will not grow in the absence of D-glutamic acid (Pucci et al, 1995, J Bacteriol. 177: 336-342). A further example includes a gene involved in the synthesis of diaminopimelic acid. Such synthesis genes encode beta-semialdehyde dehydrogenase, and when inactivated, renders a mutant auxotrophic for this synthesis pathway (Sizemore et al, 1995, Science 270: 299-302). In another embodiment, the dga protein any other Listeria dga protein known in the art. In another embodiment, the dga protein any other gram-positive dga protein known in the art. Each possibility represents a separate embodiment of the present invention.
[093] In another embodiment, the metabolic enzyme is encoded by an air (alanine racemase) gene. In another embodiment, the metabolic enzyme is any other enzyme known
in the art that is involved in alanine synthesis. In another embodiment, the metabolic enzyme is any other enzyme known in the art that is involved in L-alanine synthesis. In another embodiment, the metabolic enzyme is any other enzyme known in the art that is involved in D-alanine synthesis. Bacteria auxotrophic for alanine synthesis are well known in the art, and are described in, for example, E. coli (Strych et al, 2002, J. Bacteriol. 184:4321-4325), Corynebacterium glutamicum (Tauch et al, 2002, J. Biotechnol 99:79-91), and Listeria monocytogenes (Frankel et al, U.S. Patent 6,099,848)), Lactococcus species, and Lactobacillus species, (Bron et al, 2002, Appl Environ Microbiol, 68: 5663-70). In another embodiment, any D-alanine synthesis gene known in the art is inactivated. Each possibility represents a separate embodiment of the present invention.
[094] In another embodiment, the metabolic enzyme is an amino acid aminotransferase.
[095] In another embodiment, the metabolic enzyme is encoded by serC, a phosphoserine aminotransferase. In another embodiment, the metabolic enzyme is encoded by asd (aspartate beta-semialdehyde dehydrogenase), involved in synthesis of the cell wall constituent diaminopimelic acid. In another embodiment, the metabolic enzyme is encoded by gsaB- glutamate-1-semialdehyde aminotransferase, which catalyzes the formation of 5- aminolevulinate from (S)-4-amino-5-oxopentanoate. In another embodiment, the metabolic enzyme is encoded by HemL, which catalyzes the formation of 5-aminolevulinate from (S)- 4-amino-5-oxopentanoate. In another embodiment, the metabolic enzyme is encoded by aspB, an aspartate aminotransferase that catalyzes the formation of oxalozcetate and L- glutamate from L-aspartate and 2-oxoglutarate. In another embodiment, the metabolic enzyme is encoded by argF-1, involved in arginine biosynthesis. In another embodiment, the metabolic enzyme is encoded by aroE, involved in amino acid biosynthesis. In another embodiment, the metabolic enzyme is encoded by aroB, involved in 3-dehydroquinate biosynthesis. In another embodiment, the metabolic enzyme is encoded by aroD, involved in amino acid biosynthesis. In another embodiment, the metabolic enzyme is encoded by aroC, involved in amino acid biosynthesis. In another embodiment, the metabolic enzyme is encoded by hisB, involved in histidine biosynthesis. In another embodiment, the metabolic enzyme is encoded by hisD, involved in histidine biosynthesis. In another embodiment, the metabolic enzyme is encoded by hisG, involved in histidine biosynthesis. In another embodiment, the metabolic enzyme is encoded by metX, involved in methionine biosynthesis. In another embodiment, the metabolic enzyme is encoded by proB, involved in
proline biosynthesis. In another embodiment, the metabolic enzyme is encoded by argR, involved in arginine biosynthesis. In another embodiment, the metabolic enzyme is encoded by argj, involved in arginine biosynthesis. In another embodiment, the metabolic enzyme is encoded by thil, involved in thiamine biosynthesis. In another embodiment, the metabolic enzyme is encoded by LMOf2365_1652, involved in tryptophan biosynthesis. In another embodiment, the metabolic enzyme is encoded by aroA, involved in tryptophan biosynthesis. In another embodiment, the metabolic enzyme is encoded by ilvD, involved in valine and isoleucine biosynthesis. In another embodiment, the metabolic enzyme is encoded by ilvC, involved in valine and isoleucine biosynthesis. In another embodiment, the metabolic enzyme is encoded by leuA, involved in leucine biosynthesis. In another embodiment, the metabolic enzyme is encoded by dapF, involved in lysine biosynthesis. In another embodiment, the metabolic enzyme is encoded by thrB, involved in threonine biosynthesis (all GenBank Accession No. NC_002973).
[096] In another embodiment, the metabolic enzyme is a tRNA synthetase. In another embodiment, the metabolic enzyme is encoded by the trpS gene, encoding tryptophanyltRNA synthetase. In another embodiment, the metabolic enzyme is any other tRNA synthetase known in the art. Each possibility represents a separate embodiment of the present invention.
[097] In another embodiment, the host strain bacteria is Δ(trpS aroA), and both markers are contained in the integration vector.
[098] In another embodiment, the metabolic enzyme is encoded by murE, involved in synthesis of diaminopimelic acid (GenBank Accession No: NC_003485).
[099] In another embodiment, the metabolic enzyme is encoded by LMOf2365_2494, involved in teichoic acid biosynthesis.
[0100] In another embodiment, the metabolic enzyme is encoded by WecE (Lipopolysaccharide biosynthesis protein rffA; GenBank Accession No: AEO 14075.1). In another embodiment, the metabolic enzyme is encoded by amiA, an N-acetylmuramoyl-L- alanine amidase. In another embodiment, the metabolic enzyme is aspartate aminotransferase. In another embodiment, the metabolic enzyme is histidinol-phosphate
aminotransferase (GenBank Accession No. NP_466347). In another embodiment, the metabolic enzyme is the cell wall teichoic acid glycosylation protein GtcA.
[0101] In another embodiment, the metabolic enzyme is a synthetic enzyme for a peptidoglycan component or precursor. In another embodiment, the component is UDP-N- acetylmuramyl-pentapeptide. In another embodiment, the component is UDP-N- acetylglucosamine. In another embodiment, the component is MurNAc-(pentapeptide)- pyrophosphoryl-undecaprenol. In another embodiment, the component is GlcNAc-β-(l,4)-
MurNAc-(pentapeptide)-pyrophosphoryl-undecaprenol. In another embodiment, the component is any other peptidoglycan component or precursor known in the art. Each possibility represents a separate embodiment of the present invention.
[0102] In another embodiment, the metabolic enzyme is encoded by murG. In another embodiment, the metabolic enzyme is encoded by murD. In another embodiment, the metabolic enzyme is encoded by murA-1. In another embodiment, the metabolic enzyme is encoded by murA-2 (all set forth in GenBank Accession No. NC_002973). In another embodiment, the metabolic enzyme is any other synthetic enzyme for a peptidoglycan component or precursor. Each possibility represents a separate embodiment of the present invention.
[0103] In another embodiment, the metabolic enzyme is a trans-glycosylase. In another embodiment, the metabolic enzyme is trans-peptidase. In another embodiment, the metabolic enzyme is a carboxy-peptidase. In another embodiment, the metabolic enzyme is any other class of metabolic enzyme known in the art. Each possibility represents a separate embodiment of the present invention.
[0104] In another embodiment, the metabolic enzyme is any other Listeria monocytogenes metabolic enzyme known in the art.
[0105] In another embodiment, the metabolic enzyme is any other Listeria metabolic enzyme known in the art.
[0106] In another embodiment, the metabolic enzyme is any other gram-positive bacteria metabolic enzyme known in the art.
[0107] In another embodiment, the metabolic enzyme is any other metabolic enzyme known in the art. Each possibility represents a separate embodiment of the present invention.
[0108] In another embodiment, the gene encoding the metabolic enzyme is expressed under the control of the Listeria p60 promoter. In another embodiment, the inlA (encodes internalin) promoter is used. In another embodiment, the hly promoter is used. In another embodiment, the ActA promoter is used. In another embodiment, the integrase gene is expressed under the control of any other gram positive promoter. In another embodiment, the gene encoding the metabolic enzyme is expressed under the control of any other promoter that functions in Listeria. The skilled artisan will appreciate that other promoters or polycistronic expression cassettes may be used to drive the expression of the gene. Each possibility represents a separate embodiment of the present invention.
[0109] The gene expressed on a plasmid of the present invention comprises, in one embodiment, an isolated nucleic acid encoding a protein that complements the auxotrophic mutant. In another embodiment, if the auxotrophic bacteria is deficient in a gene encoding a vitamin synthesis gene (e.g. pantothenic acid) necessary for bacterial growth, the plasmid DNA comprises a gene encoding a protein for pantothenic acid synthesis. Thus, the auxotrophic bacteria, when expressing the gene on the plasmid, can grow in the absence of pantothenic acid, whereas an auxotrophic bacteria not expressing the gene on the plasmid cannot grow in the absence of pantothenic acid.
[0110] In another embodiment, an auxotrophic bacterium utilized in methods and compositions of the present invention is deficient in the metabolic enzyme of methods and compositions of the present invention. In another embodiment, the gene encoding the metabolic enzyme is mutated in the genome of the bacterium. In another embodiment, the gene encoding the metabolic enzyme is deleted from the genome of the bacterium. Each possibility represents a separate embodiment of the present invention.
[011 1] The attPP' of methods and compositions of the present invention is, in another embodiment, a Ul 53 attPP' site. In another embodiment, the attPP site has a sequence contained in SEQ ID No: 26:
[0112] aagctttaaagaaattcaagaagaaacatcggtaactagccataaattaaccaaagttctaatctcgcttgaagagaacaa actgattgaaaaaattggacaatctagagcaacaaaatacaaattaattgaatctacagaggaatatctaaccaatcttcaacacacatt tcgaaaaattgttcaattttatgttgaaaatgataaataaaaatatgaatgtttttttatttgttagtagtgtaactttccatgcgagaggagaa cggaaatgaaggcagctatttatatacgcgtatctactcaagaacaaatagagaattactctatacaagctcaaactgaaaagctaaca gccttgtgccgctcgaaggattgggacgtatacgatattttcatagacggcggatacagcggttcaaacatgaatcgccccgcactaa atgaaatgctaagtaaattacatgaaattgatgctgttgttgtatatcgcttagatagactttcccgctcacaaagagatacgataacgctt attgaagaatacttcttaaaaaacaatgtagaatttgttagtttgtctgaaactcttgacacctctagcccatttgggcgcgcgatgattgg tatattatccgtatttgctcaattagagcgcgaaactatacgtgatcgtatggtgatggggaaaattnagcgtattgaagcaggtcttcct ttaacgactgcaaaaggtagaacattcggctatgatgttatagatactaaattatatattaatgaagaagaagcaaaacaattacaaatg atttatgatatttttgaggaagaaaaaagcattaccactttacagaagagactaaaaaaattaggattcaaagtgaaatcatatagcagtt acaacaattggctaactaatgatttatactgtggttatgtatcttatgcggataaagtgcatacaaaaggtgttcatgagcctattatttcag aggaacaattttatcgagttcaagaaattttttctcgcatgggtaaaaatccaaatatgaatagagattcagcatcgttgctaaataatttg gtagtgtgtggaaaatgtgggttgggttttgttcatcggagaaaagatactgtttcccgcggaaaaaaatatcattatagatattatagttg caagacttacaaacatactcatgaactagaaaaatgtggaaataaaatttggagagctgacaaactcgaggaattaattattgatcgcg tgaataactatagtttcgcttctaggaatgtagataaagaagacgaattagatagcttaaatgaaaaacttaaaacagaacacgtaaaa aagaaacggctatttgatttatatatcagcggttcttacgaagtttcagaacttgatgctatgatggctgatatcgatgctcaaattaattatt atgaagcacaaatagaagctaacgaagaattgaagaaaaataaaaagatacaagaaaatttagctgatttagcaacagttgattttgac tctttagagttccgagaaaagcaactttatttaaaatcactaattaataaaatttatattgacggtgaacaagttactattgaatggctctagt agcttgtttatttagattgtttagttcctcgttttctctcgttggacggaaacgaatcgagaaactaaaattataaataaaaagtaacctgttt ttctatagattgctttttatcaattatatagaagaaagccgctttttattagattataattgatgttttttgatttatatttcactccctgtgcaaata atgatataacagcaacctcgaactttttagttcggggtatttttttgaaattaatttataaaaacacttgcaattatataatacatgtattataat ataaatatagaaaggagttgagaaagtgaaagacatcttagaggaaataaaaacagtccttgaaattgtaactcttgcagtagcgctg ataacattacgcaagatagacaaaaacaaggacaagtaaccagaggggtgaaactcccctccctctataaaagtatatcacgtctttc ataaattatgaataaatatatctgggttatattaattgttatatgcgttaacggactcgctagttactttcagaacacagcattgaccatcatt gctatactgactacattagcttgtttagtatatttaataaaaaataggaagtgattaattatgacgaaaaaaacgacctctgacgcgcagtt gaaagcaaataaggaatggcaaagcaagaacaaagaacatgcaaactatttaaaatctcgttcagctgcgcgttcttttataaagaata aagctacgttggaagatttgaaggaacttgaaaaattaattatagagggaaaaattaatcataagggaatgattaaggataaatgatgc acgctaagcacatgcttggcgttttttgcataaaaaaagccctaacgttgaagttagggactgacatatataaaaaatagaagttgaca actttaaggcgactaccacgacaggcagcttacaagctatgactagccttgactaatcatttatgcgacactcaaagaattattatctaa cttcttaatcaagaataacaaaaatcaaacaagttagcaagtatttcaggcattttatttataacaaatatctagatcacaaaaatgtcgcg gaaaataatggtcacaaccaatattacataaacttaaaagttctctatttctcttatcaggtttatgtgctgttacgtgatttctacatactcta aaaactgtattagcgaataagtctacaacttgaattaaatctttattttgtgaatccttatatgatgtttcaacagaagagaaaattggatgtt ccattgtaaatttaatagttaaatattcttgtaagctatttaatgattcaattgcggtatttctatcatctatttgcattttcaaatagttatttgctg
ggttaattggtattttagaaatttcatttaccgttagataaataaaataattaaaagacaaagatgtattattcaaaagatgattgactagttg gtggttatcgactatcttaaaatgaaatttagcatctgattttgttgaaagcatattaaatattaattttttcatttcaaaaggcatctccgaac cttttatctcttttgtaatatctaacttactagatggataccttttaagatattttaattttgcatctctgaactgtctaattacattatatggtttctc tgtttctaaaaaagcaataacaaaatatctgttattaaaatttttatttttagttatagttcctgattcatctacaaaaagtctcatcccagttcct ccacttttttacttaaattatattatactaattaagtttgaggaagtggaacgtatgtacttataattcgaagttatgaaaaatccccccatca atataaaacaaaaaagcccccgaaataataatcgagggcattaaactaaatctttttaacaaacttcggtgttagcagtgagatagtaac cagatttcgttttcaagcgaggtgttccgccttttgttttcgccattcctgtaatcgtgaagatagtgcctaccggatatgtgccaccggttt tatgcttctcagtaaagtctactgaattgtatagatcacactgtactagtgttttaacttttcgcggattttctgtgtagtatgtgtttttgcttgc tggtgtgtgtggttttcctgcttttaacttcgctaataatgttgtgttctgcgttgctgttcctttataatccttaattccgtattgatttgctagttt tttacgattcgcaaagctt (SEQ ID No: 26; att site is underlined). In another embodiment, the attPP' site, core integration site, and/or surrounding sequence are homologous to SEQ ID No: 26. In another embodiment, the attPP' site, core integration site, and/or surrounding sequence are a variant of SEQ ID No: 26. In another embodiment, the attPP' site is any other Ul 53 attPP' site known in the art. Each possibility represents a separate embodiment of the present invention.
[0113] In another embodiment, the attPP' site is an Al 18 attPP' site. In another embodiment, the sequence of the site is:
[0114] tttagtttctcgtttcttcttcttccaacgagagaaaacgaggaactaaa (SEQ ID No: 42; att site is underlined; GenBank Accession No: AJ242593). In another embodiment, the attPP' site, core integration site, and/or surrounding sequence are homologous to SEQ ID No: 42. In another embodiment, the attPP' site, core integration site, and/or surrounding sequence are a variant of SEQ ID No: 42. In another embodiment, the attPP' site is a site set forth GenBank Accession No. NC_003216. In another embodiment, the attPP' site is any other Al 18 attPP' site known in the art. Each possibility represents a separate embodiment of the present invention.
[01 15] In another embodiment, the attPP' site is a PSA attPP' site. In another embodiment, the sequence of the site is:
[01 16] ttacataaaatgtttgtggtattatttgtggtatatatatcctaaatggctttatatcagtgtgtgttaatccctctcaggacgtta aatagtaa (SEQ ID No: 43; att site is underlined; GenBank Accession No: AJ312240). In another embodiment, the attPP' site, core integration site, and/or surrounding sequence are homologous to SEQ ID No: 43. In another embodiment, the attPP' site, core integration site,
and/or surrounding sequence are a variant of SEQ ID No: 43. In another embodiment, the attPP' site is any other PSA attPP' site known in the art. Each possibility represents a separate embodiment of the present invention.
[0117] In another embodiment, the attPP' site is any other attPP' site known in the art. Each possibility represents a separate embodiment of the present invention.
[0118] The attBB' site of methods and compositions of the present invention is, in another embodiment, an attBB' site for Al 18. In another embodiment, the attBB' site has the sequence:
[0119] ttacataaaatgtttgtggtattatttgtggtattccaaaaaaacttaagaaggttcttacnattcttagtttttcatatattcttact ccaaaaagctaggcatttccctgtgaattttattcattttttctgtaagtttcataaattccgctttgttcctattatcgagagctttatcaatttc agctctaagttgttctaattttctctcttctaggagcatcgtcaggaagcattcgataaaaacgtttgttaattctttttcacccttaaggaca cccacctgattcatcaacgaattagaaaaatcacgcatttccacgactaccactccttcactcatatttattacaatcttaaaaaattgtaat atgccaagaaaaaacagaaaacagcttgaaaatacaactttactaatatctaatgacttgcaaattaccatgtgctataatgacaaaaaa taactcataactaactttgatgcttagtcgttacttagaagttttgcttattaggcaataactctaggtttcttcttagacataaatacaaacat agaggagttgaatgaaatgaaaaaagaacaaatcagtactcagttttatgaagtaaacccgcacacgatgattatttttccaaaaaaat ctggaagtatagtctattcagaaatttatgaagttgattctcattatacttctaaatttaccccgtttgagctaattaaaaccagctgtaacttt ttcggatcaagctatgaaggacgcaaagagggaactaaacacttaattggtgttacccataagccacccattatcattgacccagtca cttctacttatgtatttccaactgtagcaccaagttcaacagaatgcatttggattttcccacaacatattaaagattatcatgcaattggatt taaccacactttaataacattttctaatatggaaacctttgagattgatatgtctttagcatcttttaataatcagattgccagaacctccatgt tacatatgaaattttctcaaaaaatgcgtatgatggagagtaatttcccttcaatgaataggtttttcccaccaaccactcttgctgctgaac ctaagacgttattacagcaccatgcttccaaataatgaagaacctaatgatcctcaagatcccgagcaataaatttaaaactaaataaaa gccagctacgtaatagtagctggcttttccttaaaatcattttttattctcaatcgcatctgcaattcgttttaacattaataactcatcctctga gtatgtataaggtagttctaaataccatttctcgagttcaggatttccaattaaaggaaaggcgtttaccgaattcttttctcgcaaaccag ctacatcatctaataagaaatcggttgttgttccaagaatttctgctaatttagccaaaataaaaattggcggtcggtggttatcattttcat acttgcttattgtggatgcagttgtcccgattttcgccgccagttgttttntgtgttaacctatttttctttcgtaaatgaattaatttttctccaa attccaatacgcccacctcacttccttccagtatagcaatttttcggaaagaattcgagaaattctaaaaagaaatcgctttttaggtttca aaagacattttcccgtatttatacag (SEQ ID No: 44; att site is underlined; GenBank Accession No: AFl 74588). In another embodiment, the attBB' site is homologous to SEQ ID No: 44. In another embodiment, the attBB' site is a variant of SEQ ID No: 44. In another embodiment, the attBB' site is any other Al 18 attBB' site known in the art. Each possibility represents a separate embodiment of the present invention.
[0120] In another embodiment, the attBB' site is an attBB' site for PSA. In another embodiment, the attBB' site has the sequence:
[0121] tgtcctgatagctcagctggatagagcaacggccttctaagccgtcggtcgggggttcgaatccctctcaggacgtaaat agctatatta (SEQ ID No: 45; att site is underlined; GenBank Accession No: AJ314913). In another embodiment, the attBB' site is homologous to SEQ ID No: 45. In another embodiment, the attBB' site is a variant of SEQ ID No: 45. In another embodiment, the attBB' site is any other PSA attBB' site known in the art. Each possibility represents a separate embodiment of the present invention.
[0122] In another embodiment, the attBB' site is an attBB' site for U 153.
[0123] In another embodiment, the attBB' site is within the gene for tRNA^8. In another embodiment, the attBB' site is near the gene for tRNA^8. In another embodiment, the attBB' site is within the gene for comK. In another embodiment, the attBB' site is near the gene for comK. In another embodiment, the attBB' site is within any other LM gene known in the art. In another embodiment, the attBB' site is near any other LM gene known in the art. Each possibility represents a separate embodiment of the present invention.
[0124] In another embodiment, the attBB' site is any other attBB' site known in the art. Each possibility represents a separate embodiment of the present invention.
[0125] The integrase protein of methods and compositions of the present invention is, in another embodiment, a Ul 53 integrase. In another embodiment, the integrase protein is encoded by a nucleotide molecule having the sequence set forth in residues 272-1630 of SEQ ID No: 26. In another embodiment, the nucleotide encoding the integrase is homologous to SEQ ID No: 26. In another embodiment, the nucleotide encoding the integrase is a variant of SEQ ID No: 26. In another embodiment, the nucleotide encoding the integrase is a fragment of SEQ ID No: 26. In another embodiment, the integrase protein is encoded by any other Ul 53 integrase gene known in the art. Each possibility represents a separate embodiment of the present invention.
[0126] In another embodiment, the integrase protein has the sequence:
[0127] MKAAIYIRVSTQEQIENYSIQAQTEKLTALCRSKDWDVYDIFIDGGYSGSNM NRPALNEMLSKLHEIDAVVVYRLDRLSRSQRDTΓΓLIEEYFLKNNVEFVSLSETLDTS
SPFGRAMIGILSVFAQLERETIRDRMVMGKIXRIEAGLPLTTAKGRTFGYDVIDTKLY INEEEAKQLQMIYDIFEEEKSΠTLQKRLKKLGFKVKSYSSYNNWLTNDLYCGYVSY ADKVHTKGVHEPIISEEQFYRVQEIFSRMGKNPNMNRDSASLLNNLVVCGKCGLGF VHRRKDTVSRGKKYHYRYYSCKTYKHTHELEKCGNKIWRADKLEELIIDRVNNYS FASRNVDKEDELDSLNEKLKTEHVKKKRLFDLYISGSYEVSELDAMMADIDAQINY YEAQIEANEELKKNKKIQENLADLATVDFDSLEFREKQLYLKSLINKIYIDGEQVTIE
WL (SEQ ID No: 27). In another embodiment, the integrase is homologous to SEQ ID No: 27. In another embodiment, the integrase is a variant of SEQ ID No: 27. In another embodiment, the integrase is an isoform of SEQ ID No: 27. In another embodiment, the integrase is a fragment of SEQ ID No: 27. In another embodiment, the integrase is any other Ul 53 integrase known in the art. Each possibility represents a separate embodiment of the present invention.
[0128] In another embodiment, the integrase is a PSA integrase. In another embodiment, the integrase is encoded by a gene having the sequence:
[0129] ttattccgttgtttttgtggcatttgtggtaaaatttgtggtattttcatctgtttttagtgtgaaaaaagcatctactttggactgatt atgttgtcttaaattagagcttagatgactatagtattttaatgttgtattaatgtcatcatgaccaagcctatcagctacataaataatatcca tacccgcttctacacataagcctgtatgcgtatgtcgtagcttgtgtaatgtcactggttcagaattgattgtactacatatcttcttcaaag ctttattacaagacgcgttgtctactggcttattgtggtaagtgatgaataataacatcaatggattcttaatagcatgttccttcatataatc agtatgccaatttaaatacgaatgtaaatattgagcggtagagttatcaatatagatcactcgtgatttttttgttttggtatcaatgaatgtat tagtgtacttgtaatcccaagctttattcacagttattgaacgtttagtgaaattaatatccttctttgttagtgcaataatttcttcgaacctca tgcctgtctggacagctagaaagataactgctcgtgatatagaatgaaattttgcaagttcttctaatagtaaatgaactttgtctgtttcca taaattgtgctttatttttcgctacgtcctgtccgcttatatgagcccctatagtggggtttttcttcatgtaacctaaatgaacagccttgtta aaaatcgctctaattttgcggtgtctggtgtctacagtggatattgcatagtctacagataaatgattaataaattgttgatattgaaccgca tcaatcgaattaagtttaattttttcatcgaaataatcaacgaattgattataagcaagatcgtataaattaatagtagattgactacttttccc atctttaaatgttttcatgaatagcgtataaaattctttgaagttccattctttcagagaactactatcatgctgaacttgttttaataatttagat gctttatacattaagtttgtttcacttgtatctgtcaaacgcttttctttccattcaccatcgacttttatacgtaggcgaacacaatatttaccg tttgctaatttttttatcttcat (SEQ ID No: 46; GenBank Accession No: AJ312240). In another embodiment, the nucleotide encoding the integrase is homologous to SEQ ID No: 46. In another embodiment, the nucleotide encoding the integrase is a variant of SEQ ID No: 46. In another embodiment, the nucleotide encoding the integrase is a fragment of SEQ ID No: 46. In another embodiment, the integrase protein is encoded by any other PSA integrase
gene known in the art. Each possibility represents a separate embodiment of the present invention.
[0130] In another embodiment, the sequence of the integrase is:
[0131] MKIKKLANGKYCVRLRIKVDGEWKEKRLTDTSETNLMYKASKLLKQVQH DSSSLKEWNFKEFYTLFMKTFKDGKSSQSTINLYDLAYNQFVDYFDEKIKLNSIDAV QYQQFINHLSVDYAISTVDTRHRKIRAIFNKAVHLGYMKKNPTIGAHISGQDVAKN KAQFMETDKVHLLLEELAKFHSiSRA viFLA VQTGMRFEEIIALTKKDINFTKRSΓΓV NKAWDYKYTNTFIDTKTKKSRVIYIDNSTAQYLHSYLNWHTDYMKEHAIKNPLML LFITYHNKPVDNASCNKALKKICSTINSEPVTLHKLRHTHTGLCVEAGMDΠYVADR LGHDDINTTLKYYSHLSSNLRQHNQSKVDAFFTLKTDENTTNFTTNATKTTE (SEQ
ID No: 47; GenBank Accession No: AJ312240). In another embodiment, the integrase is homologous to SEQ ID No: 47. In another embodiment, the integrase is a variant of SEQ ID No: 47. In another embodiment, the integrase is an isoform of SEQ ID No: 47. In another embodiment, the integrase is a fragment of SEQ ID No: 47. In another embodiment, the integrase is any other PSA integrase known in the art. Each possibility represents a separate embodiment of the present invention.
[0132] In another embodiment, the integrase is an Al 18 integrase. In another embodiment, the integrase is encoded by a gene having the sequence:
[0133] caagctactagagccattcaatagtaacttgttcaccatcaatataaattttgtttattagtgattttaaataaagttgcttttctct gaactctaaagagtcaaaatcaactgttgctaaatcagctaaattttcttgtatctttttgtttttcttcaattcttcgttagcttctatttgtgatt cataataattaatttgagcatcaatatcattcatcatagaatcaagttctgaaacttcatacgagccatttatatataaatcaaataatcgtttt ttctttgcatgttctattttaagcttttcatttaagctatctaattcatcttctttatctacatttctggaagcgaaactataattattcacacgatta ataattaattcttcaagtttgtcagctctccaaattttattcccgcatttttcgagttcatgagtatgtttataagtcttgcaactataatatctat aatgatattttttaccacgcgacattgtatcttttctacgatgaacaaagcctaacccgcatttactacaaactactaaattatttagcaacg atgctgaatctctattcatgttcggatttttacccatacgagtaaatatttcttgaactctatagaattgctcttcactgatgataggttcatga ataccttttacatgaactttatctttatatgaaacataaccacaatacaaatcattagttagccagttgttatagcgattatatgttctaacttta aagcctaatttttttagtcttttctgtaaaaaagttatactttgttcttcttcgaaaatatcataaatcagttgtaactgttttgcttcttcttcatta atgtataattttgtatctataacatcatagccgaacgttctacctttcgcagttgttaacggaagacctgcttcaatacgcttaattttcccca tcaccatacgatctcggattgtttcgcgctctagctgtgcgaatactgataatataccaatcattgcacgaccgaaaggggaactagtat caagcgtttcagacaaactaacaaactctacattgttttttaagaagtattcttcaataagcgttattgtgtctctttgtgagcgggatagtct gtctaatcgatatacgactacagcatcaatttcgtgtagtttacttagcatttcatttaatgcgggacgattcatatttgagccggagtatcc
gccgtcaatgaaaatatcgtatacgtcccagtccttcgagcggcacaatgctgttagtttttcagtttgagcttgtattgaataattttctact tgctcttgagtagaaacacgtatataaatagctgccttcatttcc (SEQ ID No: 48; GenBank Accession No: AJ242593). In another embodiment, the nucleotide encoding the integrase is homologous to SEQ ID No: 48. In another embodiment, the nucleotide encoding the integrase is a variant of SEQ ID No: 48. In another embodiment, the nucleotide encoding the integrase is a fragment of SEQ ID No: 48. In another embodiment, the integrase protein is encoded by any other Al 18 integrase gene known in the art. Each possibility represents a separate embodiment of the present invention.
[0134] In another embodiment, the sequence of the integrase is:
[0135] MKAAIYIRVSTQEQVENYSIQAQTEKLTALCRSKDWDVYDIFIDGGYSGSN MNRPALNEMLSKLHEIDAVVVYRLDRLSRSQRDTITLIEEYFLKNNVEFVSLSETLD TSSPFGRAMIGDLSVFAQLERETIRDRMVMGKIKR IEAGLPLTTAKGRTFGYDVIDTK LYINEEEAKQLQLIYDIFEEEQSITFLQKRLKKLGFKVRTYNRYNNWLTNDLYCGYV SYKDKVHVKGIHEPIISEEQFYR VQEIFTRMGKNPNMNRDSASLLNNLVVCSKCGL GFVHRRKDTMSRGKKYHYRYYSCKTYKHTHELEKCGNKΓWRAD KLEELIINRVNN YSFASRNVDKEDELDSLNEKLKIEHAKKKRLFDLYINGSYEVSELDSMMNDIDAQI NYYESQIEANEELKKNKKIQENLADLATVDFDSLEFREKQLYLKSLINKIYIDGEQV
TIEWL (SEQ ID No: 49; GenBank Accession No: AJ242593). In another embodiment, the integrase is homologous to SEQ ID No: 49. In another embodiment, the integrase is a variant of SEQ ID No: 49. In another embodiment, the integrase is an isoform of SEQ ID No: 49. In another embodiment, the integrase is a fragment of SEQ ID No: 49. In another embodiment, the integrase is any other Al 18 integrase known in the art. Each possibility represents a separate embodiment of the present invention.
[0136] In another embodiment, the integrase gene is any other integrase gene known in the art. Each possibility represents a separate embodiment of the present invention.
[0137] In another embodiment, the integrase gene is expressed under the control of the Listeria p60 promoter. In another embodiment, the inlA (encodes internalin) promoter is used. In another embodiment, the hly promoter is used. In another embodiment, the ActA promoter is used. In another embodiment, the integrase gene is expressed under the control of any other gram positive promoter. In another embodiment, the integrase gene is expressed under the control of any other promoter that functions in Listeria. The skilled
artisan will appreciate that other promoters or polycistronic expression cassettes may be used to drive the expression of the gene. Each possibility represents a separate embodiment of the present invention.
[0138] In another embodiment, the step of incorporating the nucleic acid construct of the present invention into the genome of the auxotrophic Listeria strain utilizes two-step allelic exchange. In another embodiment, the step of incorporating utilizes a phage-based integration vector. In another embodiment, the step of incorporating utilizes any other integration method known in the art.
[0139] In another embodiment, the step of incorporating the nucleic acid construct utilizes a prophage integration site of the auxotrophic Listeria strain. In another embodiment, the step of incorporating utilizes any other integration site known in the art. Each possibility represents a separate embodiment of the present invention.
[0140] Each possibility represents a separate embodiment of the present invention.
[0141] In another embodiment, the present invention provides a Listeria monocytogenes- Escherichia coli shuttle plasmid that is retained by complementation of mutant strains deficient in a metabolic gene both in vitro and in vivo. In one embodiment, the metabolic gene is a D-alanine racemase gene. In another embodiment, the metabolic gene is any other metabolic gene of known in the art. Each possibility represents a separate embodiment of the present invention.
[0142] In another embodiment, the present invention provides a method of attenuating a bacterial vaccine strain, comprising the steps of (a) introducing into the strain a mutation in a gene encoding a metabolic enzyme; and (b) transfecting the strain with a plasmid containing a nucleotide sequence encoding the metabolic enzyme, thereby attenuating a bacterial vaccine strain.
[0143] In another embodiment, the present invention provides a method of attenuating a Listeria vaccine strain, comprising the steps of (a) introducing into the strain a mutation in a gene encoding a metabolic enzyme; (b) and transfecting the strain with an integration vector containing a nucleotide sequence encoding the metabolic enzyme, thereby attenuating a metabolic enzyme vaccine strain.
[0144] In one embodiment, a metabolic gene of methods and compositions of the present invention are expressed under an inducible promoter. In another embodiment, the promoter is a constitutive promoter. In another embodiment, the promoter is any other type of promoter known in the art. Each possibility represents a separate embodiment of the present invention.
[0145] In another embodiment, the present invention provides a bacterial vaccine strain constructed by the method of the present invention.
[0146] In another embodiment, the present invention provides a Listeria vaccine strain constructed by the method of the present invention.
[0147] In various embodiments, the antigen of methods and compositions of the present invention includes but is not limited to antigens from the following infectious diseases, measles, mumps, rubella, poliomyelitis, hepatitis A, B (e.g., GenBank Accession No. E02707), and C (e.g., GenBank Accession No. E06890), as well as other hepatitis viruses, type A influenza, other types of influenza, adenovirus (e.g., types 4 and 7), rabies (e.g., GenBank Accession No. M34678), yellow fever, Japanese encephalitis (e.g., GenBank Accession No. E07883), dengue (e.g., GenBank Accession No. M24444), hantavirus, and HIV (e.g., GenBank Accession No. Ul 8552). Bacterial and parasitic antigens will be derived from known causative agents responsible for diseases including, but not limited to, diphtheria, pertussis (e.g., GenBank Accession No. M35274), tetanus (e.g., GenBank Accession No. M64353), tuberculosis, bacterial and fungal pneumonias (e.g., Haemophilus influenzae, Pneumocystis carinii, etc.), cholera, typhoid, plague, shigellosis, salmonellosis (e.g., GenBank Accession No. LO3833), Legionnaire's Disease, Lyme disease (e.g., GenBank Accession No. U59487), malaria (e.g., GenBank Accession No. X53832), hookworm, onchocerciasis (e.g., GenBank Accession No. M27807), schistosomiasis (e.g., GenBank Accession No. L08198), trypanosomiasis, leshmaniasis, giardiasis (e.g., GenBank Accession No. M33641), amoebiasis, filariasis (e.g., GenBank Accession No. J03266), borreliosis, and trichinosis.
[0148] In other embodiments, the antigen is one of the following tumor antigens: any of the various MAGEs (Melanoma-Associated Antigen E), including MAGE 1 (e.g., GenBank Accession No. M77481), MAGE 2 (e.g., GenBank Accession No. U03735), MAGE 3,
MAGE 4, etc.; any of the various tyrosinases; mutant ras; mutant p53 (e.g., GenBank
Accession No. X54156 and AA494311); and p97 melanoma antigen (e.g., GenBank Accession No. M12154). Other tumor-specific antigens include the Ras peptide and p53 peptide associated with advanced cancers, the HPV 16/18 and E6/E7 antigens associated with cervical cancers, MUCl antigen associated with breast carcinoma (e.g., GenBank Accession No. J0365 1), CEA (carcinoembryonic antigen) associated with colorectal cancer (e.g., GenBank Accession No. X983 11), gplOO (e.g., GenBank Accession No. S73003) or MARTl antigens associated with melanoma, and the prostate-specific antigen (KLK3) associated with prostate cancer (e.g., GenBank Accession No. X14810). The p53 gene sequence is known (See e.g., Harris et al. (1986) MoI. Cell. Biol., 6:4650-4656) and is deposited with GenBank under Accession No. M14694. Tumor antigens encompassed by the present invention further include, but are not limited to, Her-2/Neu (e.g. GenBank Accession Nos. M 16789.1 , M 16790.1, M 16791.1, M 16792.1), NY-ESO-I (e.g. GenBank Accession No. U87459), hTERT (aka telomerase) (GenBank Accession. Nos. NM003219 (variant 1), NM 198255 (variant 2), NM 198253 (variant 3), and NM 198254 (variant 4), proteinase 3 (e.g. GenBank Accession Nos. M29142, M75154, M96839, X55668, NM 00277, M96628 and X56606) HPV E6 and E7 (e.g. GenBank Accession No. NC 001526) and WT-I (e.g. GenBank Accession Nos. NM000378 (variant A), NM024424 (variant B), NM 024425 (variant C), and NM024426 (variant D)), Her-2/Neu (e.g. GenBank Accession Nos. M16789.1, M16790.1, M16791.1, M16792.1), NY-ESO-I (e.g. GenBank Accession No. U87459), hTERT (aka telomerase) (GenBank Accession. Nos. NM003219 (variant 1), NM 198255 (variant 2), NM 198253 (variant 3), and NM 198254 (variant 4), proteinase 3 (e.g. GenBank Accession Nos. M29142, M75154, M96839, X55668, NM 00277, M96628 and X56606) HPV E6 and E7 (e.g. GenBank Accession No. NC 001526), WT-I (e.g. GenBank Accession Nos. NM000378 (variant A), NM024424 (variant B), NM 024425 (variant C), and NM024426 (variant D)), and stratum corneum chymotryptic enzyme (SCCE; GenBank Accession No. NM_005046 and NM_139277)). Thus, the present invention can be used as immunotherapeutics for cancers including, but not limited to, cervical, breast, colorectal, prostate, lung cancers, and for melanomas.
[0149] Each of the above antigens represents a separate embodiment of the present invention.
[0150] In another embodiment, the antigen-encoding gene is expressed under the control of the Listeria p60 promoter. In another embodiment, the inlA (encodes internalin) promoter is
used. In another embodiment, the hly promoter is used. In another embodiment, the ActA promoter is used. In another embodiment, the integrase gene is expressed under the control of any other gram positive promoter. In another embodiment, the antigen-encoding gene is expressed under the control of any other promoter that functions in Listeria. The skilled artisan will appreciate that other promoters or polycistronic expression cassettes may be used to drive the expression of the gene. Each possibility represents a separate embodiment of the present invention.
[0151] In another embodiment of methods and compositions of the present invention, a polypeptide encoded by a nucleic acid sequence thereof is a fusion protein comprising the heterologous antigen and an additional polypeptide. In one embodiment, the additional polypeptide is a non-hemolytic LLO protein or fragment thereof (Examples herein). In another embodiment, the additional polypeptide is a PEST sequence. In another embodiment, the additional polypeptide is an ActA protein or a fragment thereof. ActA proteins and fragments thereof augment antigen presentation and immunity in a similar fashion to LLO.
[0152] The additional polypeptide of methods and compositions of the present invention is, in another embodiment, a listeriolysin (LLO) peptide. In another embodiment, the additional polypeptide is an ActA peptide. In another embodiment, the additional polypeptide is a PEST-like sequence peptide. In another embodiment, the additional polypeptide is any other peptide capable of enhancing the immunogenicity of an antigen peptide. Each possibility represents a separate embodiment of the present invention.
[0153] The LLO protein utilized to construct vaccines of the present invention has, in another embodiment, the sequence:
MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSMAPPASPPASPKTPIEKKHAD EIDKYIQGLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQNNAD IQVVNAISSLTYPGALVKANSELVENQPDVLPVKRDSLTLSIDLPGMTNQDNKIVVK NATKSNVNNAVNTLVERWNEKYAQAYPNVSAKIDYDDEMAYSESQLIAKFGTAFK AVNNSLNVNFGAISEGKMQEEVISFKQIYYNVNVNEPTRPSRFFGKAVTKEQLQAL GVNAENPPAYISSVAYGRQVYLKLSTNSHSTKVKAAFDAAVSGKSVSGDVELTNII KNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATFNRETPGVPIAYTTNFLKDN ELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVNYDPEGNEIVQHKN
WSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEWWRTVIDDRNLPLVKNR NISIWGTTLYPKYSNKVDNPIE (GenBank Accession No. Pl 3128; SEQ ID NO: 56; nucleic acid sequence is set forth in GenBank Accession No. Xl 5127). The first 25 amino acids of the proprotein corresponding to this sequence are the signal sequence and are cleaved from LLO when it is secreted by the bacterium. Thus, in this embodiment, the full length active LLO protein is 504 residues long. In another embodiment, the LLO protein is a homologue of SEQ ID No: 56. In another embodiment, the LLO protein is a variant of SEQ ID No: 56. In another embodiment, the LLO protein is an isomer of SEQ ID No: 56. In another embodiment, the LLO protein is a fragment of SEQ ID No: 56. Each possibility represents a separate embodiment of the present invention.
[0154] In another embodiment, "LLO peptide" and "LLO fragment" refer to an N-terminal fragment of an LLO protein. In another embodiment, the terms refer to a full-length but non-hemolytic LLO protein. In another embodiment, the terms refer to a non-hemolytic protein containing a point mutation in cysteine 484 of sequence ID No: 56 or a corresponding residue thereof in a homologous LLO protein. In another embodiment, the LLO fragment contains about the first 400-441 AA of the 529 AA full-length LLO protein. Each possibility represents a separate embodiment of the present invention.
[0155] In another embodiment, the N-terminal fragment of an LLO protein utilized in compositions and methods of the present invention has the sequence:
MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSVAPPASPPASPKTPIEKKHAD EIDKYIQGLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQNNAD IQVVNAISSLTYPGALVKANSELVENQPDVLPVKRDSLTLSIDLPGMTNQDNKIVVK NATKSNVNNAVNTLVERWNEKYAQAYSNVSAKIDYDDEMAYSESQLIAKFGTAFK AVNNSLNVNFGAISEGKMQEEVISFKQIYYNVNVNEPTRPSRFFGKAVTKEQLQAL GVNAENPPAYISSVAYGRQVYLKLSTNSHSTKVKAAFDAAVSGKSVSGDVELTNII KNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATFNRETPGVPIA YTTNFLKDN ELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVNYD (SEQ ID NO:
57). In another embodiment, the LLO fragment is a homologue of SEQ ID No: 57. In another embodiment, the LLO fragment is a variant of SEQ ID No: 57. In another embodiment, the LLO fragment is an isomer of SEQ ID No: 57. In another embodiment, the
LLO fragment is a fragment of SEQ ID No: 57. Each possibility represents a separate embodiment of the present invention.
[0156] In another embodiment, the LLO fragment has the sequence:
MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSVAPPASPPASPKTPIEKKHAD EIDKYIQGLDYNKNNVLVYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQNNAD IQVVNAISSLTYPGALVKANSELVENQPDVLPVKRDSLTLSIDLPGMTNQDNKIVVK NATKSNVNNAVNTLVERWNEKYAQAYSNVSAKIDYDDEMAYSESQLIAKFGTAFK AVNNSLNVNFGAISEGKMQEEVISFKQIYYNVNVNEPTRPSRFFGKAVTKEQLQAL GVNAENPPAYISSVAYGRQVYLKLSTNSHSTKVKAAFDAAVSGKSVSGDVELTNII KNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATFNRETPGVPIAYTTNFLKDN
ELAVIKNNSEYIETTSKAYTD (SEQ ID NO: 58). In another embodiment, the LLO fragment is a homologue of SEQ ID No: 58. In another embodiment, the LLO fragment is a variant of SEQ ID No: 58. In another embodiment, the LLO fragment is an isomer of SEQ ID No: 58. In another embodiment, the LLO fragment is a fragment of SEQ ID No: 58. Each possibility represents a separate embodiment of the present invention.
[0157] In another embodiment, the LLO fragment is any other LLO fragment known in the art. Each possibility represents a separate embodiment of the present invention.
[0158] "ActA peptide" refers, in another embodiment, to a full-length ActA protein. In another embodiment, the term refers to an ActA fragment. Each possibility represents a separate embodiment of the present invention.
[0159] The ActA fragment of methods and compositions of the present invention is, in another embodiment, an N-terminal ActA fragment. In another embodiment, the fragment is any other type of ActA fragment known in the art. Each possibility represents a separate embodiment of the present invention.
[0160] In another embodiment, the N-terminal fragment of an ActA protein has the sequence: MRAMMVVFITANCITINPDIIFAATDSEDSSLNTDEWEEEKTEEQPSEVNTGPRYETA REVSSRDIKELEKSNKVRNTNKADLIAMLKEKAEKGPNINNNNSEQTENAAINEEAS GADRPAIQVERRHPGLPSDSAAEIKKRRKAIASSDSELESLTYPDKPTKVNKKKVAK ESVADASESDLDSSMQSADESSPQPLKANQQPFFPKVFKKIKDAGKWVRDKIDENP EVKKAIVDKSAGLIDQLLTKKKSEEVNASDFPPPPTDEELRLALPETPMLLGFNAPA TSEPSSFEFPPPPTDEELRLALPETPMLLGFNAPATSEPSSFEFPPPPTEDELEIIRETAS
SLDSSFTRGDLASLRNAINRHSQNFSDFPPIPTEEELNGRGGRP (SEQ ID No: 59). In another embodiment, the ActA fragment comprises SEQ ID No: 59. In another embodiment, the ActA fragment is a homologue of SEQ ID No: 59. In another embodiment, the ActA fragment is a variant of SEQ ID No: 59. In another embodiment, the ActA fragment is an isomer of SEQ ID No: 59. In another embodiment, the ActA fragment is a fragment of SEQ ID No: 59. Each possibility represents a separate embodiment of the present invention.
[0161] In another embodiment, the N-terminal fragment of an ActA protein has the sequence:
MRAMMVVFITANCITINPDIIFAATDSEDSSLNTDEWEEEKTEEQPSEVNTGPRYETA REVSSRDIKELEKSNKVRNTNKADLIAMLKEKAEKGPNINNN (SEQ ID NO: 60). In another embodiment, the ActA fragment is a homologue of SEQ ID No: 60. In another embodiment, the ActA fragment is a variant of SEQ ID No: 60. In another embodiment, the ActA fragment is an isomer of SEQ ID No: 60. Each possibility represents a separate embodiment of the present invention.
[0162] In another embodiment, the ActA fragment of methods and compositions of the present invention comprises a PEST-like sequence. In another embodiment, the PEST-like sequence contained in the ActA fragment is selected from SEQ ID No: 64-67. In another embodiment, the ActA fragment comprises at least 2 of the PEST-like sequences set forth in SEQ ID No: 64-67. In another embodiment, the ActA fragment comprises at least 3 of the PEST-like sequences set forth in SEQ ID No: 64-67. In another embodiment, the ActA fragment comprises the 4 PEST-like sequences set forth in SEQ ID No: 64-67. Each possibility represents a separate embodiment of the present invention.
[0163] In another embodiment, the N-terminal ActA fragment is encoded by a nucleotide molecule having the sequence:
[0164] atgcgtgcgatgatggtggttttcattactgccaattgcattacgattaaccccgacataatatttgcagcgacagatagcga agattctagtctaaacacagatgaatgggaagaagaaaaaacagaagagcaaccaagcgaggtaaatacgggaccaagatacga aactgcacgtgaagtaagttcacgtgatattaaagaactagaaaaatcgaataaagtgagaaatacgaacaaagcagacctaatagc aatgttgaaagaaaaagcagaaaaaggtccaaatatcaataataacaacagtgaacaaactgagaatgcggctataaatgaagagg cttcaggagccgaccgaccagctatacaagtggagcgtcgtcatccaggattgccatcggatagcgcagcggaaattaaaaaaag aaggaaagccatagcatcatcggatagtgagcttgaaagccttacttatccggataaaccaacaaaagtaaataagaaaaaagtggc gaaagagtcagttgcggatgcttctgaaagtgacttagattctagcatgcagtcagcagatgagtcttcaccacaacctttaaaagcaa
accaacaaccatttttccctaaagtatttaaaaaaataaaagatgcggggaaatgggtacgtgataaaatcgacgaaaatcctgaagta aagaaagcgattgttgataaaagtgcagggttaattgaccaattattaaccaaaaagaaaagtgaagaggtaaatgcttcggacttcc cgccaccacctacggatgaagagttaagacttgctttgccagagacaccaatgcttcttggttttaatgctcctgctacatcagaaccg agctcattcgaatttccaccaccacctacggatgaagagttaagacttgctttgccagagacgccaatgcttcttggttttaatgctcctg ctacatcggaaccgagctcgttcgaatttccaccgcctccaacagaagatgaactagaaatcatccgggaaacagcatcctcgctag attctagttttacaagaggggatttagctagtttgagaaatgctattaatcgccatagtcaaaatttctctgatttcccaccaatcccaaca gaagaagagttgaacgggagaggcggtagacca (SEQ No: 61). In another embodiment, the ActA fragment is encoded by a nucleotide molecule that comprises SEQ ID No: 61. In another embodiment, the ActA fragment is encoded by a nucleotide molecule that is a homologue of SEQ ID No: 61. In another embodiment, the ActA fragment is encoded by a nucleotide molecule that is a variant of SEQ ID No: 61. In another embodiment, the ActA fragment is encoded by a nucleotide molecule that is an isomer of SEQ ID No: 61. In another embodiment, the ActA fragment is encoded by a nucleotide molecule that is a fragment of SEQ ID No: 61. Each possibility represents a separate embodiment of the present invention.
[0165] In another embodiment, a recombinant nucleotide of the present invention comprises any other sequence that encodes a fragment of an ActA protein. Each possibility represents a separate embodiment of the present invention.
[0166] In another embodiment, the ActA fragment is any other ActA fragment known in the art. Each possibility represents a separate embodiment of the present invention.
[0167] In another embodiment of methods and compositions of the present invention, a PEST-like AA sequence is fused to the antigen peptide. In another embodiment, the PEST- like AA sequence has a sequence selected from SEQ ID No: 62-70. In another embodiment, the PEST-like sequence is any other PEST-like sequence known in the art. Each possibility represents a separate embodiment of the present invention.
[0168] In another embodiment, the PEST-like AA sequence is KENSISSMAPPASPPASPKTPIEKKHADEIDK (SEQ ID NO: 62). In another embodiment, the PEST-like sequence is KENSISSMAPPASPPASPK (SEQ ID No: 63). In another embodiment, fusion of an antigen peptide to any LLO sequence that includes the 1 of the PEST-like AA sequences enumerated herein is efficacious for enhancing cell- mediated immunity against an antigen.
[0169] The present invention also provides methods for enhancing cell mediated and antitumor immunity and compositions with enhanced immunogenicity which comprise a PEST- like amino acid sequence derived from a prokaryotic organism fused to an antigen. In another embodiment, the PEST-like sequence is embedded within an antigen. In another embodiment, the PEST-like sequence is fused to either the amino terminus of the antigen. In another embodiment, the PEST-like sequence is fused to the carboxy terminus. As demonstrated herein, fusion of an antigen to the PEST-like sequence of LM enhanced cell mediated and anti-tumor immunity of the antigen. Thus, fusion of an antigen to other PEST- like sequences derived from other prokaryotic organisms will also enhance immunogenicity of an antigen. PEST-like sequence of other prokaryotic organism can be identified routinely in accordance with methods such as described by, for example Rechsteiner and Rogers (1996, Trends Biochem. Sci. 21 :267-271) for LM. In another embodiment, PEST-like AA sequences from other prokaryotic organisms are identified based by this method. In another embodiment, the PEST-like AA sequence is from another Listeria species. For example, the LM protein ActA contains 4 such sequences.
[0170] In another embodiment, the PEST-like AA sequence is a PEST-like sequence from a Listeria ActA protein. In another embodiment, the PEST-like sequence is KTEEQPSEVNTGPR (SEQ ID NO: 64), KASVTDTSEGDLDSSMQSADESTPQPLK (SEQ ID NO: 65), KNEEVNASDFPPPPTDEELR (SEQ ID NO: 66), or RGGIPTSEEFSSLNSGDFTDDENSETTEEEIDR (SEQ ID NO: 67). In another embodiment, the PEST-like sequence is from Listeria seeligeri cytolysin, encoded by the lso gene. In another embodiment, the PEST-like sequence is RSEVTISPAETPESPPATP (SEQ ID NO: 68). In another embodiment, the PEST-like sequence is from Streptolysin O protein of Streptococcus sp. In another embodiment, the PEST-like sequence is from Streptococcus pyogenes Streptolysin O, e.g. KQNTASTETTTTNEQPK (SEQ ID NO: 69) at AA 35-51. In another embodiment, the PEST-like sequence is from Streptococcus equisimilis Streptolysin O, e.g. KQNTANTETTTTNEQPK (SEQ ID NO: 70) at AA 38-54. In another embodiment, the PEST-like sequence has a sequence selected from SEQ ID No: 62-70. In another embodiment, the PEST-like sequence has a sequence selected from SEQ ID No: 64-70. In another embodiment, the PEST-like sequence is another PEST-like AA sequence derived from a prokaryotic organism.
[0171] PEST-like sequences of other prokaryotic organism are identified, in another embodiment, in accordance with methods such as described by, for example Rechsteiner and Rogers (1996, Trends Biochem. Sci. 21 :267-271) for LM. Alternatively, PEST-like AA sequences from other prokaryotic organisms can also be identified based by this method. Other prokaryotic organisms wherein PEST-like AA sequences would be expected to include, but are not limited to, other Listeria species. In another embodiment, the PEST-like sequence is embedded within the antigenic protein. Thus, in another embodiment, "fusion" refers to an antigenic protein comprising both the antigen peptide and the PEST-like amino acid sequence either linked at one end of the antigen peptide or embedded within the antigen peptide.
[0172] In another embodiment, the PEST-like sequence is identified using the PEST-find program. In another embodiment, a PEST-like sequence is defined as a hydrophilic stretch of at least 12 AA in length with a high local concentration of proline (P), aspartate (D), glutamate (E), serine (S), and/or threonine(T) residues. In another embodiment, a PEST-like sequence contains no positively charged AA, namely arginine (R), histidine (H) and lysine (K).
[0173] In another embodiment, identification of PEST motifs is achieved by an initial scan for positively charged AA R, H, and K within the specified protein sequence. All AA between the positively charged flanks are counted and only those motifs are considered further, which contain a number of AA equal to or higher than the window-size parameter. In another embodiment, a PEST-like sequence must contain at least 1 P, 1 D or E, and at least 1 S or T.
[0174] In another embodiment, the quality of a PEST motif is refined by means of a scoring parameter based on the local enrichment of critical AA as well as the motifs hydrophobicity. Enrichment of D, E, P, S and T is expressed in mass percent (w/w) and corrected for 1 equivalent of D or E, 1 of P and 1 of S or T. In another embodiment, calculation of hydrophobicity follows in principle the method of J. Kyte and R.F. Doolittle (Kyte, J and Dootlittle, RF. J. MoI. Biol. 157, 105 (1982). For simplified calculations, Kyte- Doolittle hydropathy indices, which originally ranged from -4.5 for arginine to +4.5 for isoleucine, are converted to positive integers, using the following linear transformation, which yielded values from 0 for arginine to 90 for isoleucine.
[0175] Hydropathy index = 10 * Kyte-Doolittle hydropathy index + 45
[0176] In another embodiment, a potential PEST motifs hydrophobicity is calculated as the sum over the products of mole percent and hydrophobicity index for each AA species. The desired PEST score is obtained as combination of local enrichment term and hydrophobicity term as expressed by the following equation:
[0177] PEST score = 0.55 * DEPST - 0.5 * hydrophobicity index.
[0178] In another embodiment, "PEST-like sequence" or "PEST-like sequence peptide" refers to a peptide having a score of at least +4, using the above algorithm. In another embodiment, the term refers to a peptide having a score of at least 4.7. In another embodiment, the peptide has a score of at least 5. In another embodiment, the peptide has a score of at least 6. In another embodiment, the peptide has a score of at least 7. In another embodiment, the score is at least 8. In another embodiment, the score is at least 9. In another embodiment, the score is at least 10. In another embodiment, the score is at least 11. In another embodiment, the score is at least 12. In another embodiment, the score is at least 13. In another embodiment, the score is at least 14. In another embodiment, the score is at least 15. In another embodiment, the score is at least 16. In another embodiment, the score is at least 17. In another embodiment, the score is at least 18. In another embodiment, the score is at least 19. In another embodiment, the score is at least 20. In another embodiment, the score is at least 21. In another embodiment, the score is at least 22. In another embodiment, the score is at least 22. In another embodiment, the score is at least 24. In another embodiment, the score is at least 24. In another embodiment, the score is at least 25. In another embodiment, the score is at least 26. In another embodiment, the score is at least 27. In another embodiment, the score is at least 28. In another embodiment, the score is at least 29. In another embodiment, the score is at least 30. In another embodiment, the score is at least 32. In another embodiment, the score is at least 35. In another embodiment, the score is at least 38. In another embodiment, the score is at least 40. In another embodiment, the score is at least 45. Each possibility represents a separate embodiment of the present invention.
[0179] In another embodiment, the PEST-like sequence is identified using any other method or algorithm known in the art, e.g the CaSPredictor (Garay-Malpartida HM, Occhiucci JM, Alves J, Belizario JE. Bioinformatics. 2005 Jun;21 Suppl l :i 169-76). In another embodiment, the following method is used:
[0180] A PEST index is calculated for each stretch of appropriate length (e.g. a 30-35 AA stretch) by assigning a value of 1 to the AA Ser, Thr, Pro, GIu, Asp, Asn, or GIn. The coefficient value (CV) for each of the PEST residue is 1 and for each of the other AA (non- PEST) is 0.
[0181] Each method for identifying a PEST-like sequence represents a separate embodiment of the present invention.
[0182] "Fusion to a PEST-like sequence" refers, in another embodiment, to fusion to a protein fragment comprising a PEST-like sequence. In another embodiment, the term includes cases wherein the protein fragment comprises surrounding sequence other than the PEST-like sequence. In another embodiment, the protein fragment consists of the PEST-like sequence. Each possibility represents a separate embodiment of the present invention.
[0183] In one embodiment, a vector of the present invention provides the benefits of a Listeria vaccine vector without the risk of increasing antibiotic resistance in bacterial organisms.
[0184] In another embodiment, an advantage of vaccine strains of the present invention is that the recombinant nucleic acid molecules or plasmids contained therein are not likely to be retained upon potential transfer to other bacteria in the gut. In another embodiment, the advantage is that the nucleic acid molecules or plasmids do not confer an evolutionary advantage on normal cells. In another embodiment, the advantage is that the nucleic acid molecules or plasmids do not contain active retention systems such as partition sequences. Thus, outside their deficient host cells, the nucleic acid molecules or plasmids will most likely be diluted out of the population and ultimately be eliminated over time. Each possibility represents a separate embodiment of the present invention.
[0185] In another embodiment, the present invention provides a kit comprising an antibiotic resistance free bacterial strain of the present invention, a pharmaceutically-acceptable carrier, an applicator, and an instructional material for use thereof.
[0186] In another embodiment, the present invention provides a kit comprising an antibiotic resistance free Listeria strain of the present invention, an applicator, and an instructional material for use thereof.
[0187] "Alanine racemase" refers, in one embodiment, to an enzyme that converts the L- isomer of the amino acid alanine into its D-isomer. In another embodiment, such enzymes are known by the EC number 5.1.1.1.
[0188] "Amino acid metabolism enzyme" refers, in one embodiment, to a peptide or protein that has a functional role in converting an amino acid from one form to another, such as, but not limited to, altering the stereochemistry of the amino acid, hydrolyzing or adding groups to an amino acid, cleaving amino acids, and the like. Each possibility represents a separate embodiment of the present invention.
[0189] The term "auxotrophic bacteria" refers, in one embodiment, to a bacteria strain that is not capable of growing or replicating without supplementation of a factor that will permit such growth or replication. Each factor represents a separate embodiment of the present invention.
[0190] "Fusion protein" refers, in one embodiment, to a protein that comprises two or more proteins linked together. In one embodiment, the proteins are linked by peptide bonds. In another embodiment, the proteins are linked by other chemical bonds. In another embodiment, the proteins are linked by with one or more amino acids between the two or more proteins, which may be referred to as a spacer. Each possibility represents a separate embodiment of the present invention.
[0191] In another embodiment, the tumor targeted by methods and compositions of the present invention is a breast cancer. In another embodiment, the cancer is a melanoma. In another embodiment, the cancer is a glioma tumor. In another embodiment, the cancer is an ovarian neoplasm. In another embodiment, the cancer is a mammary carcinoma. In another embodiment, the cancer is an ependymoma.
[0192] In another embodiment, the cancer is a melanoma. In another embodiment, the cancer is a sarcoma. In another embodiment, the cancer is a carcinoma. In another embodiment, the cancer is a lymphoma. In another embodiment, the cancer is a leukemia. In another embodiment, the cancer is mesothelioma. In another embodiment, the cancer is a glioma. In another embodiment, the cancer is a germ cell tumor. In another embodiment, the cancer is a choriocarcinoma. Each possibility represents a separate embodiment of the present invention.
[0193] In another embodiment, the cancer is pancreatic cancer. In another embodiment, the cancer is ovarian cancer. In another embodiment, the cancer is gastric cancer. In another embodiment, the cancer is a carcinomatous lesion of the pancreas. In another embodiment, the cancer is pulmonary adenocarcinoma. In another embodiment, the cancer is colorectal adenocarcinoma. In another embodiment, the cancer is pulmonary squamous adenocarcinoma. In another embodiment, the cancer is gastric adenocarcinoma. In another embodiment, the cancer is an ovarian surface epithelial neoplasm (e.g. a benign, proliferative or malignant variety thereof). In another embodiment, the cancer is an oral squamous cell carcinoma. In another embodiment, the cancer is non small-cell lung carcinoma. In another embodiment, the cancer is an endometrial carcinoma. In another embodiment, the cancer is a bladder cancer. In another embodiment, the cancer is a head and neck cancer. In another embodiment, the cancer is a prostate carcinoma.
[0194] In another embodiment, the cancer is an acute myelogenous leukemia (AML). In another embodiment, the cancer is a myelodysplastic syndrome (MDS). In another embodiment, the cancer is a non-small cell lung cancer (NSCLC). In another embodiment, the cancer is a Wilms' tumor. In another embodiment, the cancer is a leukemia. In another embodiment, the cancer is a lymphoma. In another embodiment, the cancer is a desmoplastic small round cell tumor. In another embodiment, the cancer is a mesothelioma (e.g. malignant mesothelioma). In another embodiment, the cancer is a gastric cancer. In another embodiment, the cancer is a colon cancer. In another embodiment, the cancer is a lung cancer. In another embodiment, the cancer is a breast cancer. In another embodiment, the cancer is a germ cell tumor. In another embodiment, the cancer is an ovarian cancer. In another embodiment, the cancer is a uterine cancer. In another embodiment, the cancer is a thyroid cancer. In another embodiment, the cancer is a hepatocellular carcinoma. In another embodiment, the cancer is a thyroid cancer. In another embodiment, the cancer is a liver cancer. In another embodiment, the cancer is a renal cancer. In another embodiment, the cancer is a kaposis. In another embodiment, the cancer is a sarcoma. In another embodiment, the cancer is another carcinoma or sarcoma. Each possibility represents a separate embodiment of the present invention.
[0195] In other embodiments, the antigen of methods and compositions of the present invention is associated with one of the above cancers.
[0196] In another embodiment, the cancer is any other cancer known in the art. Each type of cancer represents a separate embodiment of the present invention.
[0197] In other embodiments, the antigen of methods and compositions of the present invention is derived from a fungal pathogen, bacteria, parasite, helminth, or viruses. In other embodiments, the antigen is selected from tetanus toxoid, hemagglutinin molecules from influenza virus, diphtheria toxoid, HIV gpl20, HIV gag protein, IgA protease, insulin peptide B, Spongospora subterranea antigen, vibriose antigens, Salmonella antigens, pneumococcus antigens, respiratory syncytial virus antigens, Haemophilus influenza outer membrane proteins, Helicobacter pylori urease, Neisseria meningitidis pilins, N. gonorrhoeae pilins, or human papilloma virus antigens El and E2 from type HPV-16, -18, -
31, -33, -35 or -45 human papilloma viruses.
[0198] In other embodiments, the antigen is associated with one of the following diseases; cholera, diphtheria, Haemophilus, hepatitis A, hepatitis B, influenza, measles, meningitis, mumps, herpes simplex 1, herpes simplex 2, herpes zoster, Epstein-Barr virus, cytomegalovirus, pertussis, small pox, pneumococcal pneumonia, polio, rabies, rubella, tetanus, tuberculosis, typhoid, Varicella-zoster, whooping cough3 yellow fever, the immunogens and antigens from Addison's disease, allergies, anaphylaxis, Bruton's syndrome, cancer, including solid and blood borne tumors, eczema, Alzheimer's disease, Hashimoto's thyroiditis, polymyositis, dermatomyositis, type 1 diabetes mellitus, acquired immune deficiency syndrome, transplant rejection, such as kidney, heart, pancreas, lung, bone, and liver transplants, Graves' disease, polyendocrine autoimmune disease, hepatitis, microscopic polyarteritis, polyarteritis nodosa, pemphigus, primary biliary cirrhosis, pernicious anemia, coeliac disease, antibody-mediated nephritis, glomerulonephritis, rheumatic diseases, systemic lupus erthematosus, rheumatoid arthritis, seronegative spondylarthrites, rhinitis, Sjogren's syndrome, systemic sclerosis, sclerosing cholangitis, Wegener's granulomatosis, dermatitis herpetiformis, psoriasis, vitiligo, multiple sclerosis, encephalomyelitis, Guillain-Barre syndrome, myasthenia gravis, Lambert-Eaton syndrome, sclera, episclera, uveitis, chronic mucocutaneous candidiasis, urticaria, transient hypogammaglobulinemia of infancy, myeloma, X-linked hyper IgM syndrome, Wiskott- Aldrich syndrome, ataxia telangiectasia, autoimmune hemolytic anemia, autoimmune thrombocytopenia, autoimmune neutropenia, Waldenstrom's macroglobulinemia, amyloidosis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, malarial
circumsporozite protein, microbial antigens, viral antigens, autoantigens, listeriosis, and anthrax.
[0199] In another embodiment, the infectious disease of targeted by a method of the present invention is one of the diseases or conditions described hereinabove.
[0200] In one embodiment, "variant" refers to an amino acid or nucleic acid sequence (or in other embodiments, an organism or tissue) that is different from the majority of the population but is still sufficiently similar to the common mode to be considered to be one of them, for example splice variants.
[0201] In one embodiment, "isoform" refers to a version of a molecule, for example, a protein, with only slight differences compared to another isoform, or version, of the same protein. In one embodiment, isoforms may be produced from different but related genes, or in another embodiment, may arise from the same gene by alternative splicing. In another embodiment, isoforms are caused by single nucleotide polymorphisms.
[0202] In one embodiment, "fragment" refers to a protein or polypeptide that is shorter or comprises fewer amino acids than the full length protein or polypeptide. In another embodiment, fragment refers to a nucleic acid that is shorter or comprises fewer nucleotides than the full length nucleic acid. In another embodiment, the fragment is an N-terminal fragment. In another embodiment, the fragment is a C-terminal fragment. In one embodiment, the fragment is an intrasequential section of the protein, peptide, or nucleic acid. In one embodiment, the fragment is a functional fragment. In another embodiment, the fragment is an immunogenic fragment. In one embodiment, a fragment has 10-20 nucleic or amino acids, while in another embodiment, a fragment has more than 5 nucleic or amino acids, while in another embodiment, a fragment has 100-200 nucleic or amino acids, while in another embodiment, a fragment has 100-500 nucleic or amino acids, while in another embodiment, a fragment has 50-200 nucleic or amino acids, while in another embodiment, a fragment has 10-250 nucleic or amino acids.
[0203] In one embodiment, "immunogenicity" or "immunogenic" is used herein to refer to the innate ability of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response in an animal when the protein, peptide, nucleic acid, antigen or organism is administered to the animal. Thus, "enhancing the immunogenicity" in one embodiment,
refers to increasing the ability of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response in an animal when the protein, peptide, nucleic acid, antigen or organism is administered to an animal. The increased ability of a protein, peptide, nucleic acid, antigen or organism to elicit an immune response can be measured by, in one embodiment, a greater number of antibodies to a protein, peptide, nucleic acid, antigen or organism, a greater diversity of antibodies to an antigen or organism, a greater number of T- cells specific for a protein, peptide, nucleic acid, antigen or organism, a greater cytotoxic or helper T-cell response to a protein, peptide, nucleic acid, antigen or organism, and the like.
[0204] In one embodiment, "treating" refers to either therapeutic treatment or prophylactic or preventative measures, wherein the object is to prevent or lessen the targeted pathologic condition or disorder as described hereinabove. Thus, in one embodiment, treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing the severity of, delaying the onset of, reducing symptoms associated with the disease, disorder or condition, or a combination thereof. Thus, in one embodiment, "treating" refers inter alia to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to alternative therapeutics, or a combination thereof. In one embodiment, "preventing" refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof. In one embodiment, "suppressing" or "inhibiting", refers inter alia to reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.
[0205] In some embodiments, the term "comprising" refers to the inclusion of other recombinant polypeptides, amino acid sequences, or nucleic acid sequences, as well as inclusion of other polypeptides, amino acid sequences, or nucleic acid sequences, that may be known in the art, which in one embodiment may comprise antigens or Listeria polypeptides, amino acid sequences, or nucleic acid sequences. In some embodiments, the term "consisting essentially of refers to a composition for use in the methods of the present invention, which has the specific recombinant polypeptide, amino acid sequence, or nucleic acid sequence, or fragment thereof. However, other polypeptides, amino acid sequences, or
nucleic acid sequences may be included that are not involved directly in the utility of the recombinant polypeptide(s). In some embodiments, the term "consisting" refers to a composition for use in the methods of the present invention having a particular recombinant polypeptide, amino acid sequence, or nucleic acid sequence, or fragment or combination of recombinant polypeptides, amino acid sequences, or nucleic acid sequences or fragments of the present invention, in any form or embodiment as described herein.
[0206] In another embodiment, a sequence of the present invention is homologous to a sequence disclosed herein. The terms "homology," "homologous," etc, when in reference to any protein, peptide, or nucleotide sequence, refer, in one embodiment, to a percentage of amino acid residues in the candidate sequence that are identical with the residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology In another embodiment, conservative substitutions are not considered as part of the sequence identity. In another embodiment, conservative substitutions are considered. Methods and computer programs for the alignment are well known in the art.
[0207] Homology is, in another embodiment, determined by computer algorithm for sequence alignment, by methods well described in the art. For example, computer algorithm analysis of nucleic acid sequence homology can include the utilization of any number of software packages available, such as, for example, the BLAST, DOMAIN, BEAUTY (BLAST Enhanced Alignment Utility), GENPEPT and TREMBL packages.
[0208] In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 70%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 72%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 75%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 78%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 80%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 82%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 83%. In another embodiment,
"homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than
85%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26- 27, 32, and 42-70 of greater than 87%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 88%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26- 27, 32, and 42-70 of greater than 90%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 92%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ED No: 19, 26- 27, 32, and 42-70 of greater than 93%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 95%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 19, 26- 27, 32, and 42-70 of greater than 96%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 97%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 98%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of greater than 99%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 19, 26-27, 32, and 42-70 of 100%. Each possibility represents a separate embodiment of the present invention.
[0209] In another embodiment, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide of the invention. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals or organisms. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals or organisms. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.
[0210] Describing two polynucleotides as "operably linked" means, in another embodiment, that a single-stranded or double-stranded nucleic acid moiety comprises the two polynucleotides arranged within the nucleic acid moiety in such a manner that at least one of the two polynucleotides is able to exert a physiological effect by which it is characterized upon the other. By way of example, a promoter operably linked to the coding region of a gene is able to promote transcription of the coding region.
[021 1] "Promoter/regulatory sequence" refers, in one embodiment, to a nucleic acid sequence which is required for, or enhances, expression of a gene product operably linked to the promoter/regulatory sequence. In another embodiment, this sequence is the core promoter sequence. In another embodiment, this sequence also includes an enhancer sequence and other regulatory elements that are required for expression of the gene product.
Listeria Vaccine Strains
[0212] The Listeria strain of methods and compositions of the present invention is, in another embodiment, Listeria monocytogenes (ATCC No. 15313). In another embodiment, the Listeria strain is a recombinant Listeria seeligeri strain. In another embodiment, the Listeria strain is a recombinant Listeria grayi strain. In another embodiment, the Listeria strain is a recombinant Listeria ivanovii strain. In another embodiment, the Listeria strain is a recombinant Listeria murrayi strain. In another embodiment, the Listeria strain is a recombinant Listeria welshimeri strain. In another embodiment, the Listeria strain is a recombinant strain of any other Listeria species known in the art.
[0213] In other embodiments, attenuated Listeria strains, such as LM delta-actA mutant (Brundage et al, 1993, Proc. Natl. Acad. Sci., USA, 90:11890-1 1894), L. monocytogenes delta-plcA (Camilli et al, 1991 , J. Exp. Med., 173:751-754), or delta-ActA, delta INL-b (Brockstedt et al, 2004, PNAS, 101 : 13832-13837) are used in the present invention. In another embodiment, attenuated Listeria strains are constructed by introducing one or more attenuating mutations, as will be understood by one of average skill in the art when equipped with the disclosure herein. Examples of such strains include, but are not limited to Listeria strains auxotrophic for aromatic amino acids (Alexander et al, 1993, Infection and Immunity 61 :2245-2248) and mutant for the formation of lipoteichoic acids (Abachin et al, 2002, MoI. Microbiol. 43: 1-14).
[0214] In another embodiment, a recombinant Listeria strain of the present invention has been passaged through an animal host. In another embodiment, the passaging maximizes efficacy of the strain as a vaccine vector. In another embodiment, the passaging stabilizes the immunogenicity of the Listeria strain. In another embodiment, the passaging stabilizes the virulence of the Listeria strain. In another embodiment, the passaging increases the immunogenicity of the Listeria strain. In another embodiment, the passaging increases the virulence of the Listeria strain. In another embodiment, the passaging removes unstable sub-
strains of the Listeria strain. In another embodiment, the passaging reduces the prevalence of unstable sub-strains of the Listeria strain. In another embodiment, the Listeria strain contains a genomic insertion of the gene encoding the antigen-containing recombinant peptide. In another embodiment, the Listeria strain carries a plasmid comprising the gene encoding the antigen-containing recombinant peptide. In another embodiment, the passaging is performed as described herein (e.g. in Example 1). In another embodiment, the passaging is performed by any other method known in the art. In another embodiment, methods of the present invention comprise a step of passaging the recombinant bacteria, which in one embodiment, is Listeria through an animal host. Each possibility represents a separate embodiment of the present invention.
[0215] The skilled artisan, when equipped with the present disclosure and the methods herein, will readily understand that different transcriptional promoters, terminators, carrier vectors or specific gene sequences (e.g. those in commercially available cloning vectors) can be used successfully in methods and compostions of the present invention. As is contemplated in the present invention, these functionalities are provided in, for example, the commercially available vectors known as the pUC series. In another embodiment, nonessential DNA sequences (e.g. antibiotic resistance genes) are removed.
[0216] In another embodiment, a commercially available plasmid is used in the present invention. Such plasmids are available from a variety of sources, for example, Invitrogen (La Jolla, CA), Stratagene (La Jolla, CA), Clontech (Palo Alto, CA), or can be constructed using methods well known in the art. Another embodiment is a plasmid such as pCR2.1 (Invitrogen, La Jolla, CA), which is a prokaryotic expression vector with a prokaryotic origin of replication and promoter/regulatory elements to facilitate expression in a prokaryotic organism. In another embodiment, extraneous nucleotide sequences are removed to decrease the size of the plasmid and increase the size of the cassette that can be placed therein.
[0217] Such methods are well known in the art, and are described in, for example, Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York) and Ausubei et al. (1997, Current Protocols in Molecular Biology, Green & Wiley, New York).
[0218] Antibiotic resistance genes are used in the conventional selection and cloning processes commonly employed in molecular biology and vaccine preparation. Antibiotic resistance genes contemplated in the present invention include, but are not limited to, gene products that confer resistance to ampicillin, penicillin, methicillinj streptomycin, erythromycin, kanamycin, tetracycline, cloramphenicol (CAT), neomycin, hygromycin, gentamicin and others well known in the art. Each gene represents a separate embodiment of the present invention.
[0219] Methods for transforming bacteria are well known in the art, and include calcium- chloride competent cell-based methods, electroporation methods, bacteriophage-mediated transduction, chemical, and physical transformation techniques (de Boer et al, 1989, Cell 56:641-649; Miller et al, 1995, FASEB J., 9:190-199; Sambrook et al. 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York; Ausubel et al., 1997, Current Protocols in Molecular Biology, John Wiley & Sons, New York; Gerhardt et al., eds., 1994, Methods for General and Molecular Bacteriology, American Society for Microbiology, Washington, DC; Miller, 1992, A Short Course in Bacterial Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) In another embodiment, the Listeria vaccine strain of the present invention is transformed by electroporation. Each method represents a separate embodiment of the present invention.
[0220] Plasmids and other expression vectors useful in the present invention are described elsewhere herein, and can include such features as a promoter/regulatory sequence, an origin of replication for gram negative and gram positive bacteria, an isolated nucleic acid encoding a fusion protein and an isolated nucleic acid encoding an amino acid metabolism gene. Further, an isolated nucleic acid encoding a fusion protein and an amino acid metabolism gene will have a promoter suitable for driving expression of such an isolated nucleic acid. Promoters useful for driving expression in a bacterial system are well known in the art, and include bacteriophage lambda, the bla promoter of the beta-lactamase gene of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene of pBR325.
Further examples of prokaryotic promoters include the major right and left promoters of bacteriophage lambda (PL and PR), the trp, recA, lacZ, lad, and gal promoters of E. coli, the alpha-amylase (Ulmanen et al, 1985. J. Bacterid. 162:176-182) and the S28-specific promoters of B. subtilis (Gilman et al, 1984 Gene 32:1 1 -20), the promoters of the bacteriophages of Bacillus (Gryczan, 1982, In: The Molecular Biology of the Bacilli,
Academic Press, Inc., New York), and Streptomyces promoters (Ward et al, 1986, MoI. Gen. Genet. 203:468-478). Additional prokaryotic promoters contemplated in the present invention are reviewed in, for example, Glick (1987, J. Ind. Microbiol. 1 :277-282); Cenatiempo, (1986, Biochimie, 68:505-516); and Gottesman, (1984, Ann. Rev. Genet. 18:415-442). Further examples of promoter/regulatory elements contemplated in the present invention include, but are not limited to the Listeria] prfA promoter, the Listeria! hly promoter, the Listerial p60 promoter and the Listeria] ActA promoter (GenBank Ace. No. NC_003210) or fragments thereof.
[0221] In another embodiment, a plasmid of methods and compositions of the present invention comprises a gene encoding a fusion protein. In another embodiment, subsequences are cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments are then, in another embodiment, ligated to produce the desired DNA sequence. In another embodiment, DNA encoding the antigen is produced using DNA amplification methods, for example polymerase chain reaction (PCR). First, the segments of the native DNA on either side of the new terminus are amplified separately. The 5' end of the one amplified sequence encodes the peptide linker, while the 3' end of the other amplified sequence also encodes the peptide linker. Since the 5' end of the first fragment is complementary to the 3' end of the second fragment, the two fragments (after partial purification, e.g. on LMP agarose) can be used as an overlapping template in a third PCR reaction. The amplified sequence will contain codons, the segment on the carboxy side of the opening site (now forming the amino sequence), the linker, and the sequence on the amino side of the opening site (now forming the carboxyl sequence). The antigen is ligated into a plasmid. Each method represents a separate embodiment of the present invention.
[0222] In another embodiment, the present invention further comprises a phage based chromosomal integration system for clinical applications. A host strain that is auxotrophic for essential enzymes, including, but not limited to, d-alanine racemase will be used, for example Lmdal(-)dat(-). In another embodiment, in order to avoid a "phage curing step," a phage integration system based on PSA is used (Lauer, et al., 2002 J Bacteriol, 184:4177-
4186). This requires, in another embodiment, continuous selection by antibiotics to maintain the integrated gene. Thus, in another embodiment, the current invention enables the establishment of a phage based chromosomal integration system that does not require selection with antibiotics. Instead, an auxotrophic host strain will be complemented.
[0223] The recombinant proteins of the present invention are synthesized, in another embodiment, using recombinant DNA methodology. This involves, in one embodiment, creating a DNA sequence that encodes the fusion protein, placing the DNA in an expression cassette, such as the plasmid of the present invention, under the control of a particular promoter/regulatory element, and expressing the protein. DNA encoding the fusion protein (e.g. non-hemolytic LLO/antigen) of the present invention is prepared, in another embodiment, by any suitable method, including, for example, cloning and restriction of appropriate sequences or direct chemical synthesis by methods such as the phosphotriester method of Narang et al. (1979, Meth. Enzymol. 68: 90-99); the phosphodiester method of Brown et al. (1979, Meth. Enzymol 68: 109-151); the diethylphosphoramidite method of Beaucage et al. (1981 , Tetra. Lett., 22: 1859-1862); and the solid support method of U.S. Pat. No. 4,458,066.
[0224] In another embodiment, chemical synthesis is used to produce a single stranded oligonucleotide. This single stranded oligonucleotide is converted, in various embodiments, into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill in the art would recognize that while chemical synthesis of DNA is limited to sequences of about 100 bases, longer sequences can be obtained by the ligation of shorter sequences. In another embodiment, subsequences are cloned and the appropriate subsequences cleaved using appropriate restriction enzymes. The fragments are then be ligated to produce the desired DNA sequence.
[0225] In another embodiment, DNA encoding the fusion protein or the recombinant protein of the present invention is cloned using DNA amplification methods such as polymerase chain reaction (PCR). Thus, the gene for non-hemolytic LLO is PCR amplified, using a sense primer comprising a suitable restriction site and an antisense primer comprising another restriction site, e.g. a non-identical restriction site to facilitate cloning. The same is repeated for the isolated nucleic acid encoding an antigen. Ligation of the nonhemolytic LLO and antigen sequences and insertion into a plasmid or vector produces a vector encoding non-hemolytic LLO joined to a terminus of the antigen. The two molecules are joined either directly or by a short spacer introduced by the restriction site.
[0226] In another embodiment, the molecules are separated by a peptide spacer consisting of one or more amino acids, generally the spacer will have no specific biological activity
other than to join the proteins or to preserve some minimum distance or other spatial relationship between them. In another embodiment, the constituent AA of the spacer are selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. In another embodiment, the nucleic acid sequences encoding the fusion or recombinant proteins are transformed into a variety of host cells, including E. coli, other bacterial hosts, such as Listeria, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. The recombinant fusion protein gene will be operably linked to appropriate expression control sequences for each host. Promoter/ regulatory sequences are described in detail elsewhere herein. In another embodiment, the plasmid further comprises additional promoter regulatory elements, as well as a ribosome binding site and a transcription termination signal. For eukaryotic cells, the control sequences will include a promoter and an enhancer derived from e.g. immunoglobulin genes, SV40, cytomegalovirus, etc., and a polyadenylation sequence. In another embodiment, the sequences include splice donor and acceptor sequences.
[0227] The antigens of these and other diseases are well known in the art, and the skilled artisan, when equipped with the present disclosure and the methods and techniques described herein will readily be able to construct a fusion protein comprising a nonhemolytic LLO protein and an antigen for use in the present invention. In another embodiment, in order to select for an auxotrophic bacteria comprising the plasmid, transformed auxotrophic bacteria are grown on a media that will select for expression of the amino acid metabolism gene. In another embodiment, a bacteria auxotrophic for D- glutamic acid synthesis is transformed with a plasmid comprising a gene for D-glutamic acid synthesis, and the auxotrophic bacteria will grow in the absence of D-glutamic acid, whereas auxotrophic bacteria that have not been transformed with the plasmid, or are not expressing the plasmid encoding a protein for D-glutamic acid synthesis, will not grow. In another embodiment, a bacterium auxotrophic for D-alanine synthesis will grow in the absence of D-alanine when transformed and expressing the plasmid of the present invention if the plasmid comprises an isolated nucleic acid encoding an amino acid metabolism enzyme for D-alanine synthesis. Such methods for making appropriate media comprising or lacking necessary growth factors, supplements, amino acids, vitamins, antibiotics, and the like are well known in the art, and are available commercially (Becton-Dickinson, Franklin Lakes, NJ). Each method represents a separate embodiment of the present invention.
[0228] In another embodiment, once the auxotrophic bacteria comprising the plasmid of the present invention have been selected on appropriate media, the bacteria are propagated in the presence of a selective pressure. Such propagation comprises growing the bacteria in media without the auxotrophic factor. The presence of the plasmid expressing an amino acid metabolism enzyme in the auxotrophic bacteria ensures that the plasmid will replicate along with the bacteria, thus continually selecting for bacteria harboring the plasmid. The skilled artisan, when equipped with the present disclosure and methods herein will be readily able to scale-up the production of the Listeria vaccine vector by adjusting the volume of the media in which the auxotrophic bacteria comprising the plasmid are growing.
[0229] In one embodiment, the present invention provides a fusion protein comprising an antigen, a metabolic enzyme and an integrase gene. In another embodiment, the present invention provides a plasmid comprising a nucleic acid molecule of the present invention, which in one embodiment, comprises a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises a protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a third open reading frame encoding a Al 18 or Ul 53 integrase gene. In another embodiment, the present invention provides a cell comprising a fusion protein, peptide, plasmid, nucleic acid molecule, or recombinant Listeria of the present invention. In another embodiment, the present invention provides a composition comprising a fusion protein, peptide, plasmid, nucleic acid molecule, or recombinant Listeria of the present invention. In another embodiment, the present invention provides a composition comprising a recombinant Listeria of the present invention and an adjuvant, as are known in the art.
[0230] In one embodiment, the present invention provides a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein said integrated nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises a protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a phage attachment site, a third open reading frame encoding an integrase gene, or a combination thereof. In one embodiment, the phage attachment site is an Al 18 phage attachment site or, in another embodiment, a Ul 53 attachment site. In one embodiment, the integrase gene is a Al 18 or, in another embodiment, a Ul 53 integrase gene
[0231] The skilled artisan will appreciate that, in another embodiment, other auxotroph strains and complementation systems may be adopted for the use with this invention.
EXPERIMENTAL DETAILS SECTION
EXAMPLE 1: A PLASMID CONTAINING AN AMINO ACID METABOLISM ENZYME INSTEAD OF AN ANTIBIOTIC RESISTANCE GENE IS RETAINED IN E. COLI AND LM BOTH IN VITRO AND IN VIVO
MATERIALS AND EXPERIMENTAL METHODS
Bacterial strains, transformation and selection
[0232] E. coli strain MB2159 was used for transformations, using standard protocols. Bacterial cells were prepared for electroporation by washing with H2O.
[0233] E. coli strain MB2159 (Strych U et al, FEMS Microbiol Lett. 2001 Mar 15;196(2):93-8) is an air (-)/dadX (-) deficient mutant that is not able to synthesize D- alanine racemase. Listeria strain Lm dal(-)/dat(-) (Lmdd) similarly is not able to synthesize D-alanine racemase due to partial deletions of the dal and the dat genes.
Construction of Lmdd
[0234] The dal gene was initially inactivated by means of a double-allelic exchange between the chromosomal gene and the temperature-sensitive shuttle plasmid pKSV7 (Smith K et al, Biochimie. 1992 Jul-Aug;74(7-8):705-l l) carrying an erythromycin resistance gene between a 450-bp fragment from the 5' end of the original 850-bp dal gene PCR product and a 450-bp fragment from the 3' end of the dal gene PCR product. Subsequently, a dal deletion mutant covering 82% of the gene was constructed by a similar exchange reaction with pKSV7 carrying homology regions from the 5' and 3' ends of the intact gene (including sequences upstream and downstream of the gene) surrounding the desired deletion. PCR analysis was used to confirm the structure of this chromosomal deletion.
[0235] The chromosomal dat gene was inactivated by a similar allelic exchange reaction. pKSV7 was modified to carry 450-bp fragments derived by PCR from both the 5' and 3' ends of the intact dat gene (including sequences upstream and downstream of the gene).
These two fragments were ligated by appropriate PCR. Exchange of this construct into the chromosome resulted in the deletion of 30% of the central bases of the dat gene, which was confirmed by PCR analysis.
Bacterial culture and in vivo passaging of Listeria
[0236] E. coli were cultured following Standard methods. Listeria were grown at 37° C, 250 rpm shaking in LB media (Difco, Detroit, MI). + 50 μg/ml streptomycin, and harvested during exponential growth phase. For Lm-LLOE7, 37 μg/ml chloramphenicol was added to the media. For growth kinetics determinations, bacteria were grown for 16 hours in 10 ml of LB + antibiotics. The OD6oonm was measured and culture densities were normalized between the strains. The culture was diluted 1:50 into LB + suitable antibiotics and D- alanine if applicable.
Passaging of LM in mice
[0237] 1 x 108 CFU were injected intraperitoneally (ip.) into C57BL/6 mice. On day three, spleens were isolated and homogenized in PBS. An aliquot of the spleen suspension was plated on LB plates with antibiotics as applicable. Several colonies were expanded and mixed to establish an injection stock.
Construction of antibiotic resistance factor free plasmid pTV3
[0238] Construction of p60-dal cassette. The first step in the construction of the antibiotic resistance gene-free vector was construction of a fusion of a truncated p60 promoter to the dal gene. The LM alanine racemase (dal) gene (forward primer: 5'-CCA TGG TGA CAG GCT GGC ATC-3'; SEQ ID NO: 1) (reverse primer: 5'-GCT AGC CTA ATG GAT GTA TTT TCT AGG-3'; SEQ ID NO: 2) and a minimal p60 promoter sequence (forward primer: 5'-TTA ATT AAC AAA TAG TTG GTA TAG TCC-3'; SEQ ID No: 3) (reverse primer: 5'-GAC GAT GCC AGC CTG TCA CCA TGG AAA ACT CCT CTC-3'; SEQ ID No: 4) were isolated by PCR amplification from the genome of LM strain 10403S. The primers introduced a Pad site upstream of the p60 sequence, an Nhel site downstream of the dal sequence (restriction sites in bold type), and an overlapping dal sequence (the first 18 bp) downstream of the p60 promoter for subsequent fusion of p60 and dal by splice overlap extension (SOE)-PCR. The sequence of the truncated p60 promoter was: CAAATAGTTGGTATAGTCCTCTTTAGCCTTTGGAGTATTATCTCATCATTTGTTT
TTTAGGTGAAAACTGGGTAAACTTAGTATTATCAATATAAAATTAATTCTCAAA TACTTAATTACGTACTGGGATTTTCTGAAAAAAGAGAGGAGTTTTCC (SEQ ID NO: 5, Kohler et al, J Bacterid 173: 4668-74, 1991). Using SOE-PCR, the p60 and dal PCR products were fused and cloned into cloning vector pCR2.1 (Invitrogen, La Jolla, CA).
[0239] Removal of antibiotic resistance genes from pGG55. The subsequent cloning strategy for removing the Chloramphenicol acetyltransferase (CAT) genes from pGG55 and introducing the p60-dal cassette also intermittently resulted in the removal of the gram- positive replication region (oriRep; Brand et al, Nucleic Acid Res 18: 4783-4790, 1990). In order to re-introduce the gram-positive oriRep, the oriRep was PCR-amplified from pGG55, using a 5'-primer that added a Narl/Ehel site upstream of the sequence (GGCGCCACTAACTCAACGCTAGTAG, SEQ ID NO: 6) and a 3'-primer that added a Nhel site downstream of the sequence (GCTAGCCAGCAAAGAAAAACAAACACG, SEQ ID NO: 7). The PCR product was cloned into cloning vector pCR2.1 and sequence verified.
[0240] In order to incorporate the p60-dal sequence into the pGG55 vector, the p60-dal expression cassette was excised from pCR-p60dal by Pacl/Nhel double digestion. The replication region for gram-positive bacteria in pGG55 was amplified from pCR-oriRep by PCR (primer 1 , 5'-GTC GAC GGT CAC CGG CGC CAC TAA CTC AAC GCT AGT AG- 3'; SEQ ID No: 8); (primer 2, 5'-TTA ATT AAG CTA GCC AGC AAA GAA AAA CAA ACA CG-3'; SEQ ID No: 9) to introduce additional restriction sites for Ehel and Nhel. The PCR product was ligated into pCR2.1-TOPO (Invitrogen, Carlsbad, Calif.), and the sequence was verified. The replication region was excised by Ehel/Nhel digestion, and vector pGG55 was double digested with Ehel and Nhel, removing both CAT genes from the plasmid simultaneously. The two inserts, p60-dal and oriRep, and the pGG55 fragment were ligated together, yielding pTV3. pTV3 also contains a prfA (pathogenicity regulating factor A) gene. This gene is not necessary for the function of pTV3, but can be used in situations wherein an additional selected marker is required or desired.
Preparation of DNA for real-time PCR
[0241] Total Listeria DNA was prepared using the Masterpure® Total DNA kit (Epicentre, Madison, WI). Listeria were cultured for 24 hours at 37° C and shaken at 250 rpm in 25 ml
of Luria-Bertoni broth (LB). Bacterial cells were pelleted by centrifugation, resuspended in PBS supplemented with 5 mg/ml of lysozyme and incubated for 20 minutes at 37° C, after which DNA was isolated.
[0242] In order to obtain standard target DNA for real-time PCR, the LLO-E7 gene was PCR amplified from pGG55 (5'-ATGAAAAAAATAATGCTAGTTTTTATTAC-3I (SEQ
ID NO: 10); 5'-GCGGCCGCTTAATGATGATGATGATGATGTGGTTTCTG
AGAACAGATG-3' (SEQ ID NO: H)) and cloned into vector pETbluel (Novagen, San
Diego, CA). Similarly, the plcA amplicon was cloned into pCR2.1. E. coli were transformed with pET-LLOE7 and pCR-plcA, respectively, and purified plasmid DNA was prepared for use in real-time PCR.
Real-time PCR
[0243] Taqman primer-probe sets (Applied Biosystems, Foster City, CA) were designed using the ABI PrimerExpress software (Applied Biosystems) with E7 as a plasmid target, using the following primers: S'-GCAAGTGTGACTCTACGCTTCG-S' (SEQ ID NO: 12); 5'-TGCCCATTAACAGGTCTTCCA-S' (SEQ ID NO: 13); 5'-FAM-TGCGTA CAAAGCACACACGTAGACATTCGTAC-TAMRA-3' (SEQ ID NO: 14) and the one- copy gene plcA (TGACATCGTTTGTGTTTGAGCTAG -3' (SEQ ID NO: 15), 5'- GCAGCGCTCTCTAT ACCAGGTAC-3' (SEQ ID NO: 16); 5'-TET- TTAATGTCCATGTTA TGTCTCCGTTATAGCTCATCGTA-TAMRA-S'; SEQ ID NO: 17) as a Listeria genome target.
[0244] 0.4 μM primer and 0.05 mM probe were mixed with PuRE Taq RTG PCR beads (Amersham, Piscataway, NJ) as recommended by the manufacturer. Standard curves were prepared for each target with purified plasmid DNA, pET-LLOE7 and pCR-plcA (internal standard) and used to calculate gene copy numbers in unknown samples. Mean ratios of E7 copies / plcA copies were calculated based on the standard curves and calibrated by dividing the results for Lmdd-TV3 and Lm-LLOE7 with the results from Lm-E7, a Listeria strain with a single copy of the E7 gene integrated into the genome. All samples were run in triplicate in each qPCR assay which was repeated three times. Variation between samples was analyzed by Two-Way ANOVA using the KyPlot software. Results were deemed statistically significant if p < 0.05.
Growth measurements
[0245] Bacteria were grown at 37°C, 250 rpm shaking in Luria Bertani (LB) Medium +/- 100 micrograms (μg)/ml D-alanine and/or 37 μg/ml chloramphenicol. The starting inoculum was adjusted based on OD60O nm measurements to be the same for all strains.
RESULTS
[0246] An auxotroph complementation system based on D-alanine racemase was utilized to mediate plasmid retention in LM without the use of an antibiotic resistance gene. E. coli strain MB2159 is an air (-)/dadX (-) deficient mutant that is not able to synthesize D-alanine racemase. Listeria strain Lm dal(-)/dat(-) (Lmdd) similarly is not able to synthesize D- alanine racemase due to partial deletions of the dal and the dat genes. Plasmid pGG55, which is based on E. coli-Listeria shuttle vector pAM401, was modified by removing both CAT genes and replacing them with a p60-dal expression cassette under control of the Listeria p60 promoter to generate pTV3 (Figure 1). DNA was purified from several colonies (Figure 2).
[0247] To determine plasmid stability in vitro, LM-LLO-E7 and Lmdd(pTV3) were cultured for 70 generations in the presence and absence of selective pressure. CFU were determined daily on selective and nonselective plates for each culture. In this system, plasmid loss results in a greater number of colonies growing on nonselective plates (BHI plus D-alanine for Lmdd(pTV3), BHI only for LM-LLO-E7) versus selective plates (BHI only for Lmdd(pTV3), BHI plus chloramphenicol for LM-LLO-E7). No difference in CFU was detected between nonselective and selective plates (Figure 3A), indicating stable maintenance of the plasmid throughout the culture for at least 70 generations, when the experiment was terminated.
[0248] In addition, plasmid stability in vivo was tested in C57BL/6 mice by isolating viable bacteria at different time points after injection. Again, CFU counts on selective and nonselective plates were used to determine plasmid maintenance among the isolated bacteria ((Figure 3B). No differences in CFU were detected on selective and nonselective plates for each construct, indicating the stable presence of the recombinant plasmid in all bacteria isolated. Since viable Lmdd(pTV3) bacteria were isolated from the spleen at least until day
5, plasmid loss in vivo followed by early clearance of injected bacteria could be excluded as explaining the level of virulence observed for Lmdd(pTV3) bacteria (Example 2).
[0249] In summary, pTV3 was stably maintained in E. coli as well as in Listeria, both in vitro and in vivo. Bacterial growth on LB media that was not supplemented with additional D-alanine indicated that the dal expression cassette was active also in gram-negative E. coli. Both E. co/j-pTV3 and Lmdd-pTV3 remained sensitive to chloramphenicol, indicating the successful removal of both CAT genes from the plasmid. Representative plates are depicted in Figures 4-7.
[0250] The pTV3 copy number per cell was compared between Lm-LLOE7 in the presence of chloramphenicol and Lmdd-TV3 in the absence of chloramphenicol by real-time PCR of the E7 sequences, in both Listeria and E. coli. Lm-LLOE7 expresses LLO/E7 fusion protein from pGG55. Plasmid copy numbers of Lmdd-TV3 and Lm-LLOE7 did not significantly differ from one another, showing stable retention of plasmid pTV3 in both Listeria and E. coli.
[0251] In order to verify the complementation of bacterial functions, in vitro growth kinetics were compared among Lmdd, Lmdd-TV3 and Lm-LLOE7. Lmdd-TV3, but not non-complemented Lmdd was able to grow in alanine-free media (Figure 8). In fact, Lmdd- TV3 reached logarithmic growth phase sooner than both Lm-LL0E7 and Lmdd complemented with exogenous D-alanine. This growth attenuation of Lm-LLOE7 was partially due to the metabolic burden of CAT expression. However, even in the absence of chloramphenicol, Lm-LLOE7 still grew more slowly in vitro than Lmdd-TV3.
EXAMPLE 2: PLASMIDS CONTAINING A METABOLIC ENZYME DO NOT INCREASE THE VIRULENCE OF BACTERIA
MATERIALS AND EXPERIMENTAL METHODS
Hemolytic Lysis Assay
[0252] 4 x 109 CFU of Listeria were thawed, pelleted by centrifugation (1 minute, 14000 rpm) and resuspended in 100 μl PBS, pH 5.5 with 1 M cysteine. Bacteria were serially diluted 1 :2 and incubated for 45 minutes at 37° C in order to activate secreted LLO. Defibrinated total sheep blood (Cedarlane, Hornby, Ontario, Canada) was washed twice
with 5 volumes of PBS and three to four times with 6 volumes of PBS-Cysteine until the supernatant remained clear, pelleting cells at 3000 x g for 8 minutes between wash steps, then resuspended to a final concentration of 10 % (v/v) in PBS-Cysteine. 100 μl of 10% washed blood cells were mixed with 100 μl of Listeria suspension and incubated for additional 45 minutes at 37° C. Un-lysed blood cells were then pelleted by centrifugation (10 minutes, 1000 x g). 100 μl of supernatant was transferred into a new plate and the ODs3Onn, was determined and plotted against the sample dilution.
RESULTS
[0253] As virulence is linked to LLO function, the hemolytic lysis activity between Lmdd- TV3 and Lm-LLOE7 was compared. This assay tests LLO function by lysis of red blood cells and can be performed with culture supernatant, purified LLO or bacterial cells. Lmdd- TV3 displayed higher hemolytic lysis activity than Lm-LLOE7.
[0254] In vivo virulence was also measured by determining LD50 values, a more direct, and therefore accurate, means of measuring virulence. The LD50 of Lmdd-TV3 (0.75 x 109) was very close to that of Lm-LLOE7 (1 x 109), showing that plasmids containing a metabolic enzyme do not increase the virulence of bacteria.
EXAMPLE 3; VACCINE STRAINS CARRYING PLASMIDS CONTAINING A METABOLIC ENZYME MEDIATE ANTIGEN EXPRESSION
[0255] Antigen expression from the metabolic enzyme-containing plasmid was tested in vitro by Western blot. When analyzing equal amounts of total protein from bacterial culture supernatants, Lmdd-TV3 cultures contained approximately double the amount of total antigen than Lm-LLOE7 cultures. This difference may be a result of a higher overall metabolic load in Lm-LLOE7, due to the larger size of the plasmid (12.8 kB) compared to Lmdd-TV3 (7.6 kB).
[0256] Thus, metabolic enzymes can be used instead of antibiotic resistance genes to mediate plasmid retention in auxtrophic bacteria. Further, such plasmids have utility in expression of heterologous proteins in bacteria.
EXAMPLE 4: INDUCTION OF ANTI-TUMOR IMMUNITY BY PLASMIDS CONTAINING A METABOLIC ENZYME
MATERIALS AND EXPERIMENTAL METHODS
Experimental design
[0257] 105 TC-I (ATCC, Manassas, VA) were implanted subcutaneously in C57BL/6 mice (n=8) and allowed to grow for about 7 days, after which tumors were palpable. TC-I is a C57BL/6 epithelial cell line that was immortalized with HPV E6 and E7 and transformed with activated ras, which forms tumors upon subcutaneous implantation. Mice were immunized with 0.1 LD50 of the appropriate Listeria strain on days 7 and 14 following implantation of tumor cells. A non-immunized control group (naive) was also included. Tumor growth was measured with electronic calipers.
RESULTS
[0258] Efficacy of the metabolic enzyme-containing plasmid as a cancer vaccine was determined in a tumor regression model. The TC-I cell line model, which is well characterized for HPV vaccine development and which allowed for a controlled comparison of the regression of established tumors of similar size after immunization with Lmdd-TV3 or Lm-LLOE7, was used. In two separate experiments, immunization of mice with Lmdd- TV3 and Lm-LLOE7 resulted in similar tumor regression (Figure 9) with no statistically significant difference (p < 0.05) between vaccinated groups. All immunized mice were still alive after 63 days, whereas non-immunized mice had to be sacrificed when their tumors reached 20 mm diameter. Cured mice remained tumor-free until the termination of the experiment.
[0259] Thus, metabolic enzyme-containing plasmids are efficacious as a therapeutic cancer vaccine. Because immune responses required for a therapeutic cancer vaccine are stronger than those required for a prophylactic cancer vaccine, these results demonstrate utility as well for a prophylactic cancer vaccine.
EXAMPLE 5: PLASMIDS CONTAINING A METABOLIC ENZYME INDUCE
ANTIGEN-SPECIFIC, TUMOR INFILTRATING T-CELLS
MATERIALS AND EXPERIMENTAL METHODS
T-cell Analysis
[0260] T-cells from spleen and tumor infiltrating T-cells were analyzed for CD8 and CD4 surface markers and E7 specificity according to standard protocols (Gunn et al. (2001, J. Immunol, 167: 6471-6479). C57BL/6 mice were immunized ip. 7 and 14 days after tumor implantation with Lmdd-TV3 or Lm-LLOE7. Splenocytes and tumors were harvested 5 days after the second injection, and were stained at room temperature with H-2Db tetramers loaded with the E7 peptide (RAHYNIVTF, SEQ ID NO: 18) or a control (HIV-Gag) peptide at a 1 :200 dilution. Tetramers were provided by the National Institute of Allergy and Infectious Diseases Tetramer Core Facility and the National Institutes of Health AIDS Research and Reference Reagent Program.
[0261] Three-color flow cytometry for CD8 (53-6.7, PE conjugated), and E7 H-2Db tetramer was performed using a FACSCalibur® flow cytometer with CellQuest® software (Becton Dickinson, Mountain View, CA). Intracellular gamma interferon (IFN-) staining was performed on a second subset of cells. Before staining for the cell surface antigens and IFN- production, lymphocytes were stimulated in vitro by culturing in the presence of monensin (BD Biosciences) to accumulate intracellular IFN-α in the Golgi apparatus. After culture for 5 hr in RP-10 supplemented with interleukin-2 (50 U/ml) and 1 μl of brefeldin A (monensin) per ml, the cells were surface stained for effector markers at 4°C for 20 min with phycoerythrin-conjugated anti-CD8 (PharMingen) and antigen-presenting cell-conjugated MEL- 14 (anti-CD62 ligand). Cells were gated on (selected for) CD62 ligand low to select activated cells before being analyzed for CD8+ IFN-gamma+ populations.
RESULTS
[0262] Anti-tumor efficacy of a vaccine is often linked to its ability to induce antigen- specific, tumor-infiltrating lymphocytes. To further characterize Lmdd-TV3 efficacy, the tumor-infiltrating cytotoxic T-cells (CTL) for E7 antigen specificity were therefore analyzed. Both Lmdd-TV3 and Lm-LLOE7 induce a significant percentage of E7 tetramer specific T-cells infiltrating the tumor (Table 1). No significant differences were observed in the percentages of IFN-α-producing CD8+ T cells in L. monocytogenes LLO-E7-immunized mice versus Lmdd(pTV3)-treated mice. Thus, both Lmdd-TV3 and Lm-LLOE7 induced tumor infiltrating, antigen-specific CTL that controlled tumor growth.
[0264] Cells were stained with anti-CD8 antibody and E7-tetramer and subjected to FACS analysis. After gating on (selecting) CD8+/E7-tetramer+/CD62", the percentage of CD8+/E7- tetramer+/CD62~ cells from total live cells was calculated.
EXAMPLE 6: GENERATION OF A LISTERIA VACCINE VECTOR
CONTAINING AN INTEGRATED HETEROLOGOUS GENE, WITHOUT THE USE OF AN ANTIBIOTIC RESISTANCE GENE
MATERIALS AND EXPERIMENTAL METHODS
Generation of GG-L74
[0265] GG-L74 was created from Listeria strain 10403S by double allelic exchange at the orfZ domain, using a temperature-sensitive shuttle plasmid, as described in Gunn et al. (2001, J. Immunology 167: 6471-6479). GG-L74 was generated by introducing an expression cassette containing the hly-El fusion gene into the orfZ domain of the L. monocytogenes genome. The hly promoter drives the expression of the first 441 AA of the hly gene product, which is joined by the Xhol site to the E7 gene. The result is a hly-El fusion gene that was transcribed and secreted as LLO-E7. The hly-El gene was ligated into the pKSV7 shuttle vector in the reverse orientation to avoid integration into the hly gene. The resulting plasmid, GG-L74, is an expression system that includes the previously described expression cassette inserted in the middle of a 1.6 Kb sequence that corresponds to the orfX, Y, Z domain of the L. monocytogenes genome. L. monocytogenes strain 10403S was transformed with pGG-74. The homology domains allow for insertion of the LLO-E7 gene cassette into the orfZ domain by homologous recombination as described in Gunn et al.
(2001, J. Immunology 167: 6471-6479). Clones were screened for integration of the LLO- E7 gene cassette into the orfZ domain.
RESULTS
[0266] A Listeria vaccine vector, GG-L74, expressing a fusion of a non-hemolytic LLO fragment to the E7 antigen of human papilloma virus from the Listeria chromosome was produced by transfecting Lmdd with an My-El fusion expression cassette, using p60-dal as the selectable marker. GGL74 has an LD50 in mice of 106 CFU.
EXAMPLE 7; CHROMOSOMAL INTEGRATION OF RECOMBINANT GENES BASED ON PHAGE INTEGRATION SYSTEM
MATERIALS AND EXPERIMENTAL METHODS
Construction ofpTV6-ll
[0267] pTV6-l 1 are constructed from pPLl or pPL2, which are described:
pPLl
[0268] pPLl (Figure 10, left panel) has the sequence:
gacgtcattaaccctcactaaagggaacaaaagctgggtaccgggccccccctcgaggtcgacggtatcgataagcttgatatcga attcctgcagcccgggggatccactagttctagagcggccgccaccgcggtggagctccaattcgccctatagtgagtcgtattgac gtcgctatttaacgaccctgccctgaaccgacgaccgggtcgaatttgctttcgaatttctgccattcatccgcttattatcacttattcag gcgtagcaccaggcgtttaagggcaccaataactgccttaaaaaaattacgccccgccctgccactcatcgcagtactgttgtaattc attaagcattctgccgacatggaagccatcacagacggcatgatgaacctgaatcgccagcggcatcagcaccttgtcgccttgcgt ataatatttgcccatggtgaaaacgggggcgaagaagttgtccatattggccacgtttaaatcaaaactggtgaaactcacccaggga ttggctgagacgaaaaacatattctcaataaaccctttagggaaataggccaggttttcaccgtaacacgccacatcttgcgaatatatg tgtagaaactgccggaaatcgtcgtggtattcactccagagcgatgaaaacgtttcagtttgctcatggaaaacggtgtaacaagggt gaacactatcccatatcaccagctcaccgtctttcattgccatacggaattccggatgagcattcatcaggcgggcaagaatgtgaata aaggccggataaaacttgtgcttatttttctttacggtctttaaaaaggccgtaatatccagctgaacggtctggttataggtacattgagc aactgactgaaatgcctcaaaatgttctttacgatgccattgggatatatcaacggtggtatatccagtgatttttttctccattttagcttcct tagctcctgaaaatctcgataactcaaaaaatacgcccggtagtgatcttatttcattatggtgaaagttggaacctcttacgtgccgatc aacgtctcattttcgccaaaagttggcccagggcttcccggtatcaacagggacaccaggatttatttattctgcgaagtgatcttccgt cacaggtatttattcggcgcaaagtgcgtcgggtgatgctgccaacttactgatttagtgtatgatggtgtttttgaggtgctccagtggc
ttctgtttctatcagctgtccctcctgttcagctactgacggggtggtgcgtaacggcaaaagcaccgccggacatcagcgctagcgg agtgtatactggcttactatgttggcactgatgagggtgtcagtgaagtgcttcatgtggcaggagaaaaaaggctgcaccggtgcgt cagcagaatatgtgatacaggatatattccgcttcctcgctcactgactcgctacgctcggtcgttcgactgcggcgagcggaaatgg cttacgaacggggcggagatttcctggaagatgccaggaagatacttaacagggaagtgagagggccgcggcaaagccgtttttc cataggctccgcccccctgacaagcatcacgaaatctgacgctcaaatcagtggtggcgaaacccgacaggactataaagatacca ggcgtttccccctggcggctccctcgtgcgctctcctgttcctgcctttcggtttaccggtgtcattccgctgttatggccgcgtttgtctc attccacgcctgacactcagttccgggtaggcagttcgctccaagctggactgtatgcacgaaccccccgttcagtccgaccgctgc gccttatccggtaactatcgtcttgagtccaacccggaaagacatgcaaaagcaccactggcagcagccactggtaattgatttagag gagttagtcttgaagtcatgcgccggttaaggctaaactgaaaggacaagttttggtgactgcgctcctccaagccagttacctcggtt caaagagttggtagctcagagaaccttcgaaaaaccgccctgcaaggcggttttttcgttttcagagcaagagattacgcgcagacc aaaacgatctcaagaagatcatcttattaatcagataaaatatttctagatttcagtgcaatttatctcttcaaatgtagcacctgaagtcag ccccatacgatataagttgtaattctccgccgcttgccctcatctgttacgccggcggtagccggccagcctcgcagagcaggattcc cgttgagcaccgccaggtgcgaataagggacagtgaagaaggaacacccgctcgcgggtgggcctacttcacctatcctgcccgg ctgacgccgttggatacaccaaggaaagtctacacgaaccctttggcaaaatcctgtatatcgtgcgaaaaaggatggatattccgaa aaaatcgctataatgaccccgaagcagggttatgcagcggaaaagcgctgcttccctgctgttttgtggaatatctaccgactggaaa caggcaaatgcaggaaattactgaactgaggggacaggcgagaggcatgcgataaaaagcaatctatagaaaaacaggttacttttt atttataattttagtttctcgattcgtttccgtccaacgagagaaaacgaggaactaaacaatctaaataaacaagctactagagccattc aatagtaacttgttcaccgtcaatataaattttattaattagtgattttaaataaagttgcttttctcggaactctaaagagtcaaaatcaactg ttgctaaatcagctaaattttcttgtatctttttatttttcttcaattcttcgttagcttctatttgtgcttcataataattaatttgagcatcgatatca gccatcatagcatcaagttctgaaacttcgtaagaaccgctgatatataaatcaaatagccgtttcttttttacgtgttctgttttaagtttttc atttaagctatctaattcgtcttctttatctacattcctagaagcgaaactatagttattcacgcgatcaataattaattcctcgagtttgtcag ctctccaaattttatttccacatttttctagttcatgagtatgtttgtaagtcttgcaactataatatctataatgatatttttttccgcgggaaac agtatcttttctccgatgaacaaaacccaacccacattttccacacactaccaaattatttagcaacgatgctgaatctctattcatatttgg atttttacccatgcgagaaaaaatttcttgaactcgataaaattgttcctctgaaataataggctcatgaacaccttttgtatgcactttatcc gcataagatacataaccacagtataaatcattagttagccaattgttgtaactgctatatgatttcactttgaatcctaatttttttagtctcttc tgtaaagtggtaatgcttttttcttcctcaaaaatatcataaatcatttgtaattgttttgcttcttcttcattaatatataatttagtatctataacat catagccgaatgttctaccttttgcagtcgttaaaggaagacctgcttcaatacgcttaattttccccatcaccatacgatcacgtatagttt cgcgctctaattgagcaaatacggataatataccaatcatcgcgcgcccaaatgggctagaggtgtcaagagtttcagacaaactaa caaattctacattgttttttaagaagtattcttcaataagcgttatcgtatctctttgtgagcgggaaagtctatctaagcgatatacaacaac agcatcaatttcatgtaatttacttagcatttcatttagtgcggggcgattcatgtttgaaccgctgtatccgccgtctatgaaaatatcgtat acgtcccaatccttcgagcggcacaaggctgttagcttttcagtttgagcttgtatagagtaattctctatttgttcttgagtagatacgcgt atataaatagctgccttcatttccgttctcctctcgcatggaaagttaagatctttttttcagaaaatcccagtacgtaattaagtatttgaga attaattttatattgattaatactaagtttacccagttttcacctaaaaaacaaatgatgagataatagctccaaaggctaaagaggactat
accaactatttgtaataattctgtaacagttgaaaagcgaacgtgtattcttagggcttgagatgtattgctgggtaaacctttatagtgtaa gtgggatgtgaacgttaatcaacaactttcgctatgggaaacctattgttttttgttaatagaaaaacttaatacatttgtaatataaaaacc ggcagtttttccgttcttcgtgactcgaaatgaattgccagatgagtttatggtattctataatagaaggtatggaggatgttatataatga gacagaattatgatgatcgaaagctagcttggcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaactta atcgccttgcagcacatccccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagc ctgaatggcgaatggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatatgatcccggatctggagctgt aatataaaaaccttcttcaactaacggggcaggttagtgacattagaaaaccgactgtaaaaagtacagtcggcattatctcatattata aaagccagtcattaggcctatctgacaattcctgaatagagttcataaacaatcctgcatgataaccatcacaaacagaatgatgtacct gtaaagatagcggtaaatatattgaattacctttattaatgaattttcctgctgtaataatgggtagaaggtaattactattattattgatattta agttaaacccagtaaatgaagtccatggaataatagaaagagaaaaagcattttcaggtataggtgttttgggaaacaatttccccgaa ccattatatttctctacatcagaaaggtataaatcataaaactctttgaagtcattctttacaggagtccaaataccagagaatgttttagat acaccatcaaaaattgtataaagtggctctaacttatcccaataacctaactctccgtcgctattgtaaccagttctaaaagctgtatttga gtttatcacccttgtcactaagaaaataaatgcagggtaaaatttatatccttcttgttttatgtttcggtataaaacactaatatcaatttctgt ggttatactaaaagtcgtttgttggttcaaataatgattaaatatctcttttctcttccaattgtctaaatcaattttattaaagttcatttgatatg cctcctaaatttttatctaaagtgaatttaggaggcttacttgtctgctttcttcattagaatcaatccttttttaaaagtcaatattactgtaaca taaatatatattttaaaaatatcccactttatccaattttcgtttgttgaactaatgggtgctttagttgaagaataaaagaccacattaaaaa atgtggtcttttgtgtttttttaaaggatttgagcgtagcgaaaaatccttttctttcttatcttgataataagggtaactattgcccagatccg ggatcatatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgc cctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtc atcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttctta (SEQ ID No: 19; GenBank Accession No. AJ417488).
[0269] bp 1 to 171 of pPLl contain the multiple cloning site from pBluescript KS (Alting- Mees, MA, and Short JM. 1989. pBluescript II: gene mapping vectors. Nucleic Acids Res. 17: 9494), and were subcloned using the primers 5'- GG ACGTC ATTAACCCTCACTAAAGG-3' (SEQ ID No: 20) and 5'- GG ACGTC AATACG ACTCACTATAGG-3' (SEQ ID No: 21).
[0270] bp 172 to 2253 contain the low-copy-number gram-negative origin of replication and chloramphenicol acetyltransferase (CAT) gene from pACYC184 (Chang, AC et al, 1978. Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. J. Bacteriol. 134: 1 141-1156), and were cloned after PCR with primers 5'-GGACGTCGCTATTTAACGACCCTGC-S' (SEQ ID NO: 22) and 5'-GAGCTGCAGGAGAATTACAACTTATATCGTATGGGG-S' (SEQ ID NO: 23).
[0271] bp 2254 to 2624 contain the RP4 origin of transfer (oriT) (Pansegrau, WE et al, 1994. Complete nucleotide sequence of Birmingham IncP alpha plasmids. Compilation and comparative analysis. J. MoI. Biol. 239:623-663) (for use in direct conjugation from E. coli to L. monocytogenes), and was cloned from plasmid pCTC3 (Williams, DR et al, 1990. Conjugative plasmid transfer from Escherichia coli to Clostridium acetobutylicum. J. Gen. Microbiol. 136:819-826) after PCR with primers 5'-
GCACTGCAGCCGCTTGCCCTCATCTGTTACGCC-3' (SEQ ID No: 24) and 5'- CATGCATGCCTCTCGCCTGTCCCCTCAGTTCAG-3' (SEQ ID No: 25).
[0272] bp 2629 to 4127 contain the listeriophage U 153 integrase gene and attachment site (attPP') (Gen Bank Accession Number AJ417489) that direct the site-specific integration of the plasmid, and were cloned after PCR with primers 5'- GTAGATCTTAACTTTCCATGCGAGAGGAG-3' (SEQ ID No: 28) and 5'- GGGCATGCGATAAAAAGCAATCTATAGAAAAACAGG-3' (SEQ ID No: 29).
[0273] bp 4134 to 4563 contain the LM p60 promoter, used to drive expression of the U153 integrase gene, (Kohler, SM et al, 1990. The gene coding for protein p60 of Listeria monocytogenes and its use as a specific probe for Listeria monocytogenes. Infect. Immun.
58:1943-1950), and were PCR amplified with primers 5'-
CCTAAGCTTTCGATCATCATAATTCTGTC-3' (SEQ ID No: 30) and 5'-
GGGCATGCAGATCTTTTTTTCAG AAAATCCCAGTACG-3' (SEQ ID No: 31) and cloned upstream of the integrase gene.
[0274] bp 4570 to 6101 contain a Hindlll-Aatll restriction fragment subcloned from pUC18-Cat (obtained from Nancy Freitag, University of Washington), which in turn contains (bp 4788 to 5850) the inducible gram-positive CAT gene from pC194 (Horinouchi, S, and Weisblum, B, 1982. Nucleotide sequence and functional map of pC194, a plasmid that specifies inducible chloramphenicol resistance. J. Bacteriol. 150:815-825).
Cloning of the My and actA genes into pPLl
[0275] The hly gene was subcloned from plasmid pDP-906 (Jones, S et al. 1994.
Characterization of Listeria monocytogenes pathogenesis in a strain expressing perfringolysin O in place of listeriolysin O. Infect. Immun. 62: 5608-5613) by restriction digestion with BamWl and Xbal, gel purifying a 2.9-kb fragment, and ligating it into pPLl
cut with BamHI and Spel (pPL24; Figure 10, bottom of left panel). The actA gene was PCR amplified from 10403S genomic DNA with primers 5'- GGTCTAGATCAAGCACATACCTAG-3' (SEQ ID No: 54) and 5'- CGGGATCCTGAAGCTTGGGAAGCAG-3' (SEQ ID No: 55). The 2220 bp PCR product was gel purified, cut with BamHI and Xbal, and clonedinto pPLl cut with BamHI and Spel (pPL25; Figure 10, bottom of left panel).
pPL2
[0276] pPL2 (Figure 10, right panel) has the sequence:
gacgtcattaaccctcactaaagggaacaaaagctggtaccgggccccccctcgaggtcgacggtatcgataagcttgatatcgaat tcctgcagcccgggggatccactagttctagagcggccgccaccgcggtggagctccaattcgccctatagtgagtcgtattgacgt cgctatttaacgaccctgccctgaaccgacgaccgggtcgaatttgctttcgaatttctgccattcatccgcttattatcacttattcaggc gtagcaaccaggcgtttaagggcaccaataactgccttaaaaaaattacgccccgccctgccactcatcgcagtactgttgtaattcat taagcattctgccgacatggaagccatcacaaacggcatgatgaacctgaatcgccagcggcatcagcaccttgtcgccttgcgtat aatatttgcccatggtgaaaacgggggcgaagaagttgtccatattggccacgtttaaatcaaaactggtgaaactcacccagggatt ggctgagacgaaaaacatattctcaataaaccctttagggaaataggccaggttttcaccgtaacacgccacatcttgcgaatatatgt gtagaaactgccggaaatcgtcgtggtattcactccagagcgatgaaaacgtttcagtttgctcatggaaaacggtgtaacaagggtg aacactatcccatatcaccagctcaccgtctttcattgccatacggaattccggatgagcattcatcaggcgggcaagaatgtgaataa aggccggataaaacttgtgcttatttttctttacggtctttaaaaaggccgtaatatccagetgaacggtctggttataggtacattgagca actgactgaaatgcctcaaaatgttctttacgatgccattgggatatatcaacggtggtatatccagtgatttttttctccattttagcttcctt agctcctgaaaatctcgataactcaaaaaatacgcccggtagtgatcttatttcattatggtgaaagttggaacctcttacgtgccgatca acgtctcattttcgccaaaagttggcccagggcttcccggtatcaacagggacaccaggatttatttattctgcgaagtgatcttccgtc acaggtatttattcggcgcaaagtgcgtcgggtgatgctgccaacttactgatttagtgtatgatggtgtttttgaggtgctccagtggctt ctgtttctatcagctgtccctcctgttcagctactgacggggtggtgcgtaacggcaaaagcaccgccggacatcagcgctagcgga gtgtatactggcttactatgttggcactgatgagggtgtcagtgaagtgcttcatgtggcaggagaaaaaaggctgcaccggtgcgtc agcagaatatgtgatacaggatatattccgcttcctcgctcactgactcgctacgctcggtcgttcgactgcggcgagcggaaatggc ttacgaacggggcggagatttcctggaagatgccaggaagatacttaacagggaagtgagagggccgcggcaaagccgtttttcc ataggctccgcccccctgacaagcatcacgaaatctgacgctcaaatcagtggtggcgaaacccgacaggactataaagataccag gcgtttccccctggcggctccctcgtgcgctctcctgttcctgcctttcggtttaccggtgtcattccgctgttatggccgcgtttgtctcat tccacgcctgacactcagttccgggtaggcagttcgctccaagctggactgtatgcacgaaccccccgttcagtccgaccgctgcgc cttatccggtaactatcgtcttgagtccaacccggaaagacatgcaaaagcaccactggcagcagccactggtaattgatttagagga gttagtcttgaagtcatgcgccggttaaggctaaactgaaaggacaagttttggtgactgcgctcctccaagccagttacctcggttca aagagttggtagctcagagaaccttcgaaaaaccgccctgcaaggcggttttttcgttttcagagcaagagattacgcgcagaccaa
aacgatctcaagaagatcatcttattaatcagataaaatatttctagatttcagtgcaatttatctcttcaaatgtagcacctgaagtcagcc ccatacgatataagttgtaattctccgccgcttgccctcatctgttacgccggcggtagccggccagcctcgcagagcaggattcccg ttgagcaccgccaggtgcgaataagggacagtgaagaaggaacacccgctcgcgggtgggcctacttcacctatcctgcccggct gacgccgttggatacaccaaggaaagtctacacgaaccctttggcaaaatcctgtatatcgtgcgaaaaaggatggatataccgaaa aaatcgctataatgaccccgaagcagggttatgcagcggaaaagcgctgcttccctgctgttttgtggaatatctaccgactggaaac aggcaaatgcaggaaattactgaactgaggggacaggcgagaggcatgcgtggagggaaagaagaacgctgttgaaaaaatctt ctctggactacttgaaacaaaagaattaaagtcattttataaaaaccttgagaaaaaacatcttgatataaaaactatttataacgaatattt atttcaatgtaataataaataatatttattattacataaaatgtttgtggtattatttgtggtatatatatcctaaatggctttatatcagtgtgtgtt aatccctctcaggacgttaaatagtaatgtaaagaaatctctaaaacgttgaaaagccttgatattaaagggcggatgaatgttttggag ttttttttatatcgtataatacccgttttattccgttgtttttgtggcatttgtggtaaaatttgtggtattttcatctgtttttagtgtgaaaaaagca tctactttggactgattatgttgtcttaaattagagcttagatgactatagtattttaatgttgtattaatgtcatcatgaccaagcctatcagct acataaataatatccatacccgcttctacacataagcctgtatgcgtatgtcgtagcttgtgtaatgtcactggttcagaattgattgtacta catatcttcttcaaagctttattacaagacgcgttgtctactggcttattgtggtaagtgatgaataataacatcaatggattcttaatagcat gttccttcatatattcagtatgccaatttaaatacgaatgtaaatattgagcggtagagttatcaatatagatcactcgtgatttttttgttttgg tatcaatgaatgtattagtgtacttgtaatcccaagctttattcacagttattgaacgtttagtgaaattaatatccttctttgttagtgcaataa tttcttcgaacctcatgcctgtctggacagctagaaagataactgctcgtgatatagaatgaaattttgcaagttcttctaatagtaaatga actttgtctgtttccataaattgtgctttatttttcgctacgtcctgtccgcttatatgagcccctatagtggggtttttcttcatgtaacctaaat gaacagccttgttaaaaatcgctctaattttgcggtgtctggtgtctacagtggatattgcatagtctacagataaatgattaataaattgtt gatattgaaccgcatcaatcgaattaaatttaattttttcatcgaaataatcaacgaattgattataagcaagatcgtataaattaatagtag attgactacttttcccatctttaaatgttttcatgaatagcgtataaaattctttgaagttccattctttcagagaactactatcatgctgaactt gttttaataatttagatgctttatacattaagtttgtttcacttgtatctgtcaaacgcttttctttccattcaccatcgacttttatacgtaggcga acacaatatttaccgtttgctaatttttttatcttcattaataccaccacctgtttatttttggagatctttttttcagaaaatcccagtacgtaatt aagtatttgagaattaattttatattgattaatactaagtttacccagttttcacctaaaaaacaaatgatgagataatagctccaaaggcta aagaggactataccaactatttgtaataattctgtaacagttgaaaagcgaacgtgtattcttagggcttgagatgtattgctgggtaaac ctttatagtgtaagtgggatgtgaacgttaatcaacaactttcgctatgggaaacctattgttttttgttaatagaaaaacttaatacatttgt aatataaaaaccggcagtttttccgttcttcgtgactcgaaatgaattgccagatgagtttatggtattctataatagaaggtatggaggat gttatataatgagacagaattatgatgatcgaaagctagcttggcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcg ttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaac agttgcgcagcctgaatggcgaatggcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatatgatcccgg atctggagctgtaatataaaaaccttcttcaactaacggggcaggttagtgacattagaaaaccgactgtaaaaagtacagtcggcatt atctcatattataaaagccagtcattaggcctatctgacaattcctgaatagagttcataaacaatcctgcatgataaccatcacaaacag aatgatgtacctgtaaagatagcggtaaatatattgaattacctttattaatgaattttcctgctgtaataatgggtagaaggtaattactatt attattgatatttaagttaaacccagtaaatgaagtccatggaataatagaaagagaaaaagcattttcaggtataggtgttttgggaaac
aatttccccgaaccattatatttctctacatcagaaaggtataaatcataaaactctttgaagtcattctttacaggagtccaaataccaga gaatgttttagatacaccatcaaaaattgtataaagtggctctaacttatcccaataacctaactctccgtcgctattgtaaccagttctaaa agctgtatttgagtttatcacccttgtcactaagaaaataaatgcagggtaaaatttatatccttcttgttttatgtttcggtataaaacactaa tatcaatttctgtggttatactaaaagtcgtttgttggttcaaataatgattaaatatctcttttctcttccaattgtctaaatcaattttattaaagt tcatttgatatgcctcctaaatttttatctaaagtgaatttaggaggcttacttgtctgctttcttcattagaatcaatccttttttaaaagtcaat attactgtaacataaatatatattttaaaaatatcccactttatccaattttcgtttgttgaactaatgggtgctttagttgaagaataaaagac cacattaaaaaatgtggtcttttgtgtttttttaaaggatttgagcgtagcgaaaaatccttttctttcttatcttgataataagggtaactattg cccagatccgggatcatatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacaccc gctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagag gttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttct ta (SEQ ID No: 32).
[0277] To construct pPL2, the PSA attachment site (tRNA^-attBB') DNA sequence was obtained through a combination of inverse PCR and genome walking. Inverse PCR was performed on Sau3AI-digested DP-L4061 DNA (WSLC 1042, lysogenic for PSA; GenBank Accession No: AJ314913) with the divergent primers PL95 (5'- ACATAATCAGTCCAAAGTAGATGC; SEQ ID NO: 33) and PL97 (5'- ACGAATGTAAATATTGAGCGG; SEQ ID NO: 34), which anneal within the PSA int gene. The resulting DNA sequence was used to design further oligonucleotides, and these were used with the Genome Walker® kit (Clontech).
[0278] pPLl was modified to utilize a different attachment site on the L. monocytogenes chromosome by replacing the U 153 integrase gene and attachment site in the plasmid. The PSA int and attPP' were PCR amplified from PSA genomic DNA (GenBank Accession No: AJ312240) with primers PLlOO (5'-GAAGATCTCCAAAAATAAACAGGTGGTGG; SEQ ID No: 71) and PLlOl (5'-CATGCATGCGTGGAGGGAAAGAAGAACGC; SEQ ID NO: 35) with Vent DNA polymerase, digested with BgIII and Sphl, and ligated to pPLl that had been digested with the same enzymes, generating pPL2.
[0279] The DNA sequence of the PSA tRNAArg-attBB' from serotype 1/2 L. monocytogenes strains was obtained by a plasmid trap strategy. DP-L421 1 (pPL2 integrated in 10403S) genomic DNA was digested with Nsi I and Nhel, which do not cleave in the vector, and ligated under dilute conditions to promote self-ligation. The ligations were transformed into E. coli XLl -Blue, and chloramphenicol-resistant colonies were selected.
The plasmids obtained were sequenced with the convergent primers PL94 (5'-
GGAGGGAAAGAAGAACGC; SEQ ID NO: 36) and PL95 (SEQ ID No: 33) for attPB' and attBP', respectively, which flank attPP' in the PSA genomic DNA sequence. A serotype 1/2- specific PCR assay across tRNA^-attBB' was developed from the 10403S DNA sequence and used to determine the prophage status of various LM strains. Primers PL102 (5'- TATCAGACCTAACCCAAACCTTCC; SEQ ID NO: 37) and PL103 (5'- AATCGCAAAATAAAAATCTTCTCG; SEQ ID NO: 38) specifically amplify a 533-bp PCR product in nonlysogenic serotype 1/2 strains. The primer pair NC 16 (5'- GTCAAAACATACGCTCTTATC; SEQ ID NO: 39) and PL95 specifically amplify a 499- bp PCR product in strains that either are lysogenic or contain an integration vector at tRNA^-attBB'.
Construction ofpTV6-7
[0280] The U153 integrase gene and the U153 attPP' integration site from pPLl are modified by PCR to contain restriction sites at the 5'-end and the 3'-end that are compatible with cloning these nucleic acids into shuttle plasmid pTV3. The Listeria replication region from pTV3 is removed, resulting in plasmid pTV6 (Figure HA). This plasmid contains replication functions for its amplification in E. coli, a dal gene for complementation of dal auxotroph E. coli and Listeria, and integration functions (Ul 53 integrase, attPP' site) for integration of the plasmid into the Listeria genome. pTV6 also contains a prfA (pathogenicity regulating factor A) gene. This gene is not necessary for the function of pTV6, but can be used in situations wherein an additional selected marker in the plasmid or the integration vector is required or desired. In other experiments, a similar plasmid lacking the prfA gene is utilized (pTV7; Figure HB).
Construction ofpTV8-9
[0281] The PSA integrase gene and attPP1 integration site from pPL2 are modified by PCR to contain restriction sites at the 5'-end and the 3'-end that are compatible with cloning these nucleic acids into shuttle plasmid pTV3 and the Listeria replication region from pTV3 is removed, resulting in plasmid pTV8 (Figure 12). pTV8 is similar to pTV6, except that it contains the PSA sequences instead of the U 153 sequences. pTV8 also contains a prfA gene, which is not necessary for function, as described above for pTV6, and can be removed (pTV9; Figure 13).
S l
Construction ofpTVlO-U
[0282] The Al 18 integrase gene and attPP' integration site from Al 18 DNA (GenBank Accession No. NC_003216) are modified by PCR to contain restriction sites at the 5'-end and the 3'-end that are compatible with cloning these nucleic acids into shuttle plasmid pTV3 and the Listeria replication region from pTV3 is removed, resulting in plasmid pTVIO (Figure 14). pTVIO is similar to pTV6, except that it contains the Al 18 sequences instead of the Ul 53 sequences. pTVIO also contains a prfA gene, which is not necessary for function, as described above for pTV6, and can be removed (pTVl 1; Figure 15).
Phage curing, conjugation, and molecular confirmation of plasmid integration.
[0283] For phage curing, L.monocytogenes (LM) 10403S derivatives carrying a prophage at comK-attBB' (integrated in the comK open reading frame) are grown in BHI at 37°C to 108 CFU/ml and infected with listeriophage Ul 53 at a multiplicity of infection of 20:1 in the presence of 5 mM CaCl2. Cultures are incubated with shaking at 37°C for 75 min, and inhibition of growth is monitored by comparison of the optical density at 600 nm (OD6Oo) of the infected culture with an uninfected control culture. The infected culture is diluted 10"2 and 10"4 in BHI, and both dilutions are grown at 37°C until the 10~2 dilution culture increases 100- fold in optical density. The 10"4-fold dilution culture is then diluted 10"2, and 3 microliter (mcl) is plated on BHI.
[0284] Fifty colonies are tested for phage release initially by transferring colonies into 0.25 ml of LB broth and replica plating at 300C on a lawn of Mack-4R (DP-L862), a non- lysogenic rough strain of L. monocytogenes particularly susceptible to forming plaques. Candidates are then tested for ability to form plaques by spotting 10 mcl of culture on a lawn of Mack-4R. Colonies that do not form plaques are tested for ability to support plaque formation by the phage from the parent 10403S strain (Φ10403 [Hodgson, DA. 2000. Generalized transduction of serotype 1/2 and serotype 4b strains of Listeria monocytogenes. MoI. Microbiol. 35:312-323]). Curing is confirmed molecularly by PCR with the comK- attBB-specific primer pair PL60 and PL61 (sequences follow) for the absence of a phage at comK-attBB. Approximately 10% of colonies are cured by using this procedure.
[0285] Recipient LM strains are made streptomycin resistant for counterselection in conjugation experiments by plate selection on BHI supplemented with 200 microgram (meg) of antibiotic per ml.
[0286] pPLl plasmid constructs were electroporated into E. coli strain MB2159, and bacterial strains are grown to mid-log phase (OD600 of 0.55) with shaking at 300C. E. coli donor strains are grown in LB containing 25 meg of chloramphenicol/ml, and LM recipient strains are grown in BHI. Donor culture (2.5 ml) is mixed with 1.5 ml of recipient culture and filtered onto washed 0.45-micron-pore-size HA-type filters (47 mm; Millipore). The filter is washed once with 10 ml of BHI, transferred to a BHI plate with no antibiotics, and incubated for 2 h at 300C. Bacterial cells are gently resuspended in 2.5 ml of BHI, and 25- and 50-mcl aliquots are plated in 3 ml of LB top agar on BHI plates supplemented with 7.5 meg chloramphenicol and 200 meg streptomycin per ml. Plates are incubated at 300C overnight and shifted to 37°C for 2 to 3 days.
[0287] Individual colonies are picked and screened by PCR for integration at the phage attachment, using 2 pairs of primers: The first primer pair specifically amplifies attBP', thereby detecting integrated strains (but not those containing the vector as an episomal plasmid). The second primer pair specifically amplifies comK-attBB', thereby detecting nonlysogenic strains. PCR assays are performed in a Hybaid Omn-E™ thermocycler with an annealing temperature of 55°C for 30 cycles; integrants arise at a frequency of approximately 104 per donor cell.
RESULTS
[0288] In a first experiment, a shuttle plasmid is constructed containing (1) a replication gene for E. coli, (2) a U 153 attPP' integration site, (3) a Listeria dal gene under the control of its natural promoter, and (4) a Ul 53 integrase gene under the control of the Listeria p60 promoter. The U 153 integrase gene and attPP' integration site are subcloned into shuttle plasmid pTV3, and the Listeria replication region from pTV3 is removed, generating plasmid pTV6. The plasmid is amplified in dal auxotroph E. coli strain MB2159 (Example 1), isolated, and subsequently conjugated into Listeria. Because the plasmid does not contain a Listeria replication region, only Listeria that contain a copy that is integrated into the genome are selected upon growth in LB media. In other experiments, as a further selective measure, alanine-free media is utilized.
[0289] In other experiments, to facilitate prophage integration, phage curing is performed prior to conjugation. In other experiments, an integration vector not requiring phage curing (e.g. a PSA vector) is utilized.
[0290] In another experiment, a similar shuttle plasmid, pTV8, is constructed, but using instead a PSA attPP' integration site and integrase gene. The plasmid is amplified and conjugated into Listeria, as described for pTV6.
[0291] In another experiment, a similar shuttle plasmid, pTVIO, is constructed, but using instead a Al 18 attPP' integration site and integrase gene. The plasmid is amplified and conjugated into Listeria, as described for pTV6.
EXAMPLE 8; CREATION OF GENERAL SHUTTLE INTEGRATION
VECTORS BASED ON pTV6, 8, and 11
[0292] ρTV6, 8, and 11 are digested with Kasl or Ehel and Aatll, and/or other appropriate restriction enzymes, removing the prfA gene, the LLO-E7 fusion gene, and most of the LLO promoter. A multiple cloning site consisting of BamHI, Xhol, Xbal, Notl, Spel, Smal, and Sad is introduced by ligating the following paired oligonucleotides to the vector backbone:
[0293] 5'-CGG ATC CCT CGA GCT CAG AGC GGC CGC ACT AGT CCC GGG GAG CTC G (SEQ ID No: 40).
[0294] 5'-TCG ACG AGC TCC CCG GGA CTA GTG CGG CCG CTC TGA GCT CGA GGG ATC CGA CGT (SEQ ID No: 41; overhanging ends that are compatible with the vector sites restricted with Aatl and Sail are in italics).
[0295] An antigen cassette of interest is then ligated into the multiple cloning site. The plasmid is then used to create a vaccine strain expressing the antigen encoded therein.
Claims
1. A recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein said integrated nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises a protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a third open reading frame encoding a Al 18 or Ul 53 integrase gene.
2. The recombinant Listeria strain of claim 1, wherein said nucleic acid molecule does not comprise an antibiotic resistance gene.
3. The recombinant Listeria strain of claim 1, wherein said nucleic acid molecule does not contain a replication region that functions in said auxotrophic bacterial strain.
4. The recombinant Listeria strain of claim 1, wherein said nucleic acid molecule further comprises a gene encoding a transcription factor.
5. The recombinant Listeria strain of claim 4, wherein said recombinant Listeria strain comprises an inactivating mutation in the endogenous gene encoding said transcription factor.
6. The recombinant Listeria strain of claim 1 , wherein said polypeptide is a fusion protein comprising said protein antigen and an additional polypeptide, wherein said additional peptide enhances the immunogenicity of said protein antigen.
7. The recombinant Listeria strain of claim 6, wherein said additional polypeptide is a nonhemolytic LLO protein or fragment thereof, a PEST-like amino acid sequence, or an ActA fragment.
8. The recombinant Listeria strain of claim 1, wherein said integrated nucleic acid molecule is a phage integration vector.
9. The recombinant Listeria strain of claim 1, wherein said metabolic enzyme is an amino acid metabolism enzyme.
10. The recombinant Listeria strain of claim 1 , wherein said metabolic enzyme catalyzes a formation of an amino acid used for a cell wall synthesis in said recombinant Listeria strain.
11. The recombinant Listeria strain of claim 1 , wherein said metabolic enzyme is an alanine racemase enzyme.
12. The recombinant Listeria strain of claim 1, wherein said metabolic enzyme is a D-amino acid transferase enzyme.
13. The recombinant Listeria strain of claim 1, wherein said recombinant Listeria strain has been passaged through an animal host.
14. The recombinant Listeria strain of claim 1, wherein said polypeptide is expressed under the control of an hly promoter, an ActA promoter, or a p60 promoter.
15. A method of inducing an immune response against a protein antigen of interest in a subject, comprising the step of administering to said subject a recombinant Listeria strain, comprising an integrated nucleic acid molecule, wherein said integrated nucleic acid molecule comprises (a) a first open reading frame encoding a polypeptide, wherein said polypeptide comprises said protein antigen of interest; (b) a second open reading frame encoding a metabolic enzyme; and (c) a third open reading frame encoding a Al 18 or U 153 integrase gene, thereby inducing an immune response against said protein antigen of interest in said subject.
16. The method of claim 15, wherein said integrated nucleic acid molecule is a phage integration vector.
17. The method of claim 15, wherein said nucleic acid molecule does not comprise an antibiotic resistance gene.
18. The method of claim 15, wherein said nucleic acid molecule does not contain a replication region that functions in said auxotrophic bacterial strain.
19. The method of claim 15, wherein said nucleic acid molecule further comprises a gene encoding a transcription factor.
20. The method of claim 15, wherein said recombinant Listeria strain comprises an inactivating mutation in the endogenous gene encoding said transcription factor.
21. The method of claim 15, wherein said polypeptide is a fusion protein comprising said protein antigen and an additional polypeptide, wherein said additional peptide enhances the immunogenicity of said protein antigen.
22. The method of claim 21, wherein said additional polypeptide is a non-hemolytic LLO protein or fragment thereof, a PEST-like amino acid sequence, or an ActA fragment.
23. The method of claim 15, wherein said metabolic enzyme is an amino acid metabolism enzyme.
24. The method of claim 15, wherein said metabolic enzyme catalyzes a formation of an amino acid used for a cell wall synthesis in said recombinant Listeria strain.
25. The method of claim 15, wherein said metabolic enzyme is an alanine racemase enzyme.
26. The method of claim 15, wherein said metabolic enzyme is a D-amino acid transferase enzyme.
27. The method of claim 15, wherein said recombinant Listeria strain has been passaged through an animal host.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010504068A JP2010534058A (en) | 2007-04-16 | 2008-04-15 | Listeria monocytogenes without antibiotic resistance and methods of construction and use thereof |
EP08742912A EP2147092A4 (en) | 2007-04-16 | 2008-04-15 | Antibiotic resistance free listeria strains and methods for constructing and using same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/785,249 | 2007-04-16 | ||
US11/785,249 US7855064B2 (en) | 2004-08-13 | 2007-04-16 | Antibiotic resistance free vaccines and methods for constructing and using same |
US11/818,965 US7858097B2 (en) | 2004-08-13 | 2007-04-27 | Antibiotic resistance free Listeria strains and methods for constructing and using same |
US11/818,965 | 2007-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008130551A2 true WO2008130551A2 (en) | 2008-10-30 |
WO2008130551A3 WO2008130551A3 (en) | 2008-12-24 |
Family
ID=39876122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/004861 WO2008130551A2 (en) | 2007-04-16 | 2008-04-15 | Antibiotic resistance free listeria strains and methods for constructing and using same |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2147092A4 (en) |
WO (1) | WO2008130551A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2288379A2 (en) * | 2008-05-19 | 2011-03-02 | Advaxis | Dual delivery system for heterologous antigens |
WO2012138377A3 (en) * | 2010-10-01 | 2013-07-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9084747B2 (en) | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
US9549973B2 (en) | 2000-03-27 | 2017-01-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising KLK3 or FOLH1 antigen |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
US10058599B2 (en) | 2012-03-12 | 2018-08-28 | Advaxis, Inc. | Suppressor cell function inhibition following Listeria vaccine treatment |
US10064898B2 (en) | 2011-03-11 | 2018-09-04 | Advaxis, Inc. | Listeria-based adjuvants |
US10143734B2 (en) | 2014-02-18 | 2018-12-04 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
EP3350337A4 (en) * | 2015-09-15 | 2019-04-03 | Advaxis, Inc. | Manufacturing method of an immunotherapeutic formulation comprising a recombinant listeria strain |
US10258679B2 (en) | 2014-04-24 | 2019-04-16 | Advaxis, Inc. | Recombinant Listeria vaccine strains and methods of producing the same |
US10900044B2 (en) | 2015-03-03 | 2021-01-26 | Advaxis, Inc. | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
US11179339B2 (en) | 2017-09-19 | 2021-11-23 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
US11897927B2 (en) | 2016-11-30 | 2024-02-13 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099848A (en) * | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
CA2577306A1 (en) * | 2004-08-13 | 2006-02-16 | The Trustees Of The University Of Pennsylvania | Methods for constructing antibiotic resistance free vaccines |
-
2008
- 2008-04-15 WO PCT/US2008/004861 patent/WO2008130551A2/en active Application Filing
- 2008-04-15 EP EP08742912A patent/EP2147092A4/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of EP2147092A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9549973B2 (en) | 2000-03-27 | 2017-01-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising KLK3 or FOLH1 antigen |
US11446369B2 (en) | 2007-05-10 | 2022-09-20 | Advaxis, Inc. | Compositions and methods comprising KLK3 or FOLH1 antigen |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
EP2288379A4 (en) * | 2008-05-19 | 2012-08-08 | Advaxis | Dual delivery system for heterologous antigens |
EP2288379A2 (en) * | 2008-05-19 | 2011-03-02 | Advaxis | Dual delivery system for heterologous antigens |
EP2853269A1 (en) * | 2008-05-19 | 2015-04-01 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US9644212B2 (en) | 2008-05-19 | 2017-05-09 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9084747B2 (en) | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
CN107412756A (en) * | 2010-10-01 | 2017-12-01 | 宾夕法尼亚大学理事会 | Listeria vaccine carrier is used for the purposes that immunological unresponsiveness is reversed in the individual of parasitic infection |
WO2012138377A3 (en) * | 2010-10-01 | 2013-07-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
JP2013542931A (en) * | 2010-10-01 | 2013-11-28 | トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Use of a Listeria vaccine vector to reverse vaccine unresponsiveness in a parasitically infected subject |
US9943590B2 (en) | 2010-10-01 | 2018-04-17 | The Trustees Of The University Of Pennsylvania | Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
CN103282048A (en) * | 2010-10-01 | 2013-09-04 | 宾夕法尼亚大学理事会 | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
CN103282048B (en) * | 2010-10-01 | 2017-05-17 | 宾夕法尼亚大学理事会 | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
US10064898B2 (en) | 2011-03-11 | 2018-09-04 | Advaxis, Inc. | Listeria-based adjuvants |
US10058599B2 (en) | 2012-03-12 | 2018-08-28 | Advaxis, Inc. | Suppressor cell function inhibition following Listeria vaccine treatment |
US10143734B2 (en) | 2014-02-18 | 2018-12-04 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
US10258679B2 (en) | 2014-04-24 | 2019-04-16 | Advaxis, Inc. | Recombinant Listeria vaccine strains and methods of producing the same |
US10900044B2 (en) | 2015-03-03 | 2021-01-26 | Advaxis, Inc. | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
US11702664B2 (en) | 2015-03-03 | 2023-07-18 | Advaxis, Inc. | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
EP3350337A4 (en) * | 2015-09-15 | 2019-04-03 | Advaxis, Inc. | Manufacturing method of an immunotherapeutic formulation comprising a recombinant listeria strain |
US11897927B2 (en) | 2016-11-30 | 2024-02-13 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
US11179339B2 (en) | 2017-09-19 | 2021-11-23 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or listeria strains |
Also Published As
Publication number | Publication date |
---|---|
WO2008130551A3 (en) | 2008-12-24 |
EP2147092A2 (en) | 2010-01-27 |
EP2147092A4 (en) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10426823B2 (en) | Methods for constructing antibiotic resistance free vaccines | |
US7855064B2 (en) | Antibiotic resistance free vaccines and methods for constructing and using same | |
US7858097B2 (en) | Antibiotic resistance free Listeria strains and methods for constructing and using same | |
EP2147092A2 (en) | Antibiotic resistance free listeria strains and methods for constructing and using same | |
TWI808415B (en) | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof | |
JP5985397B2 (en) | Recombinant Listeria strain and immunogenic composition containing the same | |
JP6039669B2 (en) | Use of attenuated recombinant Listeria in the preparation of a medicament against Her2 / neu expressing tumors | |
WO2016126878A2 (en) | Listeria-based immunomodulation | |
JP2015511602A (en) | Inhibition of suppressor cell function after Listeria vaccine treatment | |
US20060135457A1 (en) | Methods for constructing antibiotic resistance free vaccines | |
JP2010534058A (en) | Listeria monocytogenes without antibiotic resistance and methods of construction and use thereof | |
JP6329211B2 (en) | Use of recombinant Listeria strains in the manufacture of a medicament for delaying the onset of brain tumors or breast tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08742912 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2010504068 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008742912 Country of ref document: EP |